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ABSTRACT 
DESIGN AND ENGINEERING OF LIGAND-INDUCED CONFORMATIONAL 
RESTRAINTS IN HIV-1 ENVELOPE GP120 
Ali Emileh 
Cameron Abrams, Ph.D. 
 
 
 
We designed and produced a novel peptide triazole (PT) / HIV gp120 covalent conjugate. 
Gp120 is the main viral protein on the surface of HIV-1 virions. PTs are promising 
inhibitors of HIV-1 gp120 binding to its target receptors. In absence of a crystal structure 
of the PT / gp120 complex, we used molecular dynamics (MD) to generate a model of the 
peptide/gp120 complex. We used this model to design reactive variants of gp120 and the 
peptide. We implemented the design in the wet-lab and provided evidence that the 
resulting product showed the properties expected of the peptide/gp120 bound state.  
We first studied the conformational flexibility mechanisms of available gp120 
structures as potential targets for ligand docking experiments. We showed that in contrast 
to the activated state gp120 core which displays a bridging sheet mini-domain, the b12-
bound conformation of gp120 core is flexible in absence of this mini-domain. Further we 
showed that removal of a disulfide stitch in the engineered structure of the latter state 
greatly enhances its flexibility. Hence this part of the work provided some insight as to 
where the moving part of the gp120 machinary might be located.  
We next used temperature-accelerated molecular dynamics (TAMD) to further 
explore the conformational landscape of gp120 core. Starting from the activated state, we 
were able to see opening of the bridging sheet and exposure of conserved residues behind 
it which we saw were transiently exposed in the previous part. Using this technique, we 
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could exit the deep energy minimum of the activated state and sample a diverse range of 
different conformations. Interestingly we were able to sample multiple conformations 
similar to the recently resolved F105-bound gp120 conformation. We were not able to 
sample conformations similar to the two engineered non-activated states of gp120 in 
complex with the b12 and b13 antibodies. These results provided us with useful 
hypotheses as to where the PTs may bind, which crystal conformation might be a more 
plausible target, and how PTs might prevent bridging sheet formation.  
We used this information, in combination with past experimental data, to propose 
a binding site for PTs on gp120. We hypothesized that PTs bind closely to the F43 pocket 
on gp120 and prevent formation of the bridging sheet. We generated stably bound 
PT/gp120 complexes which displayed properties consistent with more recent 
experimental data. Furthermore, our results were in agreement with saturation transfer 
nuclear magnetic resonance (STD NMR) experiments performed by our collaborators. 
The generated model both could help us test concrete ideas to verify its validity and also 
be used to design our desired covalent conjugate. 
In the last part of the work, we used the generated model to design reactive 
variants of PTs and gp120. We characterized both variants and showed they are 
functional. We then combined the two and showed that the peptide indeed covalently 
linked to gp120. Furthermore, the covalent complex displayed conformational properties 
which we expected of a PT/gp120 complex. The generated covalent complexes can be 
used as stabilized systems for crystallization or as antibody baits for identification of new 
antibodies.  
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Human immunodeficiency virus (HIV-1)
*
 is the causative agent of acute 
immunodeficiency syndrome or AIDS (1). Since its identification in 1981, 30 million 
people have lost their lives due to complications related to AIDS (2). Introduction of 
highly active antiretroviral therapy (HAART) in 1996 had a dramatic effect on the state 
of the epidemic: mortalities fell by 70% and HIV infection turned from a death sentence 
into a chronic disease (2). Despite this spectacular success and the accompanied decrease 
in the rate of new infections, HAART does not offer a cure and increasingly resistant 
viruses are being transmitted in susceptible populations (1, 3). There are currently 34 
million people living with HIV globally, and new infections outpace treatment coverage 
by 2:1 (1-3). Therefore, novel drugs and drug targets continue to be required while 
control of the AIDS epidemic requires an effective vaccine (1, 4). 
 
HIV-1 life cycle 
HIV-1 is an enveloped retrovirus and as such, in simplistic terms, can be thought of 
as a collection of fifteen proteins and an RNA encapsulated by a lipid bilayer (5). Twelve 
of these proteins are present in the viral particle: The four Gag proteins MA (matrix), CA 
(capsid), NC (nulceocapsid) and p6 plus the two Env proteins SU (surface or gp120) and 
TM (trasmembrane or gp41) are the structural components of the virus. The three Pol 
                                                 
* HIV-2 is less pathogenic and less transmissible than HIV-1. Most patients do not become ill and only a minority of infected 
individuals progress to AIDS. We limit our discussion to HIV-1. 
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proteins PR (protease), RT (reverse transcriptase) and IN (integrase) provide essential 
enzymatic functions and along with the accessory proteins Vif, Vpr and Nef, are 
packaged into the virion (5). The three other HIV-1 encoded proteins Tat, Rev and Vpu 
serve additional accessory purposes.  
HIV-1 infects cells that display the CD4 receptor on their surface (CD4
+
) along a 
mandatory coreceptor, a member of the chemokine receptor family, CCR5 or CXCR4 
(6). Following SU binding to receptor and coreceptor, TM undergoes conformational 
changes that lead to virus-cell membrane fusion and allow the virion core, composed of 
MA, RT, IN, Vpr and RNA, to enter the cell (5). This complex is transported to the cell 
nucleus where the viral genetic code is transcribed into DNA by RT and integrated into 
the host genome by IN (5). At this point, the cell is ready to produce more viral progeny 
which bud off the cell surface membrane and continue the virus life cycle by infecting 
other targets.  
 
HIV Entry 
HIV is studded on its surface with spike-like glycoprotein structures called envelope 
spikes (Env) (7). These are target recognition and entry initiation machinery of the virus 
and each envelope spike is a trimer of non-covalent dimers of transmembrane gp41 and 
the highly glycosylated gp120 (7). The entry process happens as a sequence of events 
which are schematically illustrated in Figure 1. The initial contacts between HIV and the 
target cell might be facilitated by non-specific interactions of the positively charged 
domains of Env gp120 with the negatively charged proteoglycans or lectin binding 
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proteins on the cell surface (6). Following initial contact, gp120 binds CD4 which results 
in a presumably drastic change in the spike structure, leading to movement of loops and 
exposure of the coreceptor binding site, which is hidden on the native trimer (7-10). 
Binding of gp120 to the coreceptor brings about further conformational changes in the 
spike which result in deployment of gp41 and insertion of a hydrophobic sequence of 
residues on its N-terminus called the fusion peptide into the target cell membrane (6, 8, 
11-13). This extended conformation of gp41 with its C-terminus in the viral membrane 
and its N-terminus in the cell membrane is called the “prehairpin intermediate” (11). 
Folding of the two heptad repeats (HR) of gp41 into a hairpin is thought to result in the 
formation of a highly stable, energetically favorable six-helix bundle which places the 
two ends of gp41 in close proximity (6, 11). This brings the two membranes together and 
leads to membrane fusion and insertion of the virion core into the cell, effectively starting 
the infection (6).  
 
Structural Biology of gp120  
The sequence of events leading to viral entry depicted above demonstrates the 
pivotal role of gp120 in the viral life cycle. As the only viral component of HIV 
accessible on the virion surface and under constant immune pressure, gp120 has evolved 
an extensive set of mechanisms to evade the immune system (14-16). Moreover, a new 
class of antiviral drugs, entry inhibitors, have emerged in recent years which target the 
entry process and stop the virus from establishing a base in the host (6). Therefore, both 
as the target of antibodies and entry inhibitors, gp120 is a highly valuable target to study.  
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Gp120 is a heavily glycosylated protein with up to 50% of its molecular weight 
contributed by carbohydrates (17). Its sequence is composed of five conserved regions 
(C1-C5) interspersed with five variable loops (V1-V5) (17). Extensive biochemical 
studies had suggested that the five conserved regions make up a functional core for the 
protein from which the variable loops emanate (7, 17). A significant advance in this field 
was the solution in 1998 of the crystal structure of a deglycosylated “core” gp120 lacking 
the variable loops and some of the gp120 N and C-termini (18). This structure was 
resolved as a complex of gp120 core with the antibody binding fragment (Fab) of a 
coreceptor surrogate (17b) and the membrane distal 2 domains of CD4 (18). Additional 
studies in the past 15 years have resulted in a more complete picture of this state of gp120 
by adding other components like the V3 and V4 loops and the N and C-termini (19, 20) 
Figure 2a shows gp120 in this CD4-bound, activated state (20). Gp120 in this 
conformation can be divided into two domains: a sequentially variable, highly 
glycosylated and structurally stable outer domain and a more conserved, structurally 
variant inner domain devoid of glycans (18). Both domains contribute two β-strands to a 
minidomain at their interface called the bridging sheet which is where the coreceptor 
binds (18). There is a deep pocket at the junction of these domains which is capped with 
the bound CD4 F43 residue and is lined with conserved residues thought to be important 
for function (18).  
Thermodynamic and antibody mapping studies hinted at the presence of an unusual 
degree of flexibility in gp120, which was suggested to contribute to HIV immune evasion 
(15, 21). Further studies resulted in resolution of other conformations of gp120, gradually 
building a picture of this highly flexible molecule (Figure 2a-e) (22, 23). These 
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conformations all show a structurally invariant outer domain, a structurally variable inner 
domain and absence of the bridging sheet. Recent studies suggest that the core gp120 has 
a propensity to sample the activated state with a folded bridging sheet more frequently 
(Figure 2e) (24), while the same study suggests that the full-length gp120 monomer and 
the native-state spike-bound gp120 are flexible, conformationally diverse and not in an 
activated state (24).  
The ultimate target of antibodies and entry inhibitors is the viral spike. It is believed 
that gp120 is maintained in a highly strung, unstable state on the spike through 
interactions between the protomers (9) and that activation results in the collapse of this 
high energy state, releasing its potential to drive downstream conformational changes. No 
atomistic structures of the envelope spikes are published to date, although progressively 
more detailed structures resulting from electron microscopy studies have been produced 
and published in recent years (8, 9) (Figure 3).  
 
HIV Entry inhibitors 
The multi-step process of viral entry provides a series of targets for intervention and 
blocking the infection before the virus establishes a foothold in the host (25). Enfuvirtide 
(T20) is a subcutaneously injected 36 amino acid peptide that binds to the transiently 
exposed HR1 of gp41 and prevents formation of the six-helix bundle, preventing viral 
entry (6). It was approved for clinical use in 2003 although its low bioavailability and 
poor pharmacokinetics have spurred research for its improvement (26). Maraviroc, an 
orally administered small molecule that binds to CCR5 and inhibits gp120 recognition 
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was approved by the FDA in 2007 (6). Emergence of X4-tropic or R5X4-dualtropic 
viruses utilizing CXCR4 are the most common pathways of resistance to maraviroc (25, 
27). The success of combination therapy has shown the value of using multiple agents to 
target sequentially diverse HIV (26). Prominent examples of targeting gp120 through 
inhibiting its interactions with CD4 or CCR5/CXCR4 include: NBD-556/DMJ-II-228 
which inhibit gp120/CD4 interaction and BMS378806/BMS488043 which prevent viral 
entry through an unknown mechanism involving conformational changes in the envelope 
spike (28-30). The former is an agonist of coreceptor binding (31) although very recent 
work has shown that this undesirable phenotype can be eliminated (32), and the latter has 
a very small barrier to resistance as 1-2 mutations in gp120 result in 40-500 fold 
resistance to the inhibitor (6).  
12p1 is a small peptide (with the sequence RINNIPWSEAMM) that allosterically 
inhibits gp120 interactions with both the receptor and the coreceptor (33, 34). Replacing 
the middle proline with azidoproline and derivatizing the latter with various alkynes 
through click chemistry led to identification of peptide triazole (PT) variants with an 
approximately 400 fold increase in potency, generating a new class of peptide triazole 
entry inhibitors with low nanomolar affinity for gp120 (35, 36). HNG-156, which 
contains a ferrocenyl triazole-substitution, binds to gp120 with an equilibrium 
dissociation constant (KD) of 7 nM, compared to the 5400 nM KD of 12p1 (37). It 
antagonizes gp120 interactions with both CD4 and coreceptor and inhibits HIV-1BaL 
entry at nanomolar 50% effective concentrations (EC50). This class of entry inhibitors is 
broadly active against various HIV clades, nontoxic and can be synergistically combined 
with other entry inhibitors (38, 39). Recently it was found that some variants of the 
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peptide can disrupt the viral membrane, leading to cell-free HIV virolysis and 
inactivation (40). This virolytic process was shown to be dependent on the specific 
interactions of the peptides with gp120 (40). Clearly such peptide triazoles hold great 
promise for both therapeutic and microbicidal applications. Understanding the binding 
mode of peptide triazoles in the context of gp120 structure would help greatly in further 
developing peptide designs with improved potency and peptidomimetic character. 
Currently there are no crystal structures of a peptide triazole/gp120 complex, 
slowing down progress toward development of non-natural peptidomimetics and drug-
like molecules through structure-based design. Peptide triazoles bind the flexible gp120 
protein with a thermodynamic signature which suggests the resulting complex maintains 
significant conformational flexibility (41). A small structuring effect has been suggested 
to be a common feature of the few gp120-binding, neutralizing antibodies discovered to 
date (15). This attractive property of this class of compounds has had the unwanted 
consequence of impeding efforts toward crystallization of a PT/gp120 complex. We 
hypothesized that covalent conjugation of the peptides onto gp120 would possibly lead to 
a more stable complex, paving the way for acquiring a crystal. In addition to its obvious 
use in acquiring a crystal structure of the PT/gp120 complex, such a covalent conjugate 
might be a useful “bait” to identify antibodies that can cobind with PTs by using it as a 
bait for screening of sera. These antibodies can later be used to further stabilize the 
complex to get a crystal complex. 
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Specific Aims 
The overarching goal of this work was to design a conformationally restricted 
PT/gp120 conjugate. Such a conjugate can be used as a stabilized complex for 
crystallization studies. Since there are no crystal structures of the native state, full length 
HIV-1 gp120, nor are there any for the peptide/gp120 complex, we first aimed at 
characterizing the conformational landscape of gp120 monomer. Information gleaned 
from these studies were used to propose a binding mode for the HNG peptide triazoles to 
gp120. The latter was used to introduce a cysteine mutant on gp120 as a tethering point 
and also to guide in designing a suitable peptide construct for conjugation. Finally these 
components were reacted to produce the intended covalent conjugate. In what follows, 
we provide further details on each part of the work.  
 
Specific Aim 1: Exploring the conformational flexibility mechanisms of core 
gp120 in the b12-bound state 
b12 is a broadly neutralizing antibody (bnAb) which binds to the CD4 binding site 
(CD4bs) on gp120 and induces a very small conformational change in gp120, when 
compared to CD4 (     = 5.9 kcal.mol−1 for b12 vs. 44.2 for CD4) (18). Hence when 
bound to b12, in contrast to CD4, gp120 is still flexible and this is detrimental to 
crystallization efforts. To resolve this issue, Zhou et al. introduced four “pocket-filling” 
plus four cysteine mutations in gp120 and resolved the structure of gp120 in a 
conformation other than the activated CD4-bound state (23). This was the first non-
activated core HIV-1 gp120 structure published and had important implications for how 
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gp120 conformational flexibility was perceived. When bound to the Fab fragment of b12 
(Figure 2d), the gp120 conformation is significantly different compared to the CD4-
bound state with the bridging sheet absent from the structure. We aimed at using this 
structure as a target for generation of PT/gp120 complexes but were concerned about the 
effect of the disulfide mutations on the target structure. We were especially concerned 
about the I109C/Q428C disulfide which we thought may play a role in unfolding the α1 
domain when b12 binds to gp120. Furthermore, we were interested to see if reverting the 
engineered mutations to wild type (WT) in silico would provide a better target for peptide 
docking. In this part of the work, we sought to answer the following questions: 
1. How will removing the I109C/Q428C disulfide stitch affect the stability and 
dynamics of gp120 in the context of a b12-bound gp120 conformation and in absence 
of b12?  
2. Does the presence of I109C/Q428C disulfide stitch affect the gp120 conformations 
resulting from b12 binding? Specifically, does this disulfide affect the α-helical 
structure of inner domain α1? 
Answers to these questions could help us better decide on the target to use for generation 
of a peptide/gp120 model. 
 
Specific Aim 2: Target-blind sampling of CD4-naïve conformations in core 
gp120 
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The first step toward building a computational model of the encounter complex 
between gp120 and peptide triazoles is selection of a target structure. Gp120 is thought to 
be conformationally very flexible (15, 20, 21, 24), evidenced by the impressive collection 
of gp120 structures resolved with different ligands (24). A quick survey of the available 
crystal structures shows that the major difference between HIV-1 gp120 conformations is 
the folding state of the bridging sheet. This minidomain is the locus of the mandatory 
coreceptor binding and its folding from the unliganded state has been suggested to 
account for almost half of the structuring which accompanies the CD4/gp120 interaction 
(15, 21). Peptide triazoles bind with a much smaller structuring effect on gp120 (-
TΔS=6.3 kcalmol-1) compared to CD4 (-TΔS=44.2 kcalmol-1) (15, 41) and do not inhibit 
CD4 binding to a gp120 mutant (S375W) engineered to stay in the activated state. Recent 
studies on the structures of the unliganded gp120 core showed that full-length gp120 is 
recognized by ligands that bind the unactivated state gp120 better than ligands that 
recognize the activated state (24). In other words, full-length gp120 samples the 
unliganded conformation without a bridging sheet more frequently than activated states 
which form the bridging sheet and bind CD4 induced (CD4i) antibodies like 17b.  
Although unfolding of the bridging sheet presents an interesting opportunity for 
postulating binding mechanisms for PTs to gp120, the only CD4-naïve structure available 
at the time for our docking studies was the highly engineered gp120 structures in the b12-
bound state (23). The results from the previous section suggested that this structure would 
relax into states other than the crystal structure in absence of the disulfide stitches. With 
the goal of generating general hypotheses for conformational flexibility mechanisms in 
core gp120 and using that knowledge to generate a PT/gp120 model, we set out to 
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explore the conformational variability in the activated gp120 core using a recently 
developed molecular dynamics approach (temperature accelerated molecular dynamics or 
TAMD) (42, 43). Specifically we tried to answer the following questions:  
1. Starting from the full-length gp120 in the CD4-bound state, is it possible to reach 
other crystallographically resolved states (i.e. b12-bound) or states partially similar to 
them? 
2. What are the flexibility mechanisms in gp120? Specifically, how does the bridging 
sheet unfold?  
Information from these studies could help us better choose a target state and further, a 
target pocket, on gp120 for our docking studies.  
 
Specific Aim 3: Generation of an atomistic model of PT/gp120 core 
interaction  
Understanding the binding mode of peptide triazoles in the context of gp120 
structure would help greatly in further developing peptide designs with improved potency 
and drug-like molecules. Efforts toward that goal are impeded by the lack of a PT/gp120 
crystal complex. Binding of peptide triazoles to full-length gp120 is characterized by a 
smaller negative entropy change (-TΔS   +6.3 kcalmol-1) (41) compared to CD4/gp120 
binding (-TΔS=44.2 kcalmol-1) (15), suggesting that gp120 maintains its conformational 
flexibility when bound to the peptide. This might be one of the reasons the gp120/peptide 
complex has resisted crystallization efforts to date. In this part of the work, we set out to 
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build an atomistic model of the gp120/peptide triazoles complex. Specifically, we were 
trying to answer the following questions: 
1. Using a recently published crystal structure as a conservative target which displays 
the properties we expect of a PT/gp120 complex (discussed further in Chapter 5), can 
we develop an atomistic model of PT/gp120 complex consistent with available 
experimental data?  
2. How stable is the resulting model? How do the resulting poses fare against saturation 
transfer difference NMR (STD NMR) studies from our collaborators (Carole Bewley 
and Herman Yeh, NIDDK, NIH)?  
3. What experimentally-verifiable predictions can be drawn from the proposed docking 
pose to improve/disprove the model? 
Answers to these questions could set the stage for rational design of a covalent conjugate 
of PTs with gp120.  
 
Specific Aim 4: Design, production and characterization of a PT/gp120 
covalent conjugate 
Peptide triazoles bind the flexible gp120 protein with a thermodynamic signature that 
suggests the resulting complex maintains significant conformational flexibility (41). A 
small structuring effect has been suggested to be a common feature of the few gp120-
binding, neutralizing antibodies discovered to date (15). This attractive property of this 
class of compounds has had the unwanted consequence of impeding efforts toward 
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crystallization of a PT/gp120 complex. One approach to overcome the problem of 
complex flexibility for such gp120 ligands has been engineering mutations into the gp120 
sequence which would reduce its flexibility. Structure-guided pocket-filling mutations or 
disulfide stitches were introduced into the core gp120 sequence to stabilize its complex 
with b12 and b13, two broadly neutralizing antibodies, and resolve their crystal structures 
(22, 23). Inspired by these approaches, we set out to engineer a stabilized complex of 
gp120 and peptide triazoles. Introduction of engineered mutations in such a flexible 
target protein may have the side-effect of affecting its folding properties, as may have 
happened for the b12-bound complex (44, 45). Therefore, we hypothesized that covalent 
conjugation of the peptides onto gp120 would possibly ameliorate such unwanted effects. 
In addition to its obvious use in acquiring a crystal structure of the PT/gp120 complex, 
such a covalent conjugate might be a useful “bait” to identify antibodies that can cobind 
with PTs by using it as a bait for screening of sera. These antibodies can later be used to 
further stabilize the complex to get a crystal complex. 
This part of the work was the culmination of our computational efforts into learning 
about conformational flexibility mechanisms in gp120 and development of a PT/gp120 
core complex model. We used the model generated in the previous section as a blue-print 
for structure-based design of a PT/gp120 complex. We produced and characterized the 
resulting conjugate and we think the conformational properties of the product suggest that 
it is indeed in a PT/gp120 complex state. We think such a stabilized complex is more 
amenable to efforts towards crystallization. Additionally, since we based our conjugation 
efforts on the computationally generated model of the peptide triazole/gp120 interaction, 
we think this work lends back some support to the validity of the model, too. That in turn 
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can enable us to use the same blueprint to introduce further changes in the complex 
beyond the proof of concept work presented here.  
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Figure 1. Schematic representation of the HIV entry process. Target cell membrane is on the bottom.  
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Figure 2. Various conformations of gp120 core crystallographically resolved to date: (a) CD4/48d-bound 
(b) F105-bound (c) b13-bound (d) b12 and (e) unliganded. (d) and (e) were resolved using a highly 
engineered disulfide-stitched gp120 sequence. The sequence used in (a) contained the pocket filling 
S375W/T257S mutations. Inner domain is shown in red, outer domain in blue and components of the 
bridging sheet in cyan. Gray color depicts the outer domain residues of the F43 pocket (V255, T257, E370, 
F382, Y384, M475, S256bb, S375bb, F376bb and N377bb where the bb suffix indicates backbone atoms) 
which are conformationally invariant between different structures and yellow depicts the inner domain 
(W112) or β20/β21 (W427, I424, N425bb) members of the pocket. 
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Figure 3. Electron tomograms of HIV-1 spike at (a) 20    (8) and (b) 11    (9) resolution. 
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CHAPTER 2: EXPLORING THE CONFORMATIONAL FLEXIBILITY 
MECHANISMS OF CORE GP120 IN THE B12-BOUND STATE
*
 
 
 
 
Abstract  
Using all-atom  simulations,  we examine the role of the I109C/ Q428C 
disulfide “stitch” in altering the conformational distribution of engineered HIV-1 gp120 
core relevant for binding of the broadly neutralizing recombinant antibody b12. In 
particular, we propose that the I109C/Q428C stitch results in a conformational 
distribution favoring an unfolded inner-domain α1-helix upon binding of b12. Using 
targeted molecular dynamics, we show that folded α1 in the b12-bound conformation of 
gp120 is stable both with and without the stitch, but that with folded α1, the stitch 
requires an orientation of the β 2 0 / β 2 1 β20/β21 sheet that is sterically incompatible 
with b12 binding. Forcing β20/β21 into the orientation displayed by the b12-bound 
conformation after folding α1 with the stitch intact results in partial unfolding of α1, 
whereas without the stitch, β20/β21 reorientation does not affect the conformation of 
α1. These findings collectively support the hypothesis that the disulfide stitch shifts the 
conformational distribution of α1 to the unfolded state, meaning an unfolded α1 is not 
a strict requirement of the b12-bound conformational ensemble of gp120’s lacking the 
I109C/Q428C stitch. 
  
                                                 
*
 This part of the work was published as “A. Emileh, C.F. Abrams (2011) A mechanism by which binding of the broadly neutralizing 
antibody b12 unfolds the inner domain α1 helix in an engineered HIV-1 gp120, Proteins: Structure, Function, and Bioinformatics 
79(2):537-546” 
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Introduction  
Human immunodeficiency virus (HIV) is decorated on its surface by spike-like 
glycoprotein complexes, which mediate viral entry into cells and are therefore targets for 
developing entry inhibitors and vaccines (7, 17, 46). Each envelope spike is a trimer of 
dimers of transmembrane gp41 and the highly glycosylated gp120, which is 
noncovalently linked to gp41 (4, 7). The first crystallographically resolved conformation 
of HIV-1 gp120 showed the deglycosylated core gp120 in a ternary complex with a 
soluble form of its cognate receptor CD4 and an antibody surrogate (17b) for a 
mandatory coreceptor (18, 19, 47) (Figure 4a). In this “activated” state, gp120 assumes a 
two-domain topology where the inner and outer domains each contribute two  -strands to 
the so-called bridging sheet, which is the site of coreceptor binding (18). The inner 
domain mediates association with gp41 (22). The two domains and the bridging sheet 
come together around a small but functionally important cavity, which is capped by F43 
of bound CD4 (18).  
Binding of CD4 to gp120 is accompanied by an unusually large negative change in 
entropy (    = 38–44 kcal/mol at 37°C), which indicates structuring of gp120 out of 
more flexible unliganded conformations (21-23, 46). About half of this structural 
rearrangement can be attributed to folding of the bridging sheet (21). Despite the absence 
of an unliganded HIV gp120 structure, it has been argued that the inner domain must go 
through major conformational changes upon CD4 binding, possibly involving 
independent movements of distinct structural motifs (48). One possible structural basis 
for such movements can be inferred from the structure of gp120 in complex with the Fab 
fragment of the recombinant broadly neutralizing antibody b12 (23) (Figure 4b). 
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Relative to CD4, b12 binding to gp120 is associated with an almost seven times smaller 
negative change in entropy (15). The small entropic penalty gp120 pays upon binding 
b12 is thought to be the key to b12’s unique neutralizing ability, because it renders the 
“conformational masking” defense of gp120 less effective (15). However, the lack of 
conformational fixation also works against crystallization of a gp120/b12 complex. To 
circumvent this, Zhou et al. introduced various stabilizing mutations in the gp120 
sequence, which limited its conformational flexibility (23): four cysteine mutations, 
which created two interdomain disulfide bridges, and five so-called pocket filling 
mutations, all of which enhanced structural stability of the activated conformation. When 
considering the CD4-bound activated conformation, the engineered disulfide at 
I109C/Q428C “stitches” the tip of the loop connecting the β20/β21 strands of the 
bridging sheet to the α1 helix of the inner domain (Figure 4a). 
In the b12-bound conformation, the β20/β21 strand is flipped compared with the 
CD4-bound state and the hydrogen bond registry is shifted by one or two residues. Also 
the β2/β3 part of the bridging sheet is completely absent from the crystal structure, 
suggesting it is unstructured (23). The outerdomain, excluding the β20/β21 excursion, has 
essentially the same structure in the two conformations. In contrast with the CD4-bound 
inner domain, the α1 helix is almost completely unfolded in the b12-bound structure, 
except for a turn near its C-terminus. Evidently, b12 binding abolishes the ability of 
gp120 to form the bridging sheet, as is supported by b12/17b competition assays (49) and 
it makes contacts with the β20/β21 strands but does not contact any residues in the inner 
domain (23). It is worth noting that within the impressive collection of gp120 
conformations crsytallographically resolved to date (18, 22, 48) only two highly 
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engineered gp120’s have an unfolded α1 and these are the ones in complex with b12 and 
b13 (a closely b12-related mAb with lower neutralization ability (22)). It is therefore 
puzzling why there is an apparent link between b12 binding and an unfolded α1-helix. 
The purpose of this article is to use all-atom simulation to explore the hypothesis that 
unfolding of the α1 helix in engineered gp120’s is likely favored by the simultaneous 
presence of the disulfide mutation that stitches α1 to the β20/β21 half of the bridging 
sheet and b12 binding which, through this stitch, couples the movement of β20/β21 to α1. 
We characterize the extent to which the presence of the disulfide bridge between β20/ 
β21 and α1 couples their movements together, and we demonstrate that in the absence of 
this disulfide stitch, the helical conformation of α1 can remain unaltered upon b12 
binding. 
 
Methods 
All structural manipulations and molecular dynamics simulations are performed 
using the software package NAMD 2.7b (50) and the CHARMM22 force-field (51). 
HxBc2 strain gp120 core coordinates for the activated conformation were taken from 
the ternary crystal structure of gp120/CD4/17b (PDB 1GC1). Core is deglycosylated with 
GAG replacements in place of V1/V2 and V3 loops and lacks some residues from the N 
and C-termini (18). Initial coordinates for the b12-bound conformation of core gp120 
were taken from the crystallographic data of the gp120/b12 complex (PDB code 2NY7). 
Compared with the wild-type activated structure of gp120, this structure lacks some parts 
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of β2/β3 and the base of the V1/V2 loop in addition to the V4 loop. Missing residues 
were modeled in silico as an unstructured loop. We refer to this structure as “the stitched 
conformation” or “DS1.” Using the same crystal structure, we reverted the I109C/Q428C 
pair of mutations to arrive at the “DS1F123” sequence (23) which lacks this stitching 
disulfide bridge. We refer to this latter structure as “the nonstitched conformation” or 
“DS1*”.  
In all production MD runs, the system was solvated in a TIP3P (52) water box 
(83x89x81     for DS1 and 83x88x81    for DS1*), which resulted in a system of 56,000 
atoms. Neutralizing Na
+
 and Cl
-
 ions were added (total concentration of NaCl 0.025M). A 
2-fs timestep was used in the integrations. The temperature was set to 310 K by coupling 
all the nonhydrogen atoms to a Langevin thermostat with a friction constant of 5 ps
-1
. 
Nonbonded interactions were cut off beyond 9    and smoothed to zero beginning from 8 
  . PME long-range electrostatics with a grid spacing of 1    were used and all bonds 
involving hydrogens were constrained using RATTLE (53). Equilibration runs were 
performed using a Nose´-Hoover Langevin piston (54, 55) at 1 bar. All the initial 
configurations were first subjected to 20,000 steps of minimization and then 20 ns of 
equilibration. The end results of these initial equilibrations were used as starting points 
for targeted molecular dynamics (TMD) runs. 
In TMD, the protein is driven from a given initial conformation to a given target 
conformation through the application of a time-dependent restraining force (56). As 
implemented in NAMD, this steering force is applied to the system through a potential of 
the following form: 
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                       (1) 
where RMSD(t) is the instantaneous best-fit root-mean-squared deviation from the target 
conformation, and RMSD*(t) evolves linearly from the measured initial value to the final 
desired value of zero. k is the force constant, and N is the total number of atoms being 
forced. Our first goal was to generate a folded α1 helix as in the activated conformation 
with as many of the inner/outer domain contacts in place and as few perturbations in the 
outer domain and the F43 pocket residues as possible. All the heavy atoms of the α1 helix 
(residues 100–116) and a small part of the strand connecting the β3 and b4 motifs 
(residues 208–212) were subjected to TMD forces. This part of the strand forms a small 
but very stable b-sheet with lower portions of α1 and preliminary results showed that 
when α1 is forced through TMD into an a-helix, this strand is deformed and moves 
between the outer and inner domains and prevents formation of some crystallographic 
contacts (compared with the activated structure) between the two domains. In addition, 
all the heavy atoms of the a5 helix were used as an “anchor” to place α1 in the correct 
orientation (referenced to the activated structure) with respect to the outer domain. TMD 
runs were performed for 5 ns with a spring constant of 500 kcal.mol
-1
   -2 and with the 
barostat turned off. To create the target structures, the initial structure was aligned over 
the corresponding CD4bound conformation using the outer domain with PDB 2NY0 used 
for the nonstitched sequence and 2NY5 used for the stitched sequence, respectively. For 
each TMD run, upon completion, the barostat was turned on and the systems were 
subjected to 20 ns of equilibration. Finally, to examine β20/β21 movement in the context 
of the α1-folded 2NY7 structure, all heavy atoms of this domain were forced back to their 
crystallographic positions. As the RMSD values between the starting and end structures 
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is very small and to perform the simulation in a reasonable amount of time, the k value 
for this TMD run was set to 5000 kcal.mol
-1
   -2. Table 1 provides a summary of all 
simulations. 
 
Results 
MD equilibration of DS1 and DS1* gp120 
Figure 5 shows domain-specific RMSD for outerdomain-aligned DS1 and DS1* 
from 20 ns standard MD trajectories. As can be seen in Figure 5a, the DS1 outer domain 
has a very low (≤ 1   ) value of RMSD, which is comparable with the values reported 
previously for the activated gp120 conformation (57). The DS1 inner domain is also 
fairly stable, despite α1 lacking the helical structure it has in the activated conformation. 
Only the backbone W112.N-I108.O hydrogen bond near the C-terminus of α1 is present 
during the simulation and the rest of the segment lacks secondary structure. β2/β3 was 
modeled as an unstructured loop (see Methods Section) and its high RMSD values are 
therefore not surprising. More interesting is the RMSD trace of the β20/β21 hairpin. As 
was mentioned before, β20/β21 in the b12-bound structure is not in the same b-hairpin 
conformation as in the activated state. Carrying one of the building blocks of the 
functionally critical F43 pocket in the CD4-bound structure, namely the side-chain of 
W427, β20/β21 is tightly bound to the core of the molecule in the activated state crystal 
structures (57, 58). Despite being covalently linked to α1 in DS1, β20/β21 is flipped and 
also fairly flexible in the b12-bound conformation. This point is more pronounced in 
DS1*, which lacks the covalent bond stitching β20/β21 to the inner domain. The RMSD 
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traces of DS1* are displayed in Figure 2(b). When only the I109C/Q428C mutations are 
reverted back to wildtype, β20/β21 becomes significantly more mobile, reflected in the 
RMSD upturn of DS1* β20/β21 after 15 ns. The root mean squared fluctuations (RMSF) 
of Ca atoms in β20/β21 are increased on average by >70% (not shown). Removal of the 
covalent link also increases the RMSD of the inner domain. Relieving the constraints 
imposed on α1 by the stitch to β20/β21 is expected to result in increased conformational 
freedom which contributes to the increased RMSD of the inner domain in DS1*, so these 
results are not surprising. 
In contrast to the case of DS1, wherein β20/β21 is restrained by α1 and the bottom of 
α1 is restrained by stitching to β20/β21, in DS1* these two structural elements show large 
(≈10   )  amplitude movements while maintaining their internal structure. In particular, 
the W112.N-I108.O hydrogen bond of α1 is stable and maintains partial helicity of the C-
terminus of α1, whereas β20/β21 shows very small intradomain RMSD, which 
demonstrates its internal structural stability. 
To get a better understanding of the fluctuations in α1 and β20/β21, we measured the 
distances of both β20/ β21 and the C-terminus of α1 from the core of gp120. We used the 
center of mass of residues 108–112 as representative of the position of C-terminus of α1 
and the coordinates of the Cα atom of residue G431 as representative of β20/β21, 
respectively. The Cα atom of residue S257 was chosen as a representative of the 
hydrophobic core of gp120. The results are shown in Figure 6. In DS1, the α1 and 
β20/β21 domains have an almost constant distance from the core of the molecule but 
toward the end of the simulation, larger (≈6  ) fluctuations start to develop in the 
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β20/β21-core distance despite the α1-core distance staying almost constant. In DS1*, the 
C-terminus of α1 (particularly I108) enters the hydrophobic pocket of residues around the 
putative F43 pocket temporarily, whereas β20/β21 stays very close to this area (Figure 
7). But when β20/β21 starts to move away from this region (as can be seen from the 
increase in β20/β21-core distance around 14 ns), α1 moves back to its starting location 
relative to the core. 
Although the movements of the bottom part of α1 in DS1* structure do not seem to 
result in a significant net change in the orientation of this domain relative to the core, 
despite its fluctuations, a closer look at the residues in this part of the molecule suggests 
that the correlated movement of the bottom part of α1 with β20/β21 may result in a 
earrangement of these constituents relative to one another. This can be better viewed in 
light of the change in residue specific solvent accessible surface area (SASA) and its 
evolution throughout the trajectory. As a measure of SASA, we use the fractional SASA 
(FSASA) in which the SASA value computed for each residue is normalized to the value 
that residue has in a small standard tripeptide (59). A residue is considered buried if 
FSASA < 0.1, somewhat exposed if 0.1 < FSASA < 0.4 and fully solvent exposed if 
FSASA > 0.4 (18). From the FSASA trace for the residues 108–112 and 423–435, those 
that showed significant changes in surface exposure were three hydrophobic residues: 
I108, I109, and L111. The FSASA trace for these residues is shown in Figure 8 along 
with W112 as a reference buried residue. In DS1, the FSASA values stay more or less 
constant with regard to the surface exposure limits defined above, although some 
decrease in FSASA toward burial (FSASA < 0.1) is observed for the hydrophobic side 
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chains of I108 and I109. In contrast, FSASA values behave much differently in the DS1* 
structure. 
Although FSASA fluctuations of I108 are similar to the stitched case, I109 and L111 
become much more buried in DS1*. These changes are accommodated by movement of 
β20/β21 away from the core, which leads to exposure of Q428 and burial of I109 and 
L111. These changes seem to suggest that the disulfide bridge in the b12-bound 
conformation might have trapped some hydrophobic residues on the unstructured α1 in a 
solvent exposed state when b12 is bound. This restraint is relaxed when the disulfide 
bridge is removed, and the β20/β21 is allowed to move away from the gp120 
hydrophobic core. 
 
Folding the α1 helix using TMD 
TMD runs were performed to fold the α1 helix. After folding the helix, the structure 
was relaxed by equilibration for 20 ns. Figure 9 shows the RMSD trace of the relaxation 
process. As expected, the outer domain remains fairly stable and most of the relaxation 
takes place in the inner domain and to some (lesser) degree β20/β21. The intradomain 
RMSD of α1 shows that the helical structure is fairly stable with the helix as a whole 
moving slightly relative to the rest of the molecule. 
Examining the DS1 and DS1* TMD trajectories, it can be seen that folding of α1 
brings β20/β21 closer to the core of the molecule in both cases. To quantify this, the 
distance between Cα atoms of G431 at the tip of β20/β21 and T257 as a representative of 
the hydrophobic core around the F43 pocket was measured, and the results are shown in 
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Figure 10. The G431–T257 distance decreases during the TMD run for both cases: for 
DS1, it decreases from 23.4 to 13.4   , and for DS1*, it decreases from 26.2 to 17    . 
After TMD steering forces are lifted and the structures are left to equilibrate, almost the 
same difference between the two structures remains: β20/β21 in the stitched DS1 stays 
closer to the core (4     closer).  
Steric constraints imposed by b12 on the folding of α1 in the “stitched” 
structure  
We have shown that when α1 is folded, the stitch causes β20/β21 to move closer to 
the core compared with the nonstitched case. This raises the question of whether or not 
the position of β20/β21 in the stitched α1-folded structure could interfere with the 
binding of b12. To investigate this, we aligned the gp120 outer domain of the 2NY7 
crystal complex over gp120 of the simulation. Repeating this frame-by-frame, after 
removal of the crystal complex gp120, we produced a combined trajectory in which b12 
is overlaid on gp120. To count overlaps, at each frame and after alignment, those heavy 
atoms of b12 that were closer than 2.0    to β20/β21 domain atoms were counted as 
overlapping atoms. Each pair of overlapping atoms was counted as one overlap. As 
shown in Figure 11, we observe a drastic difference between the amount of overlap 
resulting from folding of α1 in the context of the stitched DS1 structure compared with 
the nonstitched DS1*, with folding of α1 in the stitched case resulting in  16 times more 
total overlaps. 
 
Repositioning β20/β21 with TMD after folding of α1 
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We have shown here that forcing α1 to fold in DS1 results in strong clash of β20/β21 
with an aligned b12. This raises the question whether or not forcing β20/β21 back out of 
collision with b12 results in unfolding of α1. To test this, we began with the end-point 
coordinates of the equilibrated, α1-folded DS1 simulation and launched a TMD 
simulation to force β20/β21 back to its 2NY7 crystal structure position relative to the 
core. 
As is seen from Figure 12, β20/β21 is moving away from the core during TMD, as 
shown by the G431.Cα-S257.Cα distance. β20/β21 does not reach its target conformation 
during the 2 ns TMD performed here and stays a bit closer to the core than what is 
expected. Nevertheless, we observe the destruction of at least five major backbone 
hydrogen bonds in the middle of α1, which kinks the helix (Figure 13). We did not 
perform the same TMD run on DS1*, because the end conformation of β20/β21 after 
TMD of α1 and equilibration is already farther away from the core compared with 
original 2NY7 crystal structure, so moving β20/β21 to its crystal structure position is 
equivalent to moving the domain closer to the core. TMD of α1 already showed this will 
not disrupt α1 folding in DS1*. 
 
Discussion 
According to Zhou et al., the DS1* sequence did not yield a b12-bound crystal 
structure despite lacking only one disulfide linkage compared with DS1, which yielded 
the 2NY7 structure (23). Successful crystallization was attributed to the reduced 
flexibility of the molecule, which was achieved in part by stitching the α1 and β20/β21 
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domains together. Our results are in line with the rationale for addition of this key 
constraint to the gp120 sequence, which seems to significantly affect interdomain 
fluctuations of various components of the molecule that seem to be necessary for shaping 
the F43 pocket. In particular, the DS1* mutant shows higher RMSD values for α1 and 
β20/β21 relative to the rest of the molecule (i.e., core). In its CD4-bound form, the pocket 
is made up by contributions mainly from the outer domain, W112 of the inner domain 
and W427 of the β20/β21 strand (18). In all HIV-1 gp120 conformations resolved to date, 
the outer domain components are conformationally rigid, suggesting that the 
conformationally labile components of the pocket are contributed by the inner domain 
and the bridging sheet. The 2NY7 structure shows W112 in relatively close proximity to 
its activated state position (although tilted) but the highly conserved W427 faces outward 
and away from the pocket, in contrast to its orientation in all other structures. Analysis of 
the equilibration run for DS1* suggests that the disulfide bridge is to a large extent 
responsible for bringing the various hydrophobic residues around the pocket together 
(although in a different conformation compared with the activated state) and when 
removed, the free gp120 structure tends to relax at least some of the constraints imposed 
by the disulfide bridge. This relieving of constraints is explicitly observable through the 
relaxation of the β20/β21 strand and large fluctuations (4    ) of the α1 domain toward 
and away from the core (Fig. 3). Recently, it was suggested that gp120 is structured in 
layers, which both contribute to its unusual conformational diversity and also mask the 
functionally important domains from the immune system (45, 60). This model suggests a 
conformationally plastic inner domain. The observations that even in such highly 
engineered gp120’s as those investigated here, which are “mutationally stabilized” (23), 
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we see two states of α1 (folded and unfolded) and also the mobility of the C-terminal end 
of α1 in its unfolded from, are both consistent with the above model. 
Among all gp120 conformations resolved to date, only those from the mutagenically 
stabilized ones in complex with b12 or b13 show an unfolded α1 (22, 23). The flipped 
β20/β21 in these structures (compared to the canonical CD4-bound conformation), the 
existence of a bridge from β20/β21 to the C-terminus of α1, and the proposed plasticity of 
the inner domain of gp120 all point to a possible correlation between the existence of the 
disulfide link and unfolding of α1 in the engineered mutants. To investigate this 
hypothesis, we attempted to fold α1 using TMD in both the stitched DS1 structure (2NY7 
PDB) and an in silico created mutant lacking the I109C/Q428C mutation (DS1*). The 
results of folding α1 were analyzed after equilibration of the structure to relax the 
perturbations introduced by application of TMD forces. The resulting conformations 
were found to be stable, especially when the helicity of the α1 domain was considered. 
This shows that the ensemble of conformations adopted by gp120 when bound to b12 is 
diverse enough to allow for a folded α1. This is also in line with the proposed plasticity 
of the inner domain in that it shows both the folded and unfolded α1 are stable (within the 
time frame of simulation) even in the context of the conformationally stabilized gp120’s 
considered here. These mutants were made to be structurally rigid and yet they still show 
conformational diversity in the inner domain. It is plausible that in wild-type gp120, with 
the stabilizing mutations removed, inner domain will be even more flexible, possibly 
incorporating folding/unfolding transitions of α1. 
From the crystal structure of b12-bound gp120, it can be seen that b12 latches on to 
the CD4 binding loop. Although β20/β21 in DS1 and DS1* is not in its activated state 
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conformation, folding of α1 moves β20/β21 closer to the core of the molecule in the 
stitched structure of DS1 because of the disulfide bridge, because this movement is less 
profound in DS1*. When combined with the stability of the folded α1 in both structures, 
one arrives at the conclusion that when β20/β21 is coupled to α1 through the disulfide 
bridge, binding of b12 and the slight “push” it exerts on β20/β21 may favor the unfolded 
state of α1 in these engineered mutants. We were interested to see whether simple steric 
constraints support this conclusion or not. When b12 is overlaid on the TMD runs, it can 
be seen that the TMD run of DS1 produces a large amount of steric overlap, which when 
combined with the β20/β21-core metric, suggests that movement of β20/β21 away from 
the core is required for b12 binding. It was found that DS1* has almost a four-fold larger 
on-rate for binding of b12, relative to DS1, which yielded the 2NY7 structure (compare 
DS1F123 and DS12F123 sequences in reference (22, 23)). This provides support to our 
finding that in DS1, the tighter association of β20/ β21 with the core provides a smaller 
window of opportunity for b12 to bind, considering the natural movements of β20/ β21 
toward and away from the core observed in both DS1 and DS1* equilibrations. Also, 
these data suggest that stabilized gp120 is flexible enough to allow for a folded α1 in the 
context of the b12-bound conformation, but when the I109C/Q428C stitch is introduced 
in the sequence, the resulting coupling of α1 and β20/β21 movement helps b12 translate 
its influence on β20/β21 conformation to α1, which may favor its unfolding.  
Finally, to directly test this idea, we used TMD to reposition β20/β21 back to its 
crystallographic position in α1-folded DS1 and observed that indeed α1 starts to unfold. 
This lends support to our hypothesis that although a folded α1 is stable in both the 
disulfide-stitched and  non-stitched  structures,  movement  of stitched β20/β21 
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away from the core to make room for binding of b12 can displace the equilibrium 
between the folded and unfolded α1 in favor of the unfolded state in the stabilized 
gp120’s studied here. 
 
Conclusions 
We have used MD and TMD simulations to show that introduction of the 
I109C/Q428C disulfide bridge between the α1 helix and β20/β21 in an engineered HIV-1 
gp120 leads to coupling of the natural fluctuations of the two domains and limits their 
mobility, especially restricting the motions of β20/β21 away from the core of the 
molecule and the hydrophobic patch of residues around the F43 pocket. Additionally, we 
used TMD to fold α1 both with and without the disulfide stitch. Our results suggest that a 
conformation with α1 folded is stable both in the presence and absence of the disulfide 
stitch. We find such a conformational plasticity of α1 even in the stabilized mutants, 
consistent with recent findings suggesting a conformationally plastic inner domain in 
wild-type gp120 (45). Folding α1 forces β20/β21 closer to the core of the molecule in the 
disulfide stitched mutant. When b12 is overlaid on such a conformation, a significantly 
larger number of atoms overlap between b12 and gp120. These overlaps suggest that 
binding of b12 and subsequent pushing of β20/β21 away from the core, possibly coupled 
with the pocket-filling mutations, which stabilize the bottom part of α1 close to the core, 
may contribute to α1 unfolding. To support this, we pushed β20/β21 away from the core 
in the α1 folded state of the b12-bound conformation and observed that indeed such a 
movement of β20/β21 leads to unfolding of α1. These results suggest that although b12 
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does not contact the inner domain, its effect on the conformation of β20/β21 (compared 
with the CD4-bound state) is transmitted to α1 through the disulfide bridge of 
I109C/Q428C. This was not observed when the disulfide bridge was removed. Therefore, 
in the absence of such a stitching disulfide, α1 may be able to shuttle freely between 
folded and unfolded states, even when b12 is bound. This provides an alternative picture 
of b12-bound gp120 and can be used for better design of engineered gp120 constructs, 
which might be used as improved immunogens (46). 
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Table 1. Summary of the runs discussed in this work.  
Designation Explanation 
DS1.eq equilibration (20 ns) of the b12-bound conformation of the stitched gp120 
mutant 
DS1*.eq equilibration (20 ns) of the b12-bound conformation with the I109C/Q428C 
mutation removed 
DS1.tmd all-heavy-atom folding (5 ns) of α1 in DS1 followed by equilibration (20ns) 
DS1*.tmd all-heavy-atom folding (5 ns) of α1 in DS1* followed by equilibration 
(20ns)  
DS1.β20β21  fter equilibration of DS1.tmd run, β20/β21 is moved back to its crystal 
structure state (2 ns) 
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Figure 4. (a) CD4-bound (PDB 1GC1) and (b) b12-bound (PDB 2NY7) conformations of gp120. The inner domain 
is red, outer domain blue, and the bridging sheet cyan. In (b) licorice rendering shows the two disulfide bridges 
(hydrogen atoms not shown) between the inner and outer domain and the residues shown in transparent van der 
Waals are the other stabilizing mutations (M95W, T257S, S375W, A433M). The dashed lines show the unresolved V4 
domain in both structures and also parts of the (a) CD4-bound (PDB 1GC1) and (b) b12-bound (PDB 2NY7) 
conformations of gp120. The inner domain is red, outer domain blue, and the bridging sheet cyan. In (b) licorice 
rendering shows the two disulfide bridges (hydrogen atoms not shown) between the inner and outer domain and the 
residues shown in transparent van der Waals are the other stabilizing mutations (M95W, T257S, S375W, A433M). The 
dashed lines show the unresolved V4 domain in both structures and also parts of the β2/β3 domain and base of the 
V1/V2 loop in the b12-bound c o n f o r m a t i o n .  
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Figure 5. Cα RMSD trace of different gp120 domains after alignment using the outer domain: (a) 
disulfide-”stitched” structure and (b) nonstitched structure.  
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Figure 6. Distance of (a) α1 and (b) β20/β21 from the Cα atom of core residue S257 during equilibration 
of DS1 and DS1*. β20/β21 is represented by the Cα atom of residue G431 at its tip. α1 is represented by 
the center of mass of residues 108–112. 
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Figure 7. Hydrophobic residues in and around the putative F43 pocket in the DS1* structure. Residues in 
red make up the F43 pocket.5 Residues shown in yellow are hydrophobic residues within 10     of residue 
382 and taken to be close to the pocket. The position of the β20/β21 domain at the beginning (red) and 
end (blue) of the DS1* equilibration is shown in cartoon rendering.  
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Figure 8. Evolution of fractional solvent accessible surface area (FSASA) for residues at the bottom of 
α1. The dashed lines at 0.1 and 0.4 show the limiting values for definition of buried and exposed 
residues. 
 
  
41 
 
 
CHAPTER 2: EXPLORING THE CONFORMATIONAL FLEXIBILITY MECHANISMS OF CORE GP120 IN THE 
B12-BOUND STATE 
 
Figure 9. Equilibrium backbone RMSD evolution after removal of the TMD forces. Each frame in the 
trajectory is aligned over the first frame of equilibration (i.e., last frame of TMD forcing) using the outer 
domain backbone. 
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Figure 10. Movements of the β20/β21 strand relative to the core as measured by the distance G431.CΑ-
T257.CΑ, during TMD and post-TMD equilibrations. The small arrow at 16.95  ˚ shows the value of the 
metric in the CD4-bound crystal structure (1GC1) of gp120. The vertical line indicat es the transition 
from TMD to equilibration. 
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Figure 11. Number of overlapping pairs of atoms resulting from overlaying b12 on α1-folded gp120. The 
raw data were smoothed using a triangular average method with a sampling window  size of 0.5 ns. The 
vertical line indicates where the TMD forces are lifted and equilibration is started. The small arrow at n 
5 6 overlaps shows the number of overlaps generated when using gp120 extracted the from CD4 -bound 
crystal structure (PDB 1GC1). 
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Figure 12. Distance between Cα atoms of G431 and S257 when β20/β21 is repositioned. The small arrow 
at 16.8     indicates this distance in the 2NY7 crystal structure of stitched gp120. Also plotted is the 
number of b12/gp120 overlaps (smoothed with a sampling window size of 0.02 ns) . 
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Figure 13. (a) Schematic representation of how β20/β21 was moved when it was pushed away from the 
hydrophobic core in DS1. Representative frames with a sampling rate of 1 frame per 0.5 ns are shown in 
tube rendering with the starting state in red and the final state in blue (only the β20/ β21 region is 
depicted, the coordinates of the rest of the molecule are from the starting frame). β20/β21 from the 
crystal structure is shown in blue cartoon rendering. (b) α1 helix conformation during the TMD run with 
red showing the domain in the beginning and blue in the end of the simulation. At least five hydrogen 
bonds are destroyed. 
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CHAPTER 3: TARGET-BLIND SAMPLING OF CD4-NAÏVE 
CONFORMATIONS IN CORE GP120
*
 
 
 
 
Abstract 
The surface envelope glycoprotein spikes of HIV are necessary for initiation of host 
cell infection. One major component of the trimeric spike, the glycoprotein gp120, has 
been suggested to be very flexible and conformationally diverse. Yet, essentially all 
crystallographically determined conformations of HIV-1 gp120 correspond closely to the 
“activated”, CD4-bound state.  In order to suggest possible models of unactivated gp120, 
we used Temperature Accelerated Molecular Dynamics (TAMD) to explore the 
conformational space of gp120, within the bounds of a recently proposed layered 
topology of the gp120 inner domain. We tuned the TAMD parameters so that the 
secondary structure was conserved as well as in standard MD runs, while conformation 
space exploration was significantly enhanced, as measured by RMSD deviation from the 
activated state. TAMD target-blind conformational search lead to a conformation within 
4.3     RMSD of a crystal structure of monomeric core gp120 bound to the antibody 
F105. Opening of the layers and plasticity of layer-2 (residues 97 to 221) were observed 
to be major contributors to conformational diversity. Opening of the layered structure led 
to exposure of conformationally sensitive antibody epitopes that are buried in the CD4-
bound state. Based on the conformational repertoire we generated, we propose a model 
for how gp120 relays conformational perturbations introduced by CD4 binding to the 
                                                 
*To be submitted with revisions to PLOS ONE as “Emileh,  . and  brams, C.F.  tomistic models of unliganded core HIV-1 gp120 
monomer from Temperature  ccelerated Molecular Dynamics (T MD)” 
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inner domain and possibly how such perturbations may lead to activation of gp41. 
 
Introduction 
Based on the structure of ref. (20), it has been proposed that gp120 is topologically 
configured as a layered structure, resembling the leaves of a book. In such a 
conformation, a β-sandwich makes up the book “spine” while different domains emanate 
from it: layers 1-3 make up the inner domain and the outer domain is connected to the 
rest of the structure through layer-3 (Figure 14). Based on this picture, it was suggested 
that shuffling of the layers contributes to the extraordinary plasticity of gp120 (20).  
Out of about 20 crystal structures of HIV-1 gp120 published to date, only three have been 
crystallized in a conformation other than the activated, CD4-bound conformation(22, 23, 
61), with another crystal structure with the unliganded gp120 from a homologous simian 
virus (48). Of those three liganded structure with HIV gp120, only one utilized the wild-
type (WT) sequence. That complex, with the poorly-neutralizing F105 antibody, displays 
a dissociated bridging sheet, exposing the conserved hydrophobic pocket in the core of 
the molecule (Figure 15a) (22). It was suggested that this conserved pocket was the focal 
point for binding of many CD4-binding site (CD4BS) antibodies (22). The other 
conformations were resolved using two highly engineered sequences which were 
designed to stabilize the presumably flexible gp120 into conformations amenable to 
crystallography (23). In these conformations, again the bridging sheet was absent, and 
more drastic changes were present in the inner domain (partially unfolded α1), consistent 
with the notion of a plastic inner domain (Figure 15b-c)(20, 45). Considering the 
plasticity of the inner domain, the significant perturbations introduced in the inner 
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domain of these engineered structures might be a caveat in inferring the unliganded 
structure, especially in the context of the trimeric spike (45). 
Considering the large conformational changes accompanying CD4 binding to gp120, it is 
reasonable to conclude that the activated structure may not provide the best target for 
rational design of entry inhibitor and immunogens (46, 62, 63). The impressive collection 
of gp120 conformations resolved, along with the thermodynamic signature of flexibility, 
imply that the unliganded state is not one conformation, but an ensemble of very flexible 
structures. Indeed, such conformational diversity has been suggested as a mechanism of 
viral defense against host immune response (15, 62). Previously it has been suggested 
that the activated state gp120 is very stable and does not change significantly during 
standard molecular dynamics (MD) (42, 57, 58, 64). Recently though, Temperature 
Accelerated Molecular Dynamics (TAMD) was utilized to explore a range of 
conformations outside the stable conformational space of the activated state(42). Here, 
we extend the use of TAMD in exploring the conformational diversity of gp120 by 
directly implementing the layering hypothesis into the simulation setup, hence testing 
whether the suggested layer shuffling can be used to further expand the conformational 
space outside the limited set crystallized to date. We show how TAMD can be tuned to 
successfully “unlayer” the activated-state gp120 and expose conformational antibody 
epitopes which are buried in the CD4-bound conformation. Using the sampled snapshots 
of such unliganded conformations, we propose a mechanism which may explain how 
gp120 incorporates layer plasticity to relay conformational changes from the invariant 
outer domain to the inner domain and perhaps gp41, initiating the fusion process.  
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Methods 
Simulations 
All molecular dynamic simulations were performed using the CHARMM22 force 
field (51, 65) and the NAMD v2.7 software package (50). Structural manipulations and 
analyses were done in VMD (66). Principal Component Analysis (PCA) was performed 
using MATLAB (The Mathworks Inc.). 
 All simulations used a 2 fs timestep. The temperature of the atomistic system was set to 
310 K by coupling all non-hydrogen atoms to a Langevin thermostat with several values 
of the friction coefficient γ (discussed below). Non-bonded interactions were cut-off 
beyond 9     and smoothed to zero beginning from 8   . PME long-range electrostatics 
with a grid-spacing of 1    were used and all bonds involving hydrogens were constrained 
using the RATTLE algorithm (53). The pressure was fixed at 1 bar using a Nose´-Hoover 
piston (55).  
 Theoretical background and implementation details of TAMD are provided elsewhere 
(42, 43). Briefly, in TAMD sets of auxiliary variables coupled to collective variables 
(CVs) are evolved in time according to their own equations of motion, which here we 
have taken as diffusive. The dynamics of the atomistic system are coupled to those of the 
auxiliary variables according to: 
 
       
     
   
      
     
   
    
   
 
                     (1) 
            
                        (2) 
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where mi and xi denote the mass and position of particle i in the atomistic system; V(x) is 
the interatomic potential;   
     is a CV with mass     and θj is its corresponding 
auxiliary variable. η is the thermal noise at the physical temperature β-1.   is a fictitious 
friction coefficient for the system of slow variables evolving at the fictitious temperature 
   and ξ is the thermal noise at this temperature. The advantage of TAMD is that if (a) κ 
is large enough that               and if (b)   is sufficiently large so that the slow 
variables indeed evolve slowly relative to the fundamental variables, then the first  term 
on the right-hand side of equation (2) will be approximately equal to minus the gradient 
of the free energy: 
 
         
     
   
                 (3) 
 
This implies that TAMD can enable a hyperthermal (fast) exploration of the physical 
free energy landscape. TAMD runs were launched from the end conformation of standard 
MD equilibrations. Equilibration was assessed based on RMSD saturation (Supplements 
Figure 16). 
 
Systems 
HxBc2 strain gp120 core coordinates for the CD4-activated conformation were 
extracted from the gp120/CD4/48d complex (PDB 3JWD). “Core gp120” is 
deglycosylated and the V1/V2 and V3 loops are replaced with GG and GAG linkers, 
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respectively (20). It is worth noting that this structure does contain the N- and C-termini 
and the gp41-interacting regions which were missing in the previous structures (18, 22, 
23). A stabilizing mutation (S275W/T257S) has been introduced in the sequence which 
was reverted back to the wild-type in silico. The V4 loop residues were also modeled in 
silico. The resulting starting structure was first minimized in vacuum for 10000 steps 
with all but the regrown V4 loop fixed. Then the protein was solvated in a TIP3P (52) 
water box (98x86x113    ) containing neutralizing Na+ and Cl- ions to a total 
concentration of 0.025 M, resulting in a system of ~90000 atoms. This system was 
minimized for 20000 steps and equilibrated for more than 40 ns (run #2). 
Coordinates of the HxBc2 gp120 core with nine stabilizing mutations (DS12F123 
sequence of ref (23)) in complex with b12 were extracted from 2NY7 PDB structure, 
minimized and equilibrated for about 20 ns (run #1) as explained elsewhere (44). 
To construct a core gp120 with the nine stabilizing mutations of the DS12F123 
sequence (23) in the activated (CD-4 bound) state; W96C/V275C, I109C/Q428C, M95W, 
T257S/S375W and A433M were introduced into the vacuum-minimized wild-type 3JWD 
structure containing the V4 loop mentioned above in silico. The resulting structure 
(called the “DS12F123 homology model”) was solvated in water (98x86x113    ) and 
0.025 M of Cl
-
 and Na
+
, similar to the wild-type sequence explained before. This system 
was minimized for 20000 steps and equilibrated for ~28 ns (run #3). 
 
Protocols 
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  ,   and κ were the TAMD parameters changed among the runs. σ was calculated as 
the standard deviation of   
        averaged over all collective variables. βcalc was 
calculated from σ as          
  . How close βcalc is to β is taken as a measure of how 
adiabatically separated the auxiliary and atomistic systems are during simulation. We 
defined the percent deviation from perfect adiabatic separation (%Dev) as     
                      . We also changed γ to speed up sampling, using 1 ps
-1
 instead 
of 5 ps
-1
 in some instances.  
Cartesian coordinates of the centers of mass of different sets (blocks) of protein 
residues were used as collective variables (CVs). In an attempt to gain understanding 
regarding the choice of CV's, we considered two major types of subdomain assignment 
schemes. The first (runs #4-25) assigned residues into subdomains based on knowledge 
of secondary and tertiary structure and the layering hypothesis (20): α1, β2/β3, the β-
sandwich, layer-1, layer-2 (excluding α1 and β2/β3) and layer-3 were assigned their own 
single subdomains and the outer domain residues were assigned three similarly-sized 
subdomains (Table 2 in supplements). In runs 20-25 β20β21 was not excluded from the 
outer domain. The second scheme (runs \#26-45) assigned residues into subdomains of 
more or less uniform mass (approx. 1200 Da) using a k-means clustering algorithm that 
minimized each subdomain's radius of gyration. 
We used STRIDE (67) as implemented in VMD to count the number of residues 
involved in the secondary structure of the protein throughout the trajectories. In order to 
better visualize the conformations sampled in the course of TAMD, we mapped them into 
Cα difference distance maps (68). A difference distance matrix was defined as: 
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                             (4) 
 
where di,j,f  is the distance between residues i and j at frame f, with each residue 
represented by its Cα atom. di,j,0  is the value of the distance at frame 0. The N- and C-
termini were not included in the analysis.  
Subdomain positions were recorded during TAMD and all possible intersubdomain 
distances were measured over the trajectory. These were then used to calculate a coarse-
grained distance map of subdomain center-of-mass data. Principal Component Analysis 
(PCA) was performed on this dataset to extract the major contributors to interdomain 
flexibility.  
Fractional solvent accessible surface area (FSASA) (59) was used to gauge solvent 
accessibility of gp120 residues that were experimentally found to be important for 
binding of a panel of conformational antibodies. Our panel included the L100, 15e, A32, 
1125H, 2.1H, m18, 2.2c and 2/11c antibodies, for which there are no structures in 
complex with gp120 (45, 69-74) (For the last two we were only able to retrieve inner 
domain residues important for binding from the literature). A residue with FSASA < 0.1 
is considered buried, a FSASA between 0.1 and 0.4 is considered semi-exposed and 
FSASA > 0.4 is taken as fully exposed (18). Using this information, FSASA values for 
each residue belonging to the experimentally determined antibody epitopes were 
discretized to 0 (buried), 0.5 (semi-exposed) and 1 (fully-exposed) and these discretized 
values were used to visualize the residue-specific FSASA trace of the runs. Also, the 
average FSASA of the epitope residues for each frame (using the continuous FSASA 
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data) was used as a global measure of surface exposure for the whole antibody epitope. 
 
Results 
Wild-type sequence 
Selection of TAMD parameters. We used different values of the fictitious friction 
coefficient (  ), fictitious temperature (  ), spring constant (κ) and the blocking scheme as 
the variable TAMD parameters. Three major criteria were considered for judging whether 
a specific set of TAMD parameters should be considered for further analysis: degree of 
deviation from perfect adiabatic separation (%Dev), the net number of secondary 
structure elements gained or lost (DSStruct) and the extent of conformational exploration 
based on gp120 inner domain conformational sampling (MaxRMSDInner). Based on these 
criteria, we selected the runs listed in Table 3 for further analysis. A complete list of all 
the runs along with a more detailed explanation of selection criteria and various 
parameters explored are included in the supplements.  
Sampling of conformations close to crystallographically resolved structures. The 
runs were screened for Cα RMSD matches between each frame and the crystal structure 
of gp120 in complex with F105 antibody (PDB 3HI1). Alignments were done over the 
structurally invariant outer domain and RMSD was measured for the remaining domains. 
Minimum values for the whole protein, layer-2 and β20β21 are reported in the last 
column of Table 3. Note that these minimums are not necessarily in the same frame. A 
comparison of the different conformations of gp120 resolved to date in complex with 
different ligands shows that the major differences are in the structure of the bridging 
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sheet and the inner domain (18, 20, 22, 23, 48). Therefore, we only used the values for 
layer-2 and β20/β21 and included the whole molecule as a global measure of structural 
similarity. This gave run #4 as the run that sampled a conformation closest to the F105-
bound crystal structure. The total Cα-RMSD from the crystal structure reached 4.3     
after ~3.2 ns from the start of the TAMD trajectory. The RMSD trace and an overlay of 
the crystal structure and the aforementioned TAMD frame are shown in Figure 17. As is 
evident from the RMSD trace, the major differences lie in layer-2 and β20/β21.   closer 
inspection of the “crystal hit” conformation reveals that within layer-2, the major source 
of difference is the floppy β2/β3, which when removed from the total protein Cα RMSD 
difference calculation, results in a reduction of the total distance from 4.3 to 3.1    . It 
should also be noted that this domain contributes an extensive crystal contact surface in 
the crystal structure and previous studies have pointed to its flexibility (58). Moreover, in 
the complete sequence of gp120, this domain provides the stem for the large (~65 
residues) V1/V2 loop. Considering its floppiness, it is not unreasonable that β2/β3 may 
sample conformations in gp120 monomer that are different from the crystal structure. 
Therefore, we maintain that this TAMD run was able to sample a conformation very 
close to the one resolved crystallographically in complex with F105.  
Inter-layer flexibility and opening of the layered structure. Although RMSD values 
provide a useful metric to differentiate among structures, they are not particularly 
informative regarding the interdomain movements and secondary structure changes. In 
order to better visualize the conformations sampled in the course of TAMD, we mapped 
them into difference distance maps (68). Figure 18 shows such a representation of run #4 
at some interesting points in the trajectory as a heat map. Both axes show residue 
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numbers. Major domains are annotated in the figure. Panel (a) shows the first point in the 
trajectory where the β2/β3 starts to dissociate from the bridging sheet. This is reflected in 
an increase in the distance between its residues and almost all the other core atoms, 
except for β20/β21 which is still associated with it. Also due to a subtle and temporary 
sliding down of layer-1 and especially residues in the C-terminus of α0 relative to the 
core, another gap can be observed around layer-1-β2/β3 distance. 
Panel (b) shows a time in the trajectory where β20/β21 is starting to detach from the 
core. The yellow band around y=429-439 showing this event becomes stronger and 
thicker as this domain gets farther from the core (panels b and c). The gap in the band 
representing the distance between β20/β21 and β2/β3 (around x=200 and y=435) starts to 
disappear toward the end of the trajectory, being replaced by a red blob representing a 
separation of the two bridging sheet components. Also evident in this figure is a slight 
separation of the inner and outer domains, represented by two faint rectangular features in 
the top left and bottom right corners. Panel (c) depicts the dissociation of α1 from the 
core, which starts to show as a faint band around residue 63 and then grows thicker in 
time. This domain indeed shows a surprising flexibility which is also seen in the RMSD 
trace of the trajectory is plotted in time Figure 18. Further amplification in separation of 
β2/β3 from the core is evident in panel (d), which also shows further separation of the 
bridging sheet components and also movement of layer-1 toward the β-sandwich.  
Cα-RMSD trace of run #4 shows layer-1 as the most labile domain during the run. 
When it dissociates from its binding pocket between α1 and the β3-β4 backstrand 
(residues 202-214) in layer-2, its flexible connection to the β-sandwich allows it to 
diffuse around the core, effectively exposing the relatively conserved and buried (18) 
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hydrophobic residues of the β3-β4 backstrand (A204, P206, V208, F210, P212, I213, 
P210 and I215). This dissociation of layer-1 from the core and exposure of the β3-β4 
backstrand residues is consistently observed in all the analyzed trajectories.  
TAMD exposes antibody epitopes hidden in the activated structure. All the analyzed 
trajectories lead to “unlayering” of the structure in that the domain components start to 
separate and residues buried in the activated CD4-bound conformation become exposed. 
Some of the gp120 residues found to be important for binding of conformationally 
sensitive antibodies are buried in the activated, CD4-bound structure of gp120 and 
moreover, some of the antibodies do not bind this conformational state of the protein at 
all (i.e. 15e) or bind to it poorly (m18) (23). Here we argue that gp120 residues, the 
mutation of which abrogates or significantly reduces gp120 recognition by 
conformationally sensitive antibodies while maintaining correct folding of gp120, have to 
be at least partially surface exposed in the unliganded gp120. We measured the fractional 
solvent accessible surface area (FSASA) (59) for gp120 residues that were 
experimentally found to be important for binding of a panel of conformational antibodies. 
Sample results for run #9 are shown in Figure 19.  
Relatively larger values of      as in run #9 are expected to result in overcoming of 
larger free-energy barriers (42) and lead to more opening of the structure, presumably as 
a result of breaking more inter-layer interactions. This is indeed the case when the solvent 
exposed area of the protein is measured for run #9 and the results are plotted in Figure 
19. It should be noted that for some of the antibodies (i.e. m18), the bulk of the 
mutational study was focused on the outer domain or β2/β3. Considering the 
conformational stability of the outer domain (18, 22, 57, 64), the putative m18 binding 
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site on gp120 is therefore expected to be both fairly exposed and conformationally rigid, 
if only the point mutation data are taken into account. Figure 19 shows the m18 epitope 
semi-exposed and almost invariable in time. It is interesting that even in this case, an 
average increase in surface accessibility of residues that are initially buried (W479 and 
Y384) or semi-exposed (K207, T257, E370, K421, D474, M475) is observed. The 
conformational rigidity of the experimentally-examined part of the epitope may be 
responsible for flattening of the average FSASA versus time plot. In contrast, for 
antibodies with putative epitopes mainly in the inner domain (211/c, 2.2c and A32) a 
drastic change in the surface accessibility of the epitope from barely-exposed to fully-
exposed is observed in Figure 19. A similar trend is observed in all other runs (not 
shown).  
Similarities to the b12-bound crystal structure of stabilized gp120s. The only 
structures of gp120, other than the F105-bound one, in a conformation that is not 
activated (i.e. is not the same or similar to the CD4-bound structure) are those in complex 
with the b12 and b13 antibodies (22, 23). The caveat in these structures (45) is that they 
are resolved using a “conformationally stabilized” (23) gp120 containing nine cavity-
filling and disulfide-bridging mutations. As shown in Figure 20, taking the activated 
conformation as reference, the α1 helix is increasingly unfolded in b13- and b12-bound 
conformations, respectively. These crystal snapshots point to the floppiness of the C-
terminal end of layer-2. Plus, the bridging sheet is completely absent from both b12- and 
b13-bound conformations. Half of the sheet is made up by β20/β21 which is unfolded in 
the F105-bound conformation, but in the b12- and b13-bound conformations has a 
different hydrogen bond registries. Whereas in the b13-bound conformation β20/β21 is 
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almost unfolded with only the tip held together by non-native (when compared to the 
activated state) backbone hydrogen bonds, in the b12-bound structure this domain is fully 
hydrogen-bonded and also flipped with the conserved W427 sidechain at its tip pointing 
away from the core.  
As we were able to reach within a very close distance of the F105-bound gp120 
conformation by RMSD measures, we were interested to see if the wild-type (WT) 
sequence TAMD trajectories mentioned in the previous section sample conformations 
close to the crystal structure of these two highly mutated conformations too. We 
measured the Cα  RMSD between TAMD conformations and the crystal structures and 
recorded the minimums for the whole structure, layer-2 and β20/β21. The results for the 
b13-bound conformation (3IDX) show that TAMD explores a completely different basin 
in the conformational space than the b13-bound structure as RMSD values diverge 
drastically (data not shown) and increase with time. The results for the b12-bound 
conformation are more encouraging (Table 4). In general, RMSD minimums did not 
differ much between different runs. This along with the observation that the minimum 
RMSD conformations mostly belonged to the start of simulations, point to the fact that 
with one exception, TAMD as run here; explored conformations that were more different 
than the 2NY7 PDB structure based on the RMSD metric, than the starting CD4-bound 
state.  
The one exception was run #5, which showed a very low RMSD to the β20/β21 of 
the b12-bound conformation. The conformation which yielded this low value of RMSD is 
depicted in Figure 21a along with the b12-bound gp120 from the 2NY7 structure shown 
in the same orientation in panel b. A closer examination of the trajectory reveals that in 
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this run, like run #4, β2/β3 dissociates from the core first followed by slow hydration of 
layer-2 components which is accompanied by its movement away from the core and the 
backstrand. Meanwhile, β20/β21 slides away from the outer domain. Throughout this 
movement, W427 of β20/β21 stays associated with W112 of layer-2 and this association 
seems to strain the hydrogen bond registry of β20/β21, leading to its dissolution. 
Although β20/β21 unfolds, its strands stay close together (Figure 21c); possibly due to a 
lowering of fluctuations by association with inner domain, which allows them to form 
transient hydrogen bonds. This eventually leads to a change of hydrogen bond registry in 
the base of the loop. This conformation is globally similar to many other conformations 
sampled by TAMD in that they all show a mostly folded α1, a highly hydrated layer-
2/backstrand and a layer-1 which is detached from its binding site on the core.  
A more subtle difference between the activated state and the b12-bound state 
conformations is that in the former, W427 is closely packed with the hydrophobic core of 
the protein, contributing directly to the formation of the F43 pocket; whereas in the latter, 
owing to a complete flipping of β20/β21, it is exposed to the solvent and away from the 
pocket (Figure 21e and Figure 21f, respectively). In the TAMD-generated 
conformations, we did not observe such a flipping of W427 although it did become 
solvent exposed and detached from the F43 pocket, distancing from the pocket along with 
the C-terminal α1. Figure 21a and c show this domain from the same TAMD-generated 
conformation that gave the minimum RMSD from the b12-bound state (Table 4 run #5). 
In order to see whether TAMD is able to sample conformations potentially close to a 
flipped β20/β21 state similar to the b12-bound conformations, we selected five snapshots 
from run #5 and quenched them by subjecting them to the same minimization and 
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equilibration scheme explained in the Methods section. A sample is shown in Figure 21d 
which although has a higher RMSD compared to the one in panel c, shows a W427 that is 
completely flipped out of the hydrophobic core of the protein.  
An interesting characteristic of conformations from run #5 (and some from the 
TAMD runs analyzed in the previous section, two samples of which are shown in Figure 
22) is a separation of α1, β3/β4 backstrand and layer-1 into three separate and hydrated 
components making a large cavity lined with residues important for gp120/gp41 
association. These residues are highlighted in Figure 22 as yellow (L52, F53, H72, A73, 
M100, M104, D107, I109, L111, W112, L116, I213, I215, Y217, A221) or white (V36, 
Y40, V44, W45, F53, E64, V85, N88, V89, N92, A219, A224, T232, N234, G237, E482, 
L483, Y484, V489, I491 and all residues from P493 to A501). Yellow shows residues of 
layer-1 and layer-2 the mutation of which reduced gp120/gp41 association by more than 
50\% (45) and white shows other residues (mainly the β-sandwich and the N- and C-
termini) which are important for gp41/gp120 interaction (20). 
 
The disulfide-stitched pocket-filling mutant (DS12F123 sequence)  
Although in the six TAMD runs considered up until now, α1 shows great flexibility 
and occasionally goes through folding-refolding (data not shown) similar to the ones seen 
in b12- or b13-bound conformations of gp120, β20/β21 is less similar to the crystal 
structure conformations. This domain unfolds partially or completely and dissociates 
from its binding pocket on the core of the protein but does not refold or shift hydrogen 
bond registry in the course of TAMD simulations (except for run #5 discussed above). 
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The sequence used in these runs is the WT sequence and not the sequence that the b12-
bound structure was resolved with. In order to test whether these differences are 
decreased if TAMD is run with the exact sequence of the b12/gp120 crystal complex, we 
introduced the stabilizing mutations of the disulfide-stitched pocket-filling mutant used to 
resolve the gp120/b12 crystal structure (DS12F123 sequence, ref (23)) into the wild-type 
activated-state conformation (3JWD), minimized and equilibrated the resulting gp120 for 
20 ns. Then TAMD was applied to this structure with γ of 5 ps-1, κ of 1000 kcal.mol-1    , 
  of 200 ps-1 and    of 5 (run #10) or 6 kcal.mol-1 (run #10). 
Figure 23 depicts the Cα -RMSD trace of these runs showing that these runs open up 
the layered structure, although to a lesser extent as the inner and outer domain are 
covalently bound together. In order to go from the CD4-bound conformation to the b12-
bound one, the hydrogen bond registry in β20/β21 has to shift, possibly by unfolding and 
refolding of the β hairpin plus it has to flip so that the conserved W427 which forms part 
of the F43 pocket is fully exposed to the solvent. Our two TAMD runs sample folding 
and refolding events in α1 (data not shown). In comparison, this helix starts refolding 
from the N-terminus during the MD equilibration of the b12-bound structure (data not 
shown). One major obstacle in its formation in the context of the b12-bound structure 
might be the small β strand around residue D113 which forms a small sheet with residues 
around S209 of the backstrand. This sheet is absent in the activated state and does not 
form during TAMD starting from that state. β20/β21 is very stable in the equilibration 
run and although it unfolds completely in one of the TAMD runs of the DS12F123 
structure (data not shown) about 12 ns into the run, it refolds again in the same registry 
which prevents shifting of the residues. In both TAMD runs of the DS12F123 sequence, a 
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flipping of β20/β21 characterized by side chain of W427 facing away from the core is not 
observed.  
We were not able to sample a conformation strictly close (as defined by RMSD) to 
the b12-bound structure using the DS12F123 sequence, although structures very similar 
between the two (excluding the β20/β21 strand) start to develop toward the end of the 
TAMD run (Figure 24). Due to the coupling in the dynamics of β20/β21 and α1 through 
the disulfide stitch (44), we see that shuttling of α1 away from the core is accompanied 
by sliding of β20/β21 away from the F43 pocket while it maintains its contacts with the 
core. Such a sliding does not completely dislodge this sheet from the core. Sliding away 
of α1 along with hydration of α1 and its fluctuation away from the core is present in both 
runs on the engineered DS12F123 sequence. It should be noted that these events were 
common between the WT sequence and the stabilized DS12F123 sequence (for example 
compare Figure 24a and Figure 22). Figure 25 shows the difference distance matrix for 
only α1 (residues 97-116) and the outer domain (residues 255 to 480) and therefore the 
figure can be divided into two subsectionsa: the section indicated with the blue dashed 
box in panel (a) which shows the difference distance of α1 residues from the outer 
domain, and the red dashed box which shows the difference distance map of the outer 
domain residues, which include the β20/β21, and hence serves as a good indicator of how 
the distance between this β-sheet and the outer domain changes in time. As is shown in 
panel (a), α1 starts to move away from the outer domain very early in the simulation 
(indicated by yellow and red colored regions within the blue box) although it is still 
associated with α5 (residues 474 to 480) and stays associated almost for the rest of the 
simulation. Panel (b) shows that while the outer domain stays rigid, β20/β21 moves away 
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from the rest of the inner domain, while it is still associated with the C-terminal α1. Panel 
(c) shows β20/β21 moving back toward the outer domain, and in panel (d), the 
asymmetry in how the β20/β21 band (compare the horizontal yellow band around 
residues 423-435 between panels b and d) is formed can be traced to β20 moving away 
from while β21 stays close to the outer domain. This leads to a slight twist in this domain, 
which makes it resemble the b12-bound state. This figure demonstrates that the disulfide 
stitch leads to stretching of β20/β21 when α1 is hydrated and moves away from the outer 
domain. 
 
 
Discussion 
Effect of simulation setup on conformational sampling 
Most of the gp120 crystal structures available today are resolved in a conformation 
that is almost identical to the CD4-bound activated-state gp120 (18, 19, 23, 47). We used 
TAMD to quickly traverse the conformational space of the molecule out of this stable 
conformation. The utility of TAMD in fast target-blind conformational sampling with 
many collective variables in the context of a full-atomistic system has recently been 
demonstrated (42). Here we further explored the effects of different simulation 
parameters on the behavior of our system and tried to provide possible links between our 
simulation results and the large body of biochemical data available on HIV-1 gp120.  
To maintain adiabatic separation between the atomistic system at the physical 
temperature and the “hot” fictitious system, CVs should evolve slowly enough to allow 
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for the fast degrees of freedom to sample their configurational space in the time-frame 
where the CVs are constant (75). In TAMD, this condition is enforced in the limit      
(43). For our system with block masses of 4000±2000, we tried     ratios of about 40-
80. Although an increase in the value of this parameter ensures better adiabatic separation 
of the two systems, it can slow down the ``hot'' system so much that the purpose of 
TAMD as an enhanced sampling technique is defeated. Therefore we chose to work in a 
parameter range that allowed us to sample conformations that were not achievable in 
standard MD, measured by RMSD distance, while still provided an acceptable degree of 
adiabatic separation. 
Another condition that governs the order of error in sampling the free energy surface 
is      (43). We tethered the collective variables to the ``hot'' degrees of freedom 
using a κ of 1000 kcal.mol-1    . The deviations observed in Table 5 (i.e. comparison of 
runs 29 and 33) by changing this parameter versus those seen by changing the     ratio 
suggests that in the range of low     values used in our system, such a value of κ provided 
an acceptable degree of adiabatic separation and     is a more important determinant of 
deviation from perfect adiabatic separation. 
When we used many small domains leading to “light” collective variables (runs #26-
45), not only the adiabatic separation was hit negatively, but also the enhanced sampling 
lead to complete dissociation of the secondary structure. A significant slow-down of the 
collective degrees of freedom was necessary to improve preservation of secondary 
structure and adiabatic separation. Another reason for using larger blocks was to observe 
the consequences of the recently proposed layering mechanism of gp120 flexibility (20). 
It has been proposed that gp120 (and hence the envelope spike) achieves its extraordinary 
66 
 
 
CHAPTER 3: TARGET-BLIND SAMPLING OF CD4-NAÏVE CONFORMATIONS IN CORE GP120 
flexibility through utilization of its layered topology wherein different domains of the 
molecule are arranged as “pages of a book” emanating from a common β-sandwich. A 
comparison of crystal structures has been used to suggest that gp120 possibly goes 
through a refolding transition from the unliganded state into the activated state (20). A 
significant increase in the secondary structure content of the b12-bound gp120 in the 
course of simple MD equilibration (run #1) of its apo-form and an equally significant 
decrease in the secondary structure content of the activated protein in the absence of CD4 
(run #2) are consistent with this view. This also suggests that large changes in the 
secondary structure content comparable to those seen in standard MD simulations may 
not be unrealistic in the course of TAMD simulations. Therefore, we used the change in 
the secondary structure as the main criterion for choosing better simulation parameters.  
A comparison of different crystallographically resolved conformations of HIV-1 and 
the unliganded SIV gp120 suggests that the inner domain is the more plastic part of the 
molecule (20).  While the outer domain provides most of the glycan shield, the 
comparatively more conserved inner domain serves as the (possible) refolding 
machinery, donating almost half of the cryptic coreceptor binding site and containing all 
the gp41 interacting residues. This suggests that a useful exploration of the gp120 
conformational space must be able to sample diverse conformations of the inner domain. 
The RMSDs of TAMD-generated conformations of inner domain from the starting 
structure were used to measure the degree to which conformations outside the stable 
activated basin are explored. 
The results show that TAMD can quickly explore conformations distinct from the 
activated state and leads to an opening of the layers which are stacked on each other in 
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this state. It is worth noting that although we did not employ external constraints on the 
secondary structure, our choice of the blocks to be used as CV centers of mass was 
successful in preserving the secondary structure while performing a rather extensive 
sampling of the conformational space, using the right set of TAMD parameters. This is 
evident in the DSStruct measure of runs #4-25 in Table 5 which show that most of the 
runs employing this blocking scheme preserved the secondary structure within the first 10 
ns of the simulation, as well as the standard MD runs. In conclusion, we used secondary 
structure conservation, degree of deviation from adiabatic separation and extent of inner 
domain conformational variation as the three major measures of selecting useful TAMD 
parameters.  
 
Biological relevance of TAMD-generated models to unliganded gp120 
conformations 
TAMD has been shown not only to be successful in exploring conformations outside 
the stable activated-state of gp120, albeit using a different blocking scheme, but it also 
sampled a conformation within 3.6     of the F105-bound gp120 (42). Using the blocking 
scheme based on the layered topology (runs #24-43) we were able to successfully sample 
a conformation within 4.3    of this crystal structure. Considering that in the F105-bound 
state, α1 is folded and almost in the same orientation relative to the rest of the protein as 
in the activated state, the major differences seem to be a dissolution of the bridging sheet, 
undocking of β20/β21 from the core and its exposure to the solvent along with 
dissolution of the β-sheet hydrogen bonding structure. We observe bridging sheet 
dissolution and undocking of β20/β21 from the core readily in all TAMD runs, while a 
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full dissociation of β20/β21 from the core and dissolution of its β-sheet hydrogen bonds 
are only present in some of the runs (i.e. runs #36 and #37). It has been shown previously 
that it is easier to unfold β2/β3 compared to β20/β21 within the context of a constant-
force steered MD and with an almost fixed direction (58). 
One interesting observation was how easily layer-1 and β2/β3 dissociated from the 
core (Figure 18). Undocking of these two domains from the core exposes the β3-β4 
backstrand to the solvent. This along with fluctuations of the floppy β2/β3 translates into 
a more hydrated and mobile backstrand. These observations are consistent with recent 
hydrogen exchange data which demonstrate that CD4-binding decreases the rate of 
deuterium exchange for this strand (76). In the unliganded SIV gp120 this loop is 
presumably disordered and hence; not resolved in the crystal complex (48, 77). It has also 
been found that this relatively conserved loop is important for gp120/gp41 interactions 
and it has been suggested that it may be important for relaying the cascade of 
conformational changes initiated by CD4-biding, from gp120 to gp41 (77). This is in line 
with our observations that in most of the analyzed TAMD runs, this domain (especially 
its N-terminus) detached and moved away from the outer domain and frequently shuttled 
between contacting the outer domain and the inner domain. It is therefore plausible that 
CD4 binding-induced shifting of the equilibrium position of this domain toward the outer 
domain may provide a mechanism for loosening its potential interactions with gp41 and 
relaying the conformational changes initiated by formation of the CD4-bound 
conformation, from the rigid outer domain to the plastic inner domain and eventually to 
gp41. Consistent with this proposition, mutation of N-terminal residues of the backstrand 
I213, I215 and Y217 to alanine were found to decrease gp41/gp120 association by more 
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than 50% and viruses with F210A, I213A, I215A or Y217A mutation were found to be 
non-infectious (45). Therefore, the N-terminal residues of the backstrand may play a role 
in relaying the conformational changes from the CD4-binding site to gp41. 
Many conformationally sensitive antibodies to gp120 have been identified in patient 
sera and used in various characterization schemes of this protein (45, 70-72, 74, 78, 79). 
Residues important for binding of some of these antibodies are poorly exposed in the 
CD4-bound conformation. TAMD-sampled conformations showed opening of the 
layered structure and increased solvent exposure of almost all inner domain components. 
This translated to increased exposure of epitopes from various conformational antibodies 
(Figure 19), especially those with putative binding sites on the inner domain. This lends 
support to the reliability our modeled conformations of unliganded gp120. 
In addition to the F105-bound conformation, we screened the pool of TAMD 
conformations for structures close in RMSD value to the stabilized b12- or b13-bound 
conformations (2NY7 and 3IDX PDBs, respectively). Our screening showed that TAMD 
runs with the WT HxBc2 sequence (runs #4-9, 12-45) did not sample conformations 
close to the b12 and b13-bound state. Although TAMD runs sampled conformations with 
unfolded α1, movements of the center of mass of α1 in TAMD leads to an increase in the 
final RMSD measure. Considering β20/β21, TAMD simulations did sample 
conformations with this domain undocked from the core and with its β-sheet structure 
dissolved (i.e. run #4), but we did not observe a reformation of the backbone hydrogen 
bonds like that of the b12-bound state. A screening of all TAMD runs of the WT 
sequence confirmed this observation with β20/β21 RMSD distances similar to the 
distance from the activated state, with one exception (run #5). The surprisingly low 
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RMSD value achieved for this run prompted us to examine it more closely. In this run, 
β20/β21 slides away from the F43 pocket while maintaining its contact with W112. This 
is coincidental with movement of α1 (particularly its C-terminus) away from the core. 
These events were commonly observed at the first few nanoseconds of almost all the 
TAMD runs. The modeled conformations from run #5 suggest that the inner and outer 
domains can detach, slide and rotate around each-other. Rotation of the two domains has 
been previously suggested through observation of differences in electron tomograms of 
unliganded and liganded spike (8). Relative rotation and sliding of the two domains were 
also suggested in the context of TAMD-generated conformations, although using a 
different blocking scheme (42).  
Since in the bulk of our simulations we used the WT sequence and TAMD did not 
sample conformations closer to either b13- or b12-bound structures of gp120 (except run 
#5, which only partially mimicked those conformations) and considering the highly 
mutated sequence of these gp120 crystal structures, we tried to probe the conformational 
space of the mutated DS12F123 sequence using TAMD. Although we used a limited set 
of TAMD parameters, the TAMD-generated conformations with this sequence showed 
smaller minimum RMSDs from the 2NY7 and 3IDX crystal structures when compared to 
the WT sequence TAMD runs. The presence of the Q428C/I109C disulfide bridge from 
β20/β21 to α1 along with the pocket filling-mutations in the core are expected to 
significantly stabilize these two domains closer to the core. Such stabilization seems to 
lead to a stabilization of the hydrogen-bonding pattern in β20/β21 which does not unfold 
in the TAMD runs of the mutated sequence. This observation is consistent with the 
inability of this sequence to bind F105 as the gp120/F105 crystal structure shows the 
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antibody needs β20/β21 to dissociate from the core to gain access to the conserved F43 
pocket residues. Our TAMD results show that β20/β21 can shuttle back and forth 
between two states: docked and undocked from the core and it is only the latter which 
allows access to the conserved residues of the F43 pocket. Such an access seems 
necessary for binding of F105 and has been suggested to be necessary for binding of 
many other CD4-binding site antibodies (22). Our observations with TAMD-generated 
conformations suggest that the F43 pocket residues are only transiently accessible due to 
the presence of β20/β21. When a disulfide is introduced to stitch this loop to the inner 
domain, this access will be further limited due to its stabilization close to the core.  
In conclusion, TAMD runs with the DS12F123 sequence pointed to two common 
domain motions between this highly stabilized sequence and the WT sequence: (1) 
shuttling of the β3/β4 backstrand to and away from the outer domain, (2) flexibility of α1 
and its fluctuations away from the core (especially the C-terminus). Although undocking 
of β20/β21 from the core was observed both in WT and DS12F123 sequences, it was 
severely limited in the latter and did not lead to complete unfolding of this domain, as 
was observed in the WT sequence.  
 
A mechanism for conformational switching in gp120 
It was recently suggested, based on a comparison of crystal structures, that interlayer 
hydrophobic interactions in plastic layers of inner domain are weaker than for example 
interactions between the β-sandwich and these layers (20). Based on our observed 
snapshots of free gp120 monomer conformations, we propose that in unliganded HIV 
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gp120 the plastic layers of inner domain, particularly layer-2 and especially its C-
terminus, are mostly hydrated and detached from the outer domain such that the mostly 
hydrophobic, well-conserved wall of the ``F43-pocket'' on the outer domain (residues 
V255, Y257, E370, F382, Y384, W427, M475, S256, S375, F376, N377) is more solvent 
exposed compared to the activated state. It is worth noting that even in the activated state, 
the F43 pocket still contains crystal waters  (20) and there are water accessible channels 
around it (18).  TAMD-generated snapshots of unliganded gp120 show that such a 
flexible and hydrated layer-2 is usually accompanied by β20/β21 ``sliding'' away from the 
outer domain and F43 pocket residues. 
It has been suggested that in the unliganded spike, V3 and β20/β21 both extend 
toward the trimeric axis of symmetry, potentially interacting with each other and with 
gp41 (60). Our model provides some atomistic details into what conformations such 
extended states of β20/β21 may entail. 
Our model also provides a possible mechanism for activation of spike by CD4. 
Binding of CD4 to the outer domain can slightly tilt the equilibrium position of the 
floppy β20/β21 in favor of more association with the outer domain, potentially 
destabilizing its interactions with V3 and gp41 (60). Considering the persistent pairing of 
W427 with W112 and Q428 with D113 as examples, such a change in equilibrium of 
conformations can lead to a slight movement of the C-terminal of α1 toward the core 
which further stabilizes the newly formed activated state and fixates β20/β21 into the F43 
pocket. Although W112 does not contact CD4, its mutation to alanine leads to significant 
reduction in CD4 binding and a complete loss of viral infectivity (45). Also, when D113 
which is paired with Q428 throughout the TAMD trajectories was mutated to alanine, 
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viral infectivity was reduced by \%50, despite an almost doubling of CD4 binding (45). 
W112, W427 and D113 are conserved residues (18). C-terminus of α1 connects to the 
base of the V1/V2 loop. Therefore, movements of α1 toward the outer domain may also 
affect the stability of V1/V2 interactions with V3, which are suggested to be important 
for maintaining the epitope of the broadly neutralizing antibodies PG9 and PG16 (80). 
Fluctuations of the C-terminus of α1 can also effect conformations of the conserved β3-
β4 backstrand, possibly destabilizing its interactions with gp41. All these hypothetical 
changes which can lead to the formation of the CD4-bound conformation provide 
different, redundant pathways for relaying conformational changes from the initial CD4 
binding site on the outer domain to other components of the viral spike and eventually 
gp41. Therefore, our TAMD snapshots lend some support to a mechanism in which CD4 
binding shifts the equilibrium conformations of β20/β21 and α1 from interacting with 
gp41 to interacting with the outer domain and forming the stable CD4-bound 
conformation.  
Such a gradual amplification of the conformational changes that start with CD4 
binding can also explain the important role of reaction kinetics and temperature on spike 
activation and viral infectivity (63, 81, 82). It is worth noting that about 20 years ago and 
even before crystal structures of gp120 were resolved, a mechanism similar to such a 
“conformational swing” was suggested based on temperature dependent effects of soluble 
CD4 on the envelope spike (82). Our results here support such a mechanism and provide 
atomistic models of what such a mechanism may entail. 
Based on this model, α1-β20/β21 interactions seem mainly to affect the path of 
conformational propagation from the outer domain to the inner domain and start of the 
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fusion process rather than CD4 binding ability. We find it intriguing that experimental 
results show that complete removal of β20/β21 has no effect on the gp120/CD4 
interaction, but the same deletion pseudotyped into the virus results in non-infectious 
virions (83). Based on this, it would be interesting to compare the effects of β20/β21 
removal on gp120 shedding from the virus with effect of F105 binding. b12, as a 
representative of the very few broadly neutralizing antibodies discovered to date, 
recognizes the gp120 monomer less efficiently than the trimer (63). Based on our 
hypothesis, when the gp120 interacting domains of gp41 and the metastable inter-loop 
interactions are not present to “swing” the inner domain and β20/β21 away from the core, 
the equilibrium population of gp120 monomer might be more shifted to a CD4-like state. 
This is also consistent with our recent simulations suggesting that b12-binding to the 
activated-state gp120 monomer requires movement of β20/β21 away from the outer 
domain (44). Therefore, this might explain why b12 binds the trimer better, supporting 
the notion that on the native envelope spike β20/β21 might be extended away form the 
outer domain and toward the spike axis. Recently a new broadly neutralizing antibody 
VRC01 was isolated from the serum of a long-term non-progressor (61, 84). The crystal 
structure of VRC01 Fab with a core gp120 shows that VRC01 has little interactions with 
the inner domain or the bridging sheet, yet it binds to gp120 in a CD4-like conformation 
(61). We think this is consistent with our hypothesis that in absence of the gp41 
interacting domains and with a floppy β20/β21, inner domain conformations will be more 
likely to favor a structure resembling that in complex with CD4.  
 
 Conclusion 
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In this work we have used TAMD to propose possible conformational models of 
unliganded HIV-1 gp120. Different TAMD parameters were changed to arrive at a pool 
of conformations which met certain criteria: an acceptable level of adiabatic separation 
during TAMD, conservation of secondary structure and sufficient exploration of the 
conformational space within a reasonable simulation time-scale. Analysis of the resulting 
conformations showed that TAMD was successful in opening up the layered structure of 
gp120. Such an opening of layers lead to exposure of buried residues that previously have 
been found to be important for binding of conformational antibodies for which there are 
no crystal structure. We were able to sample a conformation within 4.3  
   of a gp120 crystal structure in complex with F105. In silico introduction of the 
stabilizing mutations of DS12F123 sequence (23) onto the WT activated state and 
application of TAMD to such a structure showed similarities of the plasticity mechanisms 
present in the inner domain between the two sequences. Based on the sampled 
conformational snapshots of the unliganded gp120 monomer, we support the notion of a 
“conformational swing” mechanism for the sequence of conformational changes that 
starts from initial CD4 binding and propagates through the inner domain, leading to gp41 
exposure and initiation of the viral entry process.  
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APPENDIX:  Effects of TAMD parameters on conformational sampling 
The maximum Cα- RMSDs from the starting (CD4 bound) structure after 10 ns were 
calculated for the inner domain and reported as MaxRMSDInner. These values were used 
as a measure of how well TAMD was able to explore the conformational space. Since 
among the normal MD runs, this metric was the largest for the equilibration run of the 
b12-bound structure (5.3    for run #1; Table Table 5), we used this as a threshold value 
below which TAMD sampling was considered insufficient. As expected, simulations with 
slower moving collective variables and lower values of the fictitious temperature resulted 
in smaller deviations from the starting structure. 
We considered runs with %Dev > 50 as “negative” results. As expected, slowing 
down the dynamics of the “slow variables” by increasing   or decreasing    resulted in 
improvement of the degree of adiabatic separation (75, 85). The majority of runs were 
performed using a Langevin friction coefficient  of 5 ps
-1
 but we used 1 ps
-1
 in some 
instances too. In most of the runs (compare 21 and 22, 8 and 16, 4 and 17, 18 and 19) a 
smaller value of the friction coefficient led to a significant improvement in sampling of 
the conformational space. Overall, the friction coefficient is not expected to affect the 
thermodynamic properties of the protein as long as a good control over the temperature of 
the system is maintained (86). Moreover, a lower friction coefficient can lead to better 
sampling of the conformational space (87, 88). Monitoring the temperature of the 
simulation showed that the lower friction coefficient did not affect how well the 
temperature of the system is controlled (Figure 26), while it improved the 
conformational sampling. 
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We used the net count of secondary structure elements during equilibration of the 
CD4-bound structure (run #2; DSStruct=-16) as the threshold value for selecting runs that 
were deemed negative based on secondary structure preservation. Using smaller blocks 
lead to significant losses in secondary structure, with the present subset of TAMD 
parameters (compare runs 34 and 7 in Table 5). For example, blocking the outer domain 
into small blocks and using the TAMD parameters indicated in Table 5 leads to gradual 
opening and dissolution of this domain which is inconsistent with crystallographic and 
past MD simulation studies. We therefore modified our blocking scheme to define blocks 
that based on experimental studies were thought to either undergo conformational 
changes (i.e. α1 of the inner domain and β20/β21), inter-domain motions (i.e. β2/β3) or 
were implicated in the layered model of gp120 (i.e. the β-sandwich or layer-3). This led 
to significant improvements in the conservation of secondary structure while benefiting 
from the enhanced conformational sampling of TAMD. 
Analysis of runs with minimal secondary structure loss and effi cient 
conformational sampling 
Based on the above criteria, we selected the runs shown in Table 3 for further 
analysis. We measured the number of residues in β-sheets or α-helices as the indicator of 
the secondary structure content at each frame (Figure 27). The sum of the two 
contributions appears in Figure 28. It is interesting to note that traditional MD 
equilibration of 3JWD CD4-bound structure (run #2) leads to a net loss of secondary 
structure content. Therefore, as run here, TAMD does not affect the secondary structure 
content of gp120 more than the traditional MD. 
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For runs #4 and #9, the secondary structure content starts to drop significantly 
compared to the equilibration runs after 15 and 10 ns, respectively. Runs #6 and #7 last 
longer on this scale and for example although run #7 shows a dip around 17 ns, it 
subsequently refolds structure. This decrease can be traced back to a loss of helicity in α1 
of layer-2 and its rebuilding  (data not shown). It is also interesting how the b12-bound 
structure builds up secondary structure during MD equilibration (run #1), which again 
can be traced back to refolding of α1 (data not shown). When the secondary structure 
scans are compared on a residue-by-residue basis, it can be seen that for example during 
TAMD run #4, β20/β21 starts to unfold early in simulation whereas it is very stable 
during the long equilibration run (data not shown). In conclusion, since we considered 
only the runs which on average preserved the secondary structure of gp120 at least as 
much as the standard MD equilibrations, this metric seems to suggest that all the six runs 
analyzed here preserve secondary structure on the time-scale considered in analyses, at 
least as well as a traditional MD run will. It should be noted that no attempt was made to 
introduce external restraints on the system to preserve secondary structure as gp120 has 
been suggested to be among the ``refolding'' class of protein machinery (20) and also our 
aim was a target-blind sweep of the conformational space with the least amount of 
constraints imposed on the system. 
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Table 2. Layer-based blocking scheme used in TAMD runs.  
Block Gp120 domain Residues 
1 β-sandwich 43-48; 83-96; 223-245; 485-493 
2 Layer-1 49-82 
3 α1 97-116 
4 β2/β3 117-202 
5 Layer-2  203-222 and not (a1 or b2/b3) 
6 Layer-3 246-256; 475-484 
7 β20/β21 423-435 
8 OD1* 257-260; 263-292, 345, 348, 349, 352, 353, 364-367, 449-474 
9 OD2 335-344, 346, 347, 350, 351, 354-363, 388-412,458-467 
10 OD3 261,262,293-299, 329-334, 368-387, 413-422, 436-448 
 
* Outer domain (OD) was blocked into three domains.
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Table 3. MD equilibration (runs #1-3) along with TAMD runs selected for further analysis. See text for explanation of parameters.  
Run Sequence       γ κ βcalc %Dev #blocks DSStruct SStruct MaxRMSDInner 
3HI1 RMSDInner 
     
  
(kcal.mol-1) (ps-1) (ps-1) (kcal.mol-1    ) (kcal-1.mol) 
  
10 ns >20 ns 
   
     Total Layer-2 β20/β21 
1 DS1F123 
        
14 153 ± 8 5.3 7.51 14.36 11.34 
2 WT 
        
-16 185 ± 6 4.1 6.25 11.08 15.54 
3 DS1F123 
        
-8 191 ± 6 4.2 6.41 11.3 16.09 
4 WT 5 200 5 1000 0.34 53.05 10 -2 -2 182 ± 6 8.4 4.3 6.17 6.1 
5 WT 6 400 1 1000 0.38 37.91 10 -13 174 
 
± 8 28.1 6.33 9.48 6.41 
6 WT 3 600 5 1000 0.81 26.67 10 -6 -7 179 ± 7 10.3 6.48 10.87 11.79 
7 WT 4 600 5 1000 0.67 26.36 10 1 -14 177 ± 8 11 5.59 9.45 12.66 
8 WT 5 400 5 1000 0.47 34.68 10 -9 179 
 
± 5 13.2 5.55 9.07 5.72 
9 WT 6 400 5 1000 0.41 34.56 10 -13 180 
 
± 5 13.7 5.66 9.08 8.56 
10 DS1F123 5 200 5 1000 0.34 53.62 10 -7 -6 181 ± 7 11.4 5.02 6.57 12.42 
11 DS1F123 6 200 5 1000 0.29 53.13 10 -6 -14 169 ± 9 17.3 6.06 7 9.36 
γ of 5 ps-1, κ of 1000 kcal.mol-1    ,   of 200 ps-1 and    of 5 (run #10) or 6 kcal.mol-1 
 
81 
 
 
CHAPTER 3: TARGET-BLIND SAMPLING OF CD4-NAÏVE CONFORMATIONS IN CORE GP120 
 
Table 4. RMSD from the b12-bound structure for different production runs. See text for explanation of 
parameters. 
 
2NY7 RMSDmin 
Run Total Layer-2 B20/B21 
2 4.28 8.36 6 
4 4.22 6.93 5.5 
5 4.7 9.05 3.62 
6 4.48 8.43 5.58 
7 4.17 7 5.38 
8 4.41 8.52 5.65 
9 4.41 8.31 6.57 
10 3.69 6.86 5.05 
11 3.77 6.18 4.23 
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Table 5. Summary of all TAMD runs. 
Run Sequence       γ κ βcalc %Dev #blocks DSStruct SStruct MaxRMSDInner 
3HI1 RMSDInner 
     
  
(kcal.mol-1) (ps-1) (ps-1) (kcal.mol-1    ) (kcal-1.mol) 
  
10 ns >20 ns 
    
(kcal.mol-1) (ps-1) (ps-1) 
1 DS1F123 
        
14 153 ± 8 5.3 7.5 14.4 11.3 
2 WT 
        
-16 185 ± 6 4.1 6.3 11.1 15.5 
3 DS1F123 
        
-8 191 ± 6 4.2 6.4 11.3 16.1 
4 WT 5 200 5 1000 0.34 53.10% 10 -2 -2 182 ± 6 8.4 4.3 6.2 6.1 
5 WT 6 400 1 1000 0.38 37.90% 10 -13 
 
174 ± 8 28.1 6.3 9.5 6.4 
6 WT 3 600 5 1000 0.81 26.70% 10 -6 -7 179 ± 7 10.3 6.5 10.9 11.8 
7 WT 4 600 5 1000 0.67 26.40% 10 1 -14 177 ± 8 11 5.6 9.5 12.7 
8 WT 5 400 5 1000 0.47 34.70% 10 -9 
 
179 ± 5 13.2 5.6 9.1 5.7 
9 WT 6 400 5 1000 0.41 34.60% 10 -13 
 
180 ± 5 13.7 5.7 9.1 8.6 
10 DS1F123 5 200 5 1000 0.34 53.60% 10 -7 -6 181 ± 7 11.4 5 6.6 12.4 
11 DS1F123 6 200 5 1000 0.29 53.10% 10 -6 -14 169 ± 9 17.3 6.1 7 9.4 
12 WT 3 600 5 1000 0.81 26.60% 10 -5 
 
181 ± 5 11.9 5.6 8.1 11.8 
13 WT 4 200 5 1000 0.42 53.10% 10 -4 
 
179 ± 5 12.8 5.3 8.7 7.7 
14 WT 4 400 1 1000 0.52 38.50% 10 -28 
 
171 ± 10 29.7 6 8.9 11.8 
15 WT 4 200 1 1000 0.39 57.00% 10 -15 
 
182 ± 6 9.8 5 5.8 10.1 
16 WT 5 400 1 1000 0.44 38.10% 10 -23 
 
173 ± 8 25.3 6.1 9.2 13.4 
17 WT 5 200 1 1000 0.32 56.70% 10 -13 
 
173 ± 7 39.7 6.5 7.9 6.3 
18 WT 6 200 1 1000 0.27 56.60% 10 -26 
 
162 ± 11 30.4 6 9.3 9.7 
19 WT 6 200 5 1000 0.29 52.80% 10 -9 -23 173 ± 10 15.9 5.5 7.3 12.2 
20 WT 3 200 5 1000 0.52 54.70% 9 -6 
 
186 ± 4 3.9 5.5 8.2 15.6 
21 WT 4 200 1 1000 0.39 57.60% 9 3 
 
185 ± 5 22.3 6 7.5 9.2 
22 WT 4 100 5 1000 0.32 73.50% 9 -1 
 
184 ± 5 2.6 6.7 11.8 16.1 
23 WT 4 200 5 1000 0.41 54.40% 9 -21 
 
179 ± 7 9.6 6 8.7 14.8 
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24 WT 5 200 1 1000 0.32 57.40% 9 4 
 
182 ± 7 23.3 4.9 7 6.4 
25 WT 5 200 5 1000 0.34 53.90% 9 -1 
 
181 ± 5 12.2 4.8 4.8 13.7 
26 WT 4 500 0.5 1000 0.61 31.00% 32 -11 
 
176 ± 6 5.2 7.1 12.2 16.1 
27 WT 4 1000 1 1000 0.85 17.00% 32 -6 
 
182 ± 4 2.3 7.1 12.6 16.7 
28 WT 4 1000 0.5 1000 0.83 17.80% 32 0 
 
180 ± 4 2.2 6.8 12.1 15 
29 WT 4 500 0.5 50 0.67 26.50% 32 -72 
 
138 ± 24 19 7.1 12.8 16.1 
30 WT 4 500 0.5 50 0.7 24.60% 32 -46 
 
157 ± 15 15.6 6.5 10.6 11.7 
31 WT 4 500 0.5 100 0.73 22.40% 32 -91 
 
138 ± 26 17 6 8.5 6.1 
32 WT 4 500 0.5 100 0.71 23.50% 32 -29 
 
147 ± 13 17.8 7.2 13.1 11 
33 WT 4 500 0.5 500 0.76 21.30% 32 -93 
 
122 ± 33 19 6 9.1 6.7 
34 WT 4 500 5 1000 0.73 22.40% 32 -53 
 
150 ± 19 12 7.3 12.2 15.1 
35 WT 4 1000 5 1000 0.57 34.20% 32 -96 
 
130 ± 27 14.6 7.2 13.1 16.7 
36 WT 4 5000 5 1000 1.33 4.50% 32 -31 
 
171 ± 13 7.5 7 12.3 11 
37 WT 2 50 5 1000 0.57 82.50% 32 -2 
 
183 ± 5 
    38 WT 2 50 5 1000 0.58 81.20% 32 5 
 
182 ± 6 
    39 WT 2 50 5 1000 0.56 84.90% 32 -5 
 
182 ± 5 
    40 WT 4 50 5 1000 
  
32 
  
171 ± 12 
    41 WT 4 50 5 1000 0.3 80.70% 32 -1 
 
182 ± 5 
    42 WT 4 50 5 1000 0.3 82.10% 32 -22 
 
175 ± 7 
    43 WT 6 50 5 1000 0.2 79.80% 32 -92 
 
141 ± 24 
    44 WT 6 50 5 1000 0.21 79.20% 32 -71 
 
150 ± 21 
    45 WT 6 50 5 1000 0.2 82.00% 32 -92   135 ± 29         
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Figure 14. HIV-1 gp120 conformation in the CD4-bound state. layer-1 is colored cyan, layer-2 red, 
layer-3 yellow, outer domain blue and the β-sandwich is gray. 
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Figure 15. HIV-1 gp120 in conformations other than the CD4-bound state (a) F105-bound (b) b12-bound 
(c) b13-bound. Inner domain is colored red, outer domain blue and the bridging sheet components cyan.  
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Figure 16. (a) Secondary structure trace (top) of different residues and RMSD trace of different domains 
(bottom) during equilibration of the DS12F123 sequence in the CD4 -bound state. α-helices are indicated 
by white coloring, β-sheets by black and non-structured domains by red. STRIDE algorithm is used to 
assign secondary structure to residues (stride ref). (b) shows the same data for the wild-type sequence 
  
87 
 
 
CHAPTER 3: TARGET-BLIND SAMPLING OF CD4-NAÏVE CONFORMATIONS IN CORE GP120 
 
Figure 17. (a) Cα-RMSD of the TAMD trajectory frames from the F105-bound gp120 crystal structure 
for different domains of gp120 (b) Overlay of the F105-bound crystal structure of gp120 (cyan) and the 
closest TAMD-produced mimic of this conformation. Alignment is performed over the outer domain.  
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Figure 18. A difference distance map of run #4. Axes show residue numbers and their corresponding 
domains are noted where possible/necessary. Examples of interesting TAMD conformations are shown in 
the panels with a snapshot of the conformation in cartoon rendering: inner domain in red, outer domain 
in blue and the bridging sheet in cyan. Approximate time points in the trajectory where the examples are 
extracted from are noted in the conformation insets. (a) β2/β3 starting to move away from the core (b) 
β20/β1 starting to dissociate from the core and overall separation of inner and outer domain (the boxed 
area) (c) α0 dissociating from the core (d) movement of residues C-terminal to β3 (or N-terminus of the 
β3/β4-backstrand) away from the core and toward the putative spike axis of symmetry . 
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Figure 19. Fractional solvent accessible surface area (FSASA) of residues experimentally found to be 
important for binding of different antibodies to gp120 measured for  different frames of run #9. Only the 
first 10 ns are considered. Each panel shows residue-specific FSASA and average FSASA for all residues 
as a function of the simulation time.   
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Figure 20. Crystal structures of gp120 in (a) F105-bound (b) CD4-bound (c) b12-bound (d) b13-bound 
conformations. The outer domain is colored blue, inner domain red and the residues from the CD4 -bound 
bridging sheet in cyan.  
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Figure 21. Gp120 from (a) TAMD run #5 with WT sequence and (b) b12-bound crystal structure with 
DS1F123 sequence. Coloring is as in Figure 20 with α1 and β20/β21 emphasized. W427 is shown in 
VdW rendering without hydrogens. (c-h) Residues in and around (residues 421 to 438) the β20/β21 
domain in different gp120 conformations: (c) TAMD run #5 (d) quenched TAMD (e) b12-bound (2NY7) 
(f) CD4-bound (3JWD) (g) b13-bound (3IDX) and (h) F105-bound (3HI1) crystal structures.  
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Figure 22. Sample conformations from runs (a) #5 (b) #4 showing how layer-1 and layer-2 of the inner 
domain open-up to make a tripod-like structure which is lined on the inside with residues experimentally 
found to be important for gp41 interaction represented in yellow licorice rendering (45). Other residues 
that have previously been found to be important for gp120/gp41 interaction  are colored white (20). Q427 
is shown in gray van der Waals rendering. The left column show the str uctures roughly from the 
innerdomain-proximal side view and the right column is the same snapshot almost 90 ° rotated along the 
paper y-axis. 
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Figure 23. Cα-RMSD trace of the two DS12F123 sequence TAMD runs, starting from the CD4 -bound 
conformation for different gp120 domains partially showing how flexible layer -2 is. Not all domains are 
shown in the figure to prevent clutter.  
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Figure 24. Overall conformation of (a) a sample snapshot from TAMD of DS12F123 (run #11) (b) 
DS12F123 sequence in 2NY7 crystal structure complex with b12. Note that the former does contain the 
additional gp41 interacting regions of gp120 as it is based on t he 3JWD crystal structure (20) whereas 
the latter does not. Inner domain is shown in red, outer domain in blue and the bridging sheet in cyan 
with α1 and β20/β21 emphasized. W427 is shown in van der Waals rendering and the I109C/Q428C 
disulfide in Licorice (excluding hydrogens).  
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Figure 25. Difference distance map from run #11 with only α1 (97-116) and outer domain (255-480) at 
four different time points in the trajectory (indicated in the bottom-right corner of each panel) with a 
snapshot from those points included. The inner domain is colored red, outer domain blue and β20/β21 
cyan. W427 is shown in VdW rendering. In the distance map matrix, blue indicates a decrease in the 
inter-residue distance relative to the starting state and red indicates an increase.  
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Figure 26. Temperature of the systems during TAMD runs of Table 5. Curves are smoothed using the 
Bezier algorithm. 
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Figure 27. Number of residues participating in the formation of (a) α-helices (b)  β-sheets throughout 
the trajectory for different TAMD runs and traditional MD equilibrations.  
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Figure 28. Number of residues participating in secondary structure throughout the trajectory for 
different TAMD runs and traditional MD equilibrations, after bezier smoothing.  
 
 
 
CHAPTER 4: GENERATION OF AN ATOMISTIC MODEL OF 
PT/GP120 CORE INTERACTION
*
 
 
 
 
Abstract 
Peptide-triazole entry inhibitors prevent HIV-1 infection by inhibiting viral gp120 
binding to both HIV-1 receptor and coreceptor on target cells. Here we used all-atom 
                                                 
* This part of the work is to be resubmitted with revisions to Biochemistry as “ . Emileh, F. Tuzer, H. Yeh, U. Muddagowda, D.R.M.  
Moreira, J.M. LaLonde, C.A. Bewley, I.M. Chaiken, C.F. Abrams  A model of the peptide-triazole entry inhibitor binding to HIV-1 
gp120 and mechanism of bridging sheet disruption”  
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explicit solvent molecular dynamics (MD) to propose a model for the encounter complex 
of the peptide-triazoles with gp120. Saturation Transfer Difference NMR (STD NMR) 
experiments were performed to test the simulation results. We found that docking of the 
peptide to a conserved hydrophobic patch of residues lining the outer domain wall of the 
“F43 pocket” on gp120 led to a stable complex and prevented the formation of the 
bridging sheet minidomain, which is required for receptor/coreceptor binding. Opening of 
a pocket on gp120 at the interface of β20/β21 and the inner domain during MD buried the 
functionally important triazole component of the peptide, stabilizing the encounter 
complex. Our model suggests that the I-X-W (where X=(2S, 4S)-4-(4-phenyl-1H-1, 2, 3-
triazol-1-yl) pyrrolidine) hydrophobic motif in the peptide can serve as the binding hot-
spot, contributing most of the intermolecular interaction energy. STD NMR experiments 
provided experimental evidence that the I-X-W tripartite motif in the the peptide indeed 
makes the major contacts with the protein. Moreover, the absolute configuration of the 
Trp Cα and Pro Cγ were seen to be important for high affinity peptide binding in STD 
NMR experiments. Both observations can be justified based on the model complex 
presented here. This model provides a starting point for both rational design of higher 
affinity peptide triazoles and development of small molecule entry inhibitors that can trap 
gp120 into an inactive conformation and prevent infection. 
 
Introduction 
The multi-step process of viral entry provides a series of targets for intervention and 
blocking the infection before the virus establishes a foothold in the host (25). Enfuvirtide 
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(T20) is a subcutaneously injected 36 amino acid peptide that binds to the transiently 
exposed HR1 of gp41 and prevents formation of the six-helix bundle, preventing viral 
entry (6). It was approved for clinical use in 2003 although its low bioavailability and 
poor pharmacokinetics have spurred research for its improvement (26). Maraviroc, an 
orally administered small molecule that binds to CCR5 and inhibits gp120 recognition 
was approved by the FDA in 2007 (6). Emergence of X4-tropic or R5X4-dualtropic 
viruses utilizing CXCR4 are the most common pathways of resistance to maraviroc (25, 
27). The success of combination therapy has shown the value of using multiple agents to 
target sequentially diverse HIV (26). Prominent examples of targeting gp120 through 
inhibiting its interactions with CD4 or CCR5/CXCR4 include: NBD-556/DMJ-II-228 
which inhibit gp120/CD4 interaction and BMS378806/BMS488043 which prevent viral 
entry through an unknown mechanism involving conformational changes in the envelope 
spike (28-30). The former is an agonist of coreceptor binding (31) although very recent 
work has shown that this undesirable phenotype can be eliminated (32), and the latter has 
a very small barrier to resistance as 1-2 mutations in gp120 result in 40-500 fold 
resistance to the inhibitor (6).  
12p1 is a small peptide (with the sequence RINNIPWSEAMM) that allosterically 
inhibits gp120 interactions with both the receptor and the coreceptor (33, 34). Replacing 
the middle proline with azidoproline and derivatizing the latter with various alkynes 
through click chemistry led to identification of triazole variants with an approximately 
400 fold increase in potency, generating a new class of peptide triazole entry inhibitors 
with low nanomolar affinity for gp120 (35, 36). HNG-156, which contains a ferrocenyl 
triazole-substitution, binds to gp120 with an equilibrium dissociation constant (KD) of 7 
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nM, compared to the 5400 nM KD of 12p1 (37). This compound antagonizes gp120 
interactions with both CD4 and coreceptor and inhibits HIV-1BaL entry at nanomolar 50% 
effective concentrations (EC50). This class of entry inhibitors is broadly active against 
various HIV clades, nontoxic and can be synergistically combined with other entry 
inhibitors (38, 39). Recently it was found that some variants of the peptide can disrupt the 
viral membrane, leading to cell-free HIV virolysis and inactivation (40). This virolytic 
process was shown to be dependent on the specific interactions of the peptides with 
gp120 (40). Clearly such peptide triazoles hold great promise for both therapeutic and 
microbicidal applications. Understanding the binding mode of peptide triazoles in the 
context of gp120 structure would help greatly in further developing peptide designs with 
improved potency and peptidomimetic character. 
The crystal structure of deglycosylated HIV gp120 lacking the V1/V2/V3 variable 
loops (gp120 core) in complex with soluble CD4 and a coreceptor surrogate antibody 
(mAb 48d) shows gp120 in its canonical activated state (Figure 29a) (20). In the simplest 
interpretation, gp120 in this conformation can be divided into the inner domain, the outer 
domain and, at their interface, a four strand β-sheet (composed of β2, β3, β20 and β21) 
called the bridging sheet. The latter is where the coreceptor binds (18, 20). At the 
intersection of inner and outer domains with the bridging sheet lies a deep cavity called 
the “F43 pocket”. Residues lining this cavity are hydrophobic, well conserved and 
thought to be important for gp120 function (18). Out of 23 crystal structures of various 
HIV gp120 cores available in the PDB, only a handful are resolved in a conformation 
significantly different than the activated state (24). These include the mAb F105-bound 
(Figure 29b) (22), the mAb b13-bound (Figure 29c) (22) and the mAb b12-bound 
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(Figure 29d) (23) conformations, all of which show a structure without a bridging sheet. 
Very recent studies suggest that the core gp120 has a propensity to more frequently 
sample the activated state with a folded bridging sheet (Figure 29e) (24), while the same 
study suggests that the full-length gp120 monomer and the native-state spike-bound 
gp120 are flexible, conformationally diverse and not in an activated state (24). The latter 
is in line with previous findings suggesting conformational diversity as a mechanism of 
viral evasion (15, 21). It has been proposed that peptide triazoles inhibit gp120 
interactions with CD4 and the coreceptor surrogate, mAb 17b, by trapping the flexible 
viral protein in one or more inactive conformations (33, 34, 41) and possibly preventing 
bridging sheet formation (34). 
Currently there are no crystal structures of a peptide triazole/gp120 complex, 
hampering efforts to optimize the peptide potency and develop non-natural 
peptidomimetics through structure-based design. The only direct study aimed at 
identifying binding determinants on the peptide employed saturation transfer difference 
NMR (STD NMR) to investigate binding of the parent 12p1 peptide to gp120. Those 
results showed that the bulky hydrophobic sidechain of peptide tryptophan binds to 
gp120 (89) consistent with previous mutational studies on the peptide sequence (33-35).  
However, neither a mechanistic explanation of the interaction nor a model of the complex 
was suggested. Binding of peptide triazoles to full-length gp120 is characterized by a 
smaller negative entropy change (-TΔS   +6.3 kcal.mol-1) (41) compared to CD4/gp120 
binding (-TΔS=44.2 kcal.mol-1) (15), suggesting that gp120 maintains its conformational 
flexibility when bound to the peptide. This might be one of the reasons the gp120/peptide 
complex has resisted crystallization efforts to date. In this work we set out to build an 
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atomistic model of the gp120/peptide triazoles complex. We hypothesized that the 
peptide binds to a large hydrophobic cavity on gp120 which is exposed in the mAb F105-
bound conformation of the glycoprotein. We used all-atom, explicit-solvent molecular 
dynamics to populate various conformations of an encounter complex consistent with this 
hypothesis. The most stable and energetically favorable complex showed a specific 
orientation of the peptide with its tryptophan inside the F43 pocket and its isoleucine 
plugging a shallow cavity at the junction of the inner/outer domain. This remarkably 
stable pose was reached after backbone movements of the β20/β21 loop which buried the 
large phenyl-triazole appendage on the derivatized proline. Independently, we used 
saturation transfer difference NMR (STD NMR) to study the peptide residues that come 
into contact with gp120 using a less potent version of the peptide. These results are in 
good agreement with the simulation model and show that the hydrophobic core of the 
peptide provides the major contact surface for gp120 interaction. Altogether, these 
findings provide a working model for the mechanism of dual inhibition of peptide-
triazoles and can help both to design peptides with improved potencies and guide efforts 
to produce a stabilized complex for future crystallographic analysis.  
 
Materials and Methods 
Peptide synthesis  
Peptide triazoles (Table 6) were synthesized via manual solid-phase synthesis using 
Fmoc chemistry on a Rink amide resin at 0.25 mmol scale, purified using reverse phase 
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HPLC and validated by matrix-assisted laser desorption ionization time of flight mass 
spectrometry (MALDI-TOF MS) as detailed in Umashankara et al. (41).  
 
Protein production  
Full-length HIV-1YU2 gp120 and soluble CD4 (sCD4) were produced and purified as 
described before (41). Monoclonal antibody 17b was obtained from Strategic 
BioSolutions.  
 
Competition enzyme-linked immunosorbent assay (ELISA) 
 Peptide inhibition of sCD4 or 17b binding to gp120 was assessed via competition 
ELISA. HIV-1YU2 gp120 (100 ng) was adsorbed to a 96-well microtiter plate overnight at 
4°C. After washing the plate 3x with PBST (1x PBS with 0.1% Tween-20 v/v), the plate 
was blocked with 3% BSA in 1x PBS for 2 hours at room temperature, followed by 3x 
washing with PBST. All further incubations before detection were done in 0.5% BSA in 
PBS. For sCD4 competition experiments, 100 μL sCD4 (0.1 μg mL-1) was added to each 
well in the presence of increasing concentrations of peptide. After incubation for 1 h, the 
plate was washed 3x followed by addition of 100 μL of biotinylated anti-CD4 antibody 
OKT4 (eBiosciences) at 1:5000 dilution. After 1 hr incubation, the plate was washed 3x 
and 100 μL streptavidin-conjugated horseradish peroxidase (SA-HRP) was added and 
incubated for 1 h. The extent of HRP conjugate binding was detected by adding 200 μL 
of 40% (m/v) o-phenylenediamine dihydrochloride (Sigma-Aldrich) in 0.05M phosphate-
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citrate for 30 mins followed by measuring the optical density (OD) at 450 nm using a 
microplate reader (Molecular Devices). For 17b competition, the same protocol as above 
was followed, adding 100 μL of 0.1 μg mL-1 antibody to the immobilized gp120 in 
presence of increasing concentrations of the peptide. Detection was done using an HRP-
conjugated rabbit anti-human antibody (Millipore) at 1:5000 v/v dilution followed by 
OPD development.  
 
Saturation transfer difference (STD) NMR   
All NMR data were recorded at 298 K on a Bruker Avance 600 NMR equipped with 
a cryogenically cooled z-shielded gradient probe. Series of 1D STD spectra were 
acquired with selective irradiation at -1.5, 11 and 12 ppm for on-resonance spectra, and 
30 ppm for off resonance ‘reference’ spectra, using a train of 50 ms Gaussian-shaped 
radio frequency pulses separated by 1 ms delays and an optimized power level of 55 db. 
Water suppression was achieved using excitation sculpting (90) 
1
H and 
13
C chemical shift 
assignments were made by interpreting COSY, HOHAHA and NOESY spectra of the 
free peptides in solution.  Samples were prepared in 20 mM sodium phosphate buffer 
containing 50 mM NaCl and 1 mM EDTA at a final concentration of 15 M gp120 and 
1.2 mM peptide. The pH of each sample was adjusted to 6.85 with 0.5 mM NaOH or HCl 
(not corrected for 
2
H). The NMR data were processed and analyzed with Topspin 2.1.6; 
in particular, each on-resonance spectrum was subtracted from its corresponding off-
resonance spectrum to give a difference spectrum that was phase corrected using Topspin 
2.1.6. Relative STD enhancements were determined by integrating peak intensities and 
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normalizing to peak/s showing the largest enhancement (here Trp indole protons). To 
assure that artifacts were not being introduced with protein irradiation, enhancements for 
spectra recorded with the above three different on-resonance carrier frequencies were 
compared. Though no STD signals were observed in control spectra using the same pulse 
sequence in the absence of protein, slight differences (<5%) in enhancements were 
observed.  We therefore chose to integrate the upfield signals in spectra irradiated at 12 
ppm, and the aromatic signals in spectra irradiated at -1.5 ppm.  
 
Molecular simulations  
Molecular dynamics (MD) simulations were performed using NAMD 2.7 (50) and 
CHARRM22 force filed (65). CHARMM parameters for the triazole appendage on the 
peptide were estimated by similarity to those available in the CHARMM general force 
field (91), using ParamChem online tool v0.9.19 (Vanommeslaeghe, K. et al., manuscript 
in preparation; https://www.paramchem.org/) and if necessary, manual addition of 
missing parameters (supporting information). Initial coordinates of HIV-1 YU2 gp120 
core in complex with the antigen-binding fragment (Fab) of antibody F105 were 
extracted from PDB entry 3HI1 (22). Missing residues (V4 loop and the base of V3 loop) 
were modeled in silico as unstructured loops. Hereafter, we will refer to this system as 
the “F105-bound” state. All structural manipulations and image rendering were done in 
VMD (66).  
For a typical system setup for MD runs, the polypeptide was solvated in a TIP3P 
(52) water box with at least 20    distance between the polypeptide molecule and the 
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periodic box boundary. Neutralizing Na
+
 and Cl
-
 ions were added to a total NaCl 
concentration of 0.025 M. A 2 femtosecond timestep was used in all integrations. The 
system temperature was kept constant at 310 K by coupling all non-hydrogen atoms to a 
Langevin thermostat with a friction coefficient of 5 ps
-1
. Nonbonded interactions were cut 
off above 9    and smoothed to zero beginning from 8   . PME long-range electrostatics 
with a grid spacing of 1    was used and all bonds involving hydrogens were constrained 
using RATTLE (53). Equilibration runs were performed at constant volume (NVT 
ensemble).  
We used the F105-bound state directly from the crystal structure (3HI1) as the target 
for docking studies. UM101 or UM25 were minimized for 20 ps and equilibrated for 20 
ns to sample conformations for initial complex pose generation. The minimized 
conformation of UM25 was manually oriented close the F43 pocket of the F105-bound 
gp120 (which is open and exposed, with only the outer domain wall of the pocket 
formed) from the crystal structure (3HI1) such that the peptide tryptophan is located 
roughly close to the F43 pocket and the peptide isoleucine is at the inner-outer domain 
interface. 20 conformations were randomly selected from the UM25 equilibration run and 
aligned over this initial conformation using the heavy atoms of these two peptide 
residues. For UM101 initial poses, the same initial conformations were used, replacing 
the para-amino group on the triazole with hydrogen. Water and neutralizing ions were 
added to these initial conformations (as explained above) and the system was minimized 
for 40 ps, keeping all protein non-hydrogen atoms fixed to relieve protein/peptide 
clashes. An additional 20 ps minimization was performed allowing for movement of the 
protein atoms. After manually inspecting all runs to check for any remaining clashes, 
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runs with no overlaps were submitted for 15 ns of free MD equilibration. This resulted in 
165 and 225 ns of MD simulation for UM101 and UM25 complexes, respectively. 
For each peptide, the MD-generated systems were sampled every 100 ps and pooled. 
After orienting the conformations over the gp120 outerdomain, coordinates of the peptide 
heavy atoms were extracted and clustered using the following procedure: Each peptide 
conformation represents a point in a 3N-dimensional space of Cartesian coordinates 
where N is the number of atoms considered for analysis. We first perform standard k-
means clustering on the set of f data points extracted from the trajectory, for 2 ≤ k ≤ 50. 
The task is then to find k for which the set of cluster centers most efficiently describes the 
complete dataset, which we term k*. We opt to use similarity between the ordered 
eigenvectors of the global covariance matrix     and those of the covariance matrix 
computed from among the k-means    
 . The rationale is that, because covariance matrix 
eigenvectors define directions in Cartesian space along which the data is most variable, 
the mean values (cluster centers) whose covariance matrix eigenvectors best recapitulate 
these most highly variable directions of the global data set are themselves the most 
efficient “coarse-graining” of the dataset. We use the following rule: k* is that k for 
which the dot-products of the k −1 eigenvalue-descending ordered eigenvectors of the 
covariance matrix computed using the k-means with their respective eigenvectors of the 
global covariance matrix are all greater than 0.5, and such that this number of “near-
parallel” eigenvectors of the global and k-mean covariance matrices is at least equal to 
the number of global eigenvectors which account for at least 80% of the variance in the 
global data. The amount of the global variance accounted for by each principal 
component (PC) is equal to the variance of that PC divided by the total dataset variance 
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(92). Since the k-means algorithm is sensitive to the choice of the initial cluster seeds 
(93), the whole loop is repeated 50 times and the result which gives the most well-packed 
clusters (as measured by the sum of Euclidean distances of cluster members from the 
cluster center) is used as the global optimum. All data points were transformed to 
standard z-scores before analysis. All analyses were done in MATLAB (MathWorks). 
Protein–peptide interaction energy was measured in NAMD as the non-bonded (van der 
Waals and electrostatic) part of CHARMM energy between the two molecules, in 
absence of water and under a dielectric constant of 80. We report the root mean squared 
deviation (RMSD) of peptide atoms averaged for all member conformations of a cluster 
as a metric of cluster uniformity and stability. The average non-bonded interaction energy 
(hereafter referred to as interaction energy or simply energy) and average peptide RMSD 
of each cluster were used as the principal scoring metrics. The internal energy of the 
protein or the peptide were not included in the scoring as the former would swamp and 
smooth out any differences in the interaction energy and both were found to be fairly 
constant throughout simulations.  
We submitted the F105-bound gp120 conformation from PDB 3HI1 along with an 
initial peptide conformation, to the SwissDock server (http://swissdock.vital-it.ch/) (94). 
The top highest ranking results from the web server were selected and the top five which 
were more than 1    different in peptide RMSD submitted for explicit-solvent all-atom 
MD runs, clustered and analyzed  the same way as the two production sets explained 
above. These served as an unbiased control against which to compare our manual 
docking results. 
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Results 
Inhibitory activity of peptide triazoles used in NMR and  modeling studies 
To facilitate STD NMR studies of peptide triazole interactions with gp120, it was 
necessary to select peptide constructs that bound gp120 with sufficiently low affinity, 
since the efficiency of saturation transfer to the ligand depends on its off-rate from the 
protein (95). Thus, we synthesized peptides wherein ferrocenyl triazole was replaced with 
phenyl triazole (compare HNG156 and UM101). Moreover, we introduced a para-amino 
group on the phenyl triazole which based on past work, was expected to decrease the 
peptide affinity for gp120 (35) and increase solubility. 
We used competition ELISA to measure the peptide triazole effects on gp120 
interactions with sCD4 and 17b. The results are shown in Figure 30. Mean inhibitory 
concentrations (IC50) were calculated after fitting the data to a logistic function in Origin 
(OriginLab) and are reported in Table 6. Replacing the ferrocenyl triazole of HNG156 
with phenyl triazole in UM101 results in a decrease in 17b-inhibitory potency and a 
similar but smaller effect on sCD4-inhibitory potency (Table 6) (35, 37).  
Changing the phenyl triazole of UM101 to para-aminophenyl triazole in UM25 has a 
much stronger negative effect on the peptide potency and almost reverts the sCD4 IC50 to 
that of the parent peptide 12p1 with no triazole. 17b inhibitory potency is almost lost and 
an approximate value of 18 μM can be estimated from the dose response in Figure 2. 
These results are in line with previous findings on the correlation of the triazole 
derivative hydrophobicity and peptide affinity, with the more hydrophobic and bulky 
derivatives producing more potent inhibitors (35).  
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Previous work has shown that the stereochemistry of the chiral centers on peptide 
Pro-Cγ and Trp-Cα are very important for activity: when D-Trp is used along with a 
ferrocenyl appendage on the triazole, the peptide is almost inactive (41). Moreover, while 
the S configuration of the triazole on Pro-Cγ is active, the R configuration has similar 
activity to the parent peptide with no triazole (12p1 – see Table 6) (35). Here we aimed 
at further elucidating these findings through a systematic investigation of the 
stereochemistry around the two chiral centers and correlating that with NMR data and 
structural models. To simultaneously investigate the role of stereochemistry in both 
stereocenters of the hydrophobic X-W core in peptide activity, UM25 inhibitory potency 
was compared to other diastereomers where the Pro-Cγ and Trp-Cα atoms possessed R or 
S configurations. The original configuration with S-Pro-Cγ and S-Trp-Cα (UM25) is active 
but any change in configuration of either chiral center results in an inactive peptide 
(Figure 30 and Table 6), consistent with prior work on similar but longer peptides 
containing a ferrocenyl triazole (35, 41). Considering these results, we focused our 
modeling work only on UM101 and UM25, both of which have the S configuration in the 
chiral centers denoted above.  
 
Simulation of a peptide-triazole/gp120-core encounter complex  
Previous work has shown that the parent peptide 12p1 does not inhibit binding of 
sCD4 to a mutant gp120 (S375W) (33) that has a propensity to sample the 
activated/CD4-bound state (96), while it inhibits binding of the F105 antibody to a 
mutant gp120 (I423P) which is inefficient at assuming the activated state (33, 96). It has 
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been suggested that binding of 12p1 to gp120 traps the latter in an inactive conformation 
and allosterically inhibits receptor/coreceptor binding (33), potentially preventing the 
formation of the bridging sheet (34). Based on these observations, we hypothesized that 
the peptide triazoles also bind to a gp120 conformation that has an unstructured bridging 
sheet. Among the various crystallographically resolved gp120 conformations without a 
bridging sheet, only the F105-bound conformation was crystallized using a WT-sequence 
gp120 core and with no stabilizing mutations (22). We chose this conformation as the 
target for our peptide triazole docking studies. 
The I-X-W hydrophobic sequence in the middle of the peptide triazoles is crucial for 
their activity (41) and requires a specific X-W stereochemistry (35, 41). A survey of 103 
high-resolution peptide/protein complexes in a prior study showed that only a few amino 
acids of a peptide sequence typically contribute most of the interaction energy with its 
partner, commensurate with the “hot spot” hypothesis for general protein/protein 
interactions (97, 98). More interestingly, it was found that phenylalanine, leucine, 
tryptophan, tyrosine and isoleucine are by far the most frequently observed amino acids 
in peptide/protein interface hot spots (98). Based on these observations, and considering 
the previous work on truncated peptides (41), we hypothesized that the I-X-W 
hydrophobic core acts as the main interacting motif of the peptide.  
Examination of the F105/gp120 interface in the crystal structure reveals that the tip 
of the complementarity determining region of the third variable loop in the heavy chain 
(CDR-H3), comprised mainly of the three residues V100a, F100b, Y100c, inserts deeply 
into the (yet unformed) F43 pocket. Considering this simple observation and the above 
points, we further hypothesized that the peptide tryptophan could bind inside the F43 
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pocket, similar to Y100c of F105 and that the peptide isoleucine could insert into the 
small cavity formed between I108, I109, W112, F210, V255 and M475 of gp120, similar 
to F100b of F105 (Figure 31a). Interestingly, in the activated state of gp120, this latter 
pocket is occupied by W427 on β20/β21 which is part of the bridging sheet. This 
conserved residue is necessary for CD4/gp120 interaction (18) and its mutation can 
improve F105 recognition (14), leading one to speculate that in an unactivated 
conformation, this pocket is unoccupied. Thus, we used the Ile and Trp of the peptide to 
orient all MD-sampled peptide conformations over gp120 for initial pose generation.  
We tested the above hypotheses by applying the MD-based sampling scheme 
outlined in the Materials and Methods section to a set of initial poses for UM101 and 
UM25 peptides. Figure 31b shows the initial poses of the MD runs of UM25/gp120 
complex. As an unbiased control, we also used the SwissDock server to produce energy-
minimized peptide/gp120 docked complexes which we then subjected to the same all-
atom explicit solvent MD scheme explained above (codenamed UM101SD and 
UM25SD). After removing the solvent and neutralizing ions, a PCA-based k-means 
clustering algorithm was used to group similar conformations together. The average 
peptide/gp120 interaction energy of each cluster was used as the main scoring criterion. 
Average RMSD (root mean squared deviation) of peptide heavy atoms within each 
cluster was used as a measure of cluster uniformity and pose stability, postulating that a 
low-energy favorable encounter complex should result in a structurally stable peptide and 
a cluster of similar conformations. Note that RMSD can be calculated against any 
reference conformation and the choice of the reference conformation will not have any 
significant effect on the relative difference between clusters.  
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Figure 32 shows the mean interaction energy of each cluster plotted against the 
mean cluster RMSD. For UM101, there is a distinct collection of clusters which clearly 
are separated from the other clusters, showing a significant difference in potential energy 
and also lower intracluster fluctuations (as measured by intracluster RMSD). The top 
three best scoring clusters are on average more than 10 kcal.mol
-1
 lower in energy scale 
than the next cluster. For UM25, there is no such obvious separation of clusters using 
similar metrics, although among the top three best scoring clusters (8, 18, 22), cluster 22 
has the lowest mean RMSD, almost half the lowest energy cluster (cluster 8). As cluster 
22 demonstrated the lowest energy and most stability (lower left of the plot in Figure 32) 
we chose cluster 22 as the top ranking cluster for UM25. To compare these results with 
those of another docking method and to probe the effect of initiating our MD runs from a 
limited set of initial poses, we submitted UM101 and UM25 to the SwissDock server 
(94). We chose SwissDock over other freely available docking software primarily 
because it supports inclusion of non-natural amino acids, provides an all-atom model of 
the complex and is suitable for relatively large ligands with  many (>10) rotatable bonds. 
The results of MD runs and clustering for UM101 and UM25, starting from these 
optimized SwissDock poses, are represented in Figure 32 as UM101SD and UM25SD. It 
is clear that our initial poses, based on a priori knowledge of gp120 conformation and 
past experimental knowledge of 12p1/gp120 interactions, result in clusters which are 
more homogenous and have lower interaction energies (Figure 41). Interestingly, after 
MD equilibration, the UM101SD pose with the lowest global interaction energy resulted 
in a conformation in which the peptide hydrophobic core was roughly positioned 
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similarly to our initial UM101/UM25 docking poses, although it was initiated from a 
different conformation generated by the SwissDock server (Figure 41).  
We further examined specific gp120/peptide triazole contacts for the top ranking 
UM101/UM25 clusters. We measured the intermolecular interaction energy for all 
members of a cluster and determined the fraction of that energy contributed by each 
gp120 residue (Table 8). We also counted the intermolecular hydrogen bonds (with a 
distance cut-off of 3    and angular cut off of 30°) and determined the fraction of 
conformations in each cluster where a gp120 residue participates in hydrogen bonds. This 
fraction was used as the intermolecular hydrogen bond occupancy for that residue (Table 
9). These data are summarized in Figure 33 (and further detailed in Figure 38-Figure 
40). Here, we have colored gp120 residues which contribute more than 2% of the 
intermolecular interaction energy for each cluster in red. Gp120 residues participating in 
intermolecular hydrogen bonds are shown in blue and for residues belonging to both 
groups, if the hydrogen bond occupancy was less than 10%, we colored the residues in 
red. The top three UM101 clusters are very similar, as can be seen in their almost 
identical RMSD scores (Figure 29a), and cluster 1 can be considered a fair representative 
of all three (Figure 33a). For UM25, the top scoring cluster (cluster 22) is shown in 
Figure 33b. We have also shown the lowest energy cluster for UM25 (which is almost 
half as homogenous on the RMSD scale but only 2 kcal.mol
-1
 lower in energy) in Figure 
33c. 
The major structural difference between the top ranking clusters of UM101 and 
UM25 is the burial of the triazole moiety at the interface of α1 C-terminus and β20/β21 in 
the former. This contributes on average 26-27 kcal.mol
-1
 to the potential energy of 
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interaction between the peptide and gp120. Measuring the fraction of potential energy 
contributed by each peptide residue, and averaging the results for the top three clusters, 
shows that the X-W cluster contributed 60 and 50 percent of the interaction energy in 
UM101 and UM25, respectively (Figure 34). This is consistent with previous results 
which showed these two residues to be critical for any functionality in the peptide (41). 
Although both peptides are similar in the overall contribution of this hydrophobic core to 
the interaction energy, the relative role of the two residues is drastically different. While 
in UM101 the triazole makes up for 36 percent of the energy versus 24 percent for the 
tryptophan, in UM25 it is the tryptophan which contributes more (32%) than the triazole 
(16%). Going back to the depicted models of the complex (Figure 33), such results can 
be gleaned simply by the observation that in UM101 a large hydrophobic moiety is 
desolvated while in UM25 it stays solvated though still in contact with the protein. It is 
interesting to note that UM25 has a similar IC50 for binding to sCD4 as that of 12p1, 
which does not carry a triazole appendage (Table 6). The role of hydrophobic group 
desolvation in improving the affinity of ligands is well-documented (99, 100) and is 
consistent with previous results which show a direct correlation between the hydrophobic 
solvent accessible surface area (SASA) of different triazole derivatives and the affinity of 
peptide triazoles (35). We also observed that UM101 is about five times more potent than 
UM25 in inhibiting gp120 binding to sCD4 (Table 6). Burial of the more hydrophobic 
triazole at the interface of the inner and outer domains provides an explanation for these 
observations. 
Although the three top ranking clusters of UM101 (UM101-C1, -C25 and –C22; with 
C denoting cluster number) display very similar conformations, the top ranking clusters 
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of UM25 (UM25-C8, -C18, -C22) show more diversity (compare the spread in RMSD 
between UM101 and UM25 clusters in Figure 32). While UM25-C22 (the top cluster 
when both stability and energy metrics are considered) shows the peptide in a similar 
pose to UM101-C1, UM25-C8 (the lowest energy cluster) shows the peptide mostly 
contacting the interface of α5 helix and the N-terminal section of α1 in the inner domain. 
Moreover, while the peptide tryptophan sits inside the F43 pocket in a similar pose to 
UM101 in UM25-C22, it adopts a different orientation inside this pocket in UM25-C8. 
The tryptophan side chain slides between the N-terminus of α5 and the C-terminus of the 
loop connecting the gp120 inner and outer domains, sandwiched between T257 and the 
backbone of α5 N-terminus, while donating a hydrogen bond to gp120 N478 side-chain. 
Such positioning of the peptide tryptophan arises from the simulation and is a testament 
to the often cited unusual flexibility of gp120 (15, 101). Interestingly, during our explicit 
solvent simulations, a water molecule was frequently observed hydrogen bonding to 
N478, consistent with amenability of this deeply buried residue for exposure to solvent. 
Another major difference between the poses shown in Figure 33 b and c is in the relative 
placement of the N-terminal hydrophilic residues of the peptide relative to gp120. In 
cluster 22 (Figure 33b), focus of the N-terminal residue interactions is mainly on α5 
helix residues of gp120 (D474, R476 and M475). In contrast, in cluster 8 (Figure 33c), 
the peptide interacts with both α1 (E102, H105, E106) and α5 residues and in addition, 
with K97. Interestingly, E102, K97 and R476 were implicated in interactions of the 
parent peptide 12p1 which is longer and lacks the triazole derivative of UM25, but has 
similar sCD4 IC50 values to UM25 (Table 6) (33). E102 and K97 were found not to 
significantly impact gp120 binding to higher affinity peptide triazoles (discussed below).  
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Through analysis of peptide triazole binding to a panel of gp120 mutants, recent 
work in our group has shown that among the residues mutated, D474, T257, E370, M475, 
V255 and R476 had a significant effect on peptide/gp120 interactions (102). Since those 
studies were done using a high affinity peptide with a ferrocenyl triazole, we only 
consider our UM101 simulations for comparison (Tables S1 and S2). In simulations, 
E370 or D474 side chains serve as hydrogen bond acceptors from the charged N-terminus 
backbone of the peptide (see Table 9) accompanied by Asn3 of the peptide accepting a 
hydrogen bond from gp120 H105. In addition, such a positioning of the peptide N-
terminus puts the two asparagines at interaction distances from a series of hydrophilic 
gp120 residues on both the CD4-binding loop (E370, D368) or α5 (D474, D476) or even 
α1 (E102). Indeed the top two UM101 clusters are different only in how the N-terminus 
is placed relative to these two gp120 domains (compare Figure 33 panels a and b). In 
cluster 1, the N-terminus and N3 of the peptide interact with D474 while the citruline 
(Cit1) side chain and N2 interact with E370 and D368. In cluster 25 (the second ranking 
cluster), their placements are exchanged. M475, V255, I109 and W112 of gp120 make up 
the shallow pocket at the interface of the inner and outer domains interacting with the 
peptide isoleucine.  
S375 accepts a persistent hydrogen bond from the side chain of the peptide 
tryptophan while the methyl group of T257 rests against its phenyl ring. It was found that 
peptide triazoles are less potent in inhibiting S375A binding to CD4 and 17b (102), 
consistent with our observation of formation of this partially buried hydrogen bond inside 
the mostly hydrophobic F43 cavity. Buried hydrogen bonds are generally considered to 
contribute favorably to drug target interactions (99, 103). Moreover, the orientation of the 
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peptide tryptophan shown in UM101 cluster 1 stacks its indole ring against the highly 
conserved bulky F382 inside the pocket, commensurate with the importance of such π-π 
interactions in ligand recognition (99) and mimicking the F105 Y100c (Figure 31). In 
addition to these experimentally consistent interactions, we observed that W112, F382, 
I109, I423 and M426 contribute significantly to the interaction energy. It would be 
interesting to test whether or not mutation of these latter residues affects peptide 
triazole/gp120 interaction. Overall, these observations suggest that the proposed model of 
the peptide triazole/gp120 interaction is consistent with the current data on the role of 
different gp120 residues in modulating peptide interactions.  
 
Characterization of peptide triazole binding to gp120 by NMR  
We used Saturation Transfer Difference NMR (STD NMR) to independently 
characterize the binding of peptide triazoles to soluble gp120.  In this method, saturation 
of protein resonances results in magnetization transfer from the receptor to the bound 
ligand in a distance dependent manner. We introduced a para-aminophenyl in place of 
the phenyl in UM101 to increase the off-rate of peptide/gp120 interaction for optimal 
results in STD NMR experiments (95) and improve peptide solubility. In a difference 
spectrum, signals corresponding to protons in closest proximity to the protein in the 
bound state appear as the strongest signals. Together with full chemical shift assignments 
(Table 10) made via 
1
H-
1
H and 
1
H-
13
C 2D NMR experiments, an atomic level 
description of a binding epitope can be obtained.   
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As seen in Figure 35, strong STD enhancements (red spectrum) are seen for 
numerous protons of UM25.  These include protons of the indole ring of Trp, and the p-
aminophenyl triazole group, as well as  and  methyl groups of isoleucine.  When 
compared to the reference spectrum, the strongest signals in the difference spectrum 
correspond to H-2/4/6/7 of tryptophan (Figure 31).   
The percent enhancement for each of the remaining signals was normalized to these 
protons, and the percent enhancements for each appear in Figure 31 and Table 7.  In 
addition to Trp, the side chains of Ile and Pro-Hγ strongly contribute to the binding to 
gp120, with STD enhancements ranging from 60 to 85%. Apart from protons located 
within these three residues, there are no other large enhancements observed in the 
difference spectra. Together these data suggest that these three residues in large part 
govern binding of UM25 to gp120. This is consistent with our simulation work 
suggesting that the hydrophobic core of peptide triazoles is the major binding partner to 
gp120 with the I-X-W motif contributing about 60% of the interaction energy in UM25. 
 
Binding of UM25 to gp120 is stereospecific  
Previously we demonstrated that the S configurations on Trp-Cα and Pro-Cγ were 
important for the inhibitory function of peptide triazoles (35, 41). In this work we 
simultaneously changed the stereochemistry of these two chiral centers and observed that 
changing the Trp-Cα configuration from S to R renders the peptide almost inactive, while 
changing the Pro-Cγ at the triazole derivative attachment point from S to R reverts the 
activity back to the parent peptide without the triazole (Table 6 and Figure 30). To 
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directly compare binding interactions between the four diastereomeric analogs of UM25 
to gp120, we recorded STD NMR spectra on each of these peptides in complex with 
gp120.  All samples were prepared and spectra recorded in an identical manner 
(Materials and Methods).  For comparison, the four difference spectra are shown as 
stacked plots in Figure 37.   
The STD NMR spectra clearly show that the UM25 analog bearing D-Trp in the wild 
type background, as well as the analog bearing R-Pro-Hγ in the presence of L-Trp, do not 
bind to gp120.  Interestingly, for the UM25 analog in which both stereocenters have been 
inverted, to R-Pro-Hγ and D-Trp, binding to gp120 is observed.  However, the signal to 
noise for this spectrum is less than half that measured for wild type UM25, and while 
enhancements are seen for protons in the Pro-Hγ and Trp residues, negligible 
enhancements are observed for Ile.  Thus, in addition to an apparent reduction in binding 
affinity, these data suggest that the entire tripartite arrangement presented by Ile, S-Pro-
Hγ, and Trp are required for optimal binding to gp120. 
 
Discussion 
Peptide triazole entry inhibitors are unique in that they inhibit binding of gp120 to 
both its receptor and coreceptor at nanomolar concentrations (35, 41). They have a broad 
inhibition profile, are non-toxic and can be synergistically combined with current 
antiviral leads and recent studies have shown that some variants cause sequence-specific 
cell-free virolysis, inactivating the virus in the absence of cells (39, 40). Although no 
crystal structures of these compounds with gp120 have been obtained to date, it has been 
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suggested that their mode of action involves trapping the flexible gp120 protein in a 
conformation which is incommensurate with an activated state gp120 (33, 41).  
The first step toward building a computational model of the encounter complex 
between gp120 and peptide triazoles was selection of a target structure. Gp120 is thought 
to be conformationally very flexible (15, 20, 21, 24), evidenced by the impressive 
collection of gp120 structures resolved with different ligands (24), from which one has to 
select a target conformation for molecular docking. A quick survey of the available 
crystal structures shows that the major difference between HIV-1 gp120 conformations is 
the folding state of the bridging sheet. This minidomain is the locus of the mandatory 
coreceptor binding and its folding from the unliganded state has been suggested to 
account for almost half of the structuring which accompanies the CD4/gp120 interaction 
(15, 21). Peptide triazoles bind with a much smaller structuring effect on gp120 (-
TΔS=6.3 kcal.mol-1) compared to CD4 (-TΔS=44.2 kcal.mol-1) (15, 41) and do not inhibit 
CD4 binding to a gp120 mutant (S375W) engineered to stay in the activated state. 
However the peptide triazoles inhibit mAb F105 binding to a gp120 mutant (I423P) 
which does not sample the activated state effectively (33). Recent studies on the 
structures of the unliganded gp120 core showed that full-length gp120 is recognized by 
ligands that bind the unactivated state gp120 (like F105) better than ligands that 
recognize the activated state (24). In other words, full-length gp120 samples the 
unliganded conformation available for binding to antibodies like F105 more frequently 
than activated states which form the bridging sheet and bind CD4 induced (CD4i) 
antibodies like 17b. b12- and b13-bound conformations of gp120 do not have a folded 
bridging sheet and were crystallized with a stabilized disulfide-stitched gp120 sequence 
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(22, 23).  We did not consider these structures for this study, as past work had suggested 
that the engineered mutations might have had some effects on the conformations of the 
inner domain (44, 45). The F105-bound structure was resolved with a WT sequence and 
did not contain these engineered mutations. Interestingly, recent hydrogen/deuterium 
exchange studies on the full-length gp120 conformations in solution showed that the 
β2/β3 and β20/β21 domains which fold into the bridging sheet in the activated state, are 
largely disordered in the unliganded gp120 (104). This is a unique property of the F105-
bound conformation (relative to other crystallographically resolved structures of gp120) 
which further supports our choice of this state as the target conformation for our docking 
efforts. Finally, recent work in our group (Tuzer, F. et al., unpublished) has shown that 
the peptide triazoles have similar affinity for gp120 D5 mutants as the wild type gp120. 
Since this mutant is unable to form the bridging sheet (77), these results support peptide 
binding to a gp120 conformation which lacks this domain. Considering these points, we 
chose the F105-bound conformation of gp120 as the target conformation.  
Peptides primarily bind to the largest pockets on the protein surface (98). The F105-
bound state of gp120 presents a very large hydrophobic cavity formed by the 
outerdomain wall of the F43 pocket (22). Most of the interaction energy in 
peptide/protein interfaces is contributed by hot-spot residues. Phe, Leu, Trp, Ile and Tyr 
residues are significantly overrepresented in hotspots (98). Interestingly, the focus of the 
long CDR-H3 of F105 interaction with gp120 is a V-F-Y motif which inserts deep inside 
the (unformed) F43 pocket (22). Importantly, our previous studies have shown that the I-
X-W motif in the peptide sequence is critical for its function (41). Putting these 
124 
 
 
CHAPTER 4: GENERATION OF AN ATOMISTIC MODEL OF PT/GP120 CORE INTERACTION 
observations together, we hypothesized that the central hydrophobic I-X-W motif in the 
peptide sequence interacts with residues of F43 pocket on gp120. 
The unusual plasticity of gp120 especially in the inner domain (20) and the fact that 
we do not know what the true gp120 conformation targeted by the peptide is, necessitate 
the use of a docking method which can incorporate large scale conformational variability. 
Due to the high computational cost of including backbone flexibility, current freely 
available docking protocols only consider side-chain flexibility of the target (94, 105-
109). Considering the above points and the large number of rotatable bonds in the 
peptide, we chose molecular dynamics as the basis of our modeling approach. We 
independently scored the resulting states without taking into account our recent findings 
on the peptide triazole binding site (102). A simple scoring scheme based on the 
intermolecular non-bonded interaction energy term of the CHARMM force-field was 
used as the principal scoring criterion. A similar scoring scheme was successfully used to 
score binding poses of the PDZ domain peptides (110). After clustering the resulting 
conformations, we ranked them based on both their interaction energies and their 
homogeneity, arguing that the more homogenous clusters will likely represent more 
stable poses and hence, local minima on the free energy surface. Therefore, we chose the 
clusters with the lowest average interaction energy and the lowest intracluster RMSD (i.e. 
those closer to the lower left quadrant of the graph in Figure 32) as the highest ranking 
clusters. 
Our simulated models of gp120/peptide triazole encounter complex showed features 
that were consistent with previous experimental data on the effect of various changes in 
the peptide sequence on their inhibitory activity. For the high affinity UM101 peptide, the 
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top three highest ranking clusters were similar in that they all showed a phenyl triazole 
buried at the interface of gp120 β20/β21 and the C-terminus of the inner domain α1. In 
the top ranking cluster of UM25, the triazole simply contacts I109, W112 and M426 but 
does not bury at their interface. In UM25 cluster 8, the triazole side chain transiently 
sampled a conformation wherein it bends further toward the protein core (not shown). In 
both cases, peptide Trp6 is stabilized inside the F43 pocket via its side chain donating a 
hydrogen bond to gp120 S375, and the peptide Ile4 is wedged at the interface of inner 
domain α1 and outer domain α5 inside a small but flexible pocket. The latter pocket is 
occupied by F105 F100b in the F105-bound conformation and gp120 W427 in the CD4-
bound conformation. It should be noted that within each cluster a great degree of 
flexibility is observed: the S375-Trp6 hydrogen bond flickers on and off and its side 
chain displays a significant degree of mobility inside the F43 pocket. These observations 
are consistent with previous reports on the flexibility of this cavity (101). In general, 
ligands can bind proteins in slightly different poses and this retained variability can offset 
some of the entropy lost upon binding (111, 112). Considering the unusual flexibility of 
gp120 (20) and the comparatively small structuring signature accompanying peptide 
triazole binding to gp120 (41), such variability in structure is not unexpected. The 
conformational variability observed in simulations is greater on the hydrophilic N-
terminal residues, with the peptide N-terminus mainly hydrogen bonding to either E370 
or D474. It has been suggested that electrostatic interactions serve to guide peptide-
protein interactions to an initial, metastable encounter complex which is then stabilized 
through binding of a small number of hotspot residues (98, 111). Past work in our group 
has shown that the N-terminal hydrophilic extension on the peptides can be modified to 
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include positively or negatively charged or neutral residues without much difference in 
peptide/gp120 affinity (41). Therefore we think that hydrogen-bonding, hydrophilic  N-
terminal extension  residues of the peptide bind to the ring of charged residues 
surrounding the F43 pocket residues and localize it close to this flexible pocket and then 
in a second step, the hydrophobic hotspot residues bind to the (possibly transiently 
exposed) F43 pocket, latching the peptide onto gp120. Launching a 200 ns MD 
simulation from the minimum energy cluster 1 of UM101, we observed that the 
hydrophobic core of the peptide is solidly bound to gp120 (peptide core heavy atom 
RMSD   2   ) while the hydrophilic N-terminus is flexible (data not shown) and 
transiently samples the two hydrophilic domains surrounding the F43 cavity (centered on 
D474 and E370).  
Our simulations point to the I-X-W motif as the major contributor of intermolecular 
energy between peptide triazoles and gp120, consistent with our STD NMR data which 
show that these residues are involved in major contacts between the peptide and gp120. 
The strongest signals arise from the hydrogens on the tryptophan indole, indicating that 
this residue is in intimate contact with gp120, commensurate with the combination of 
hydrogen bonds (with S375), van der Waals (with T257) and stacking (with F382) 
interactions it makes with various gp120 residues in UM101 simulations. In UM25 
simulations (cluster 22), although the stabilizing effect of the hydrogen bond is evident, 
we do not see such an obvious stacking against F382. The next set of strong signals arises 
from Ile4 of the peptide which in our model resides inside a shallow cavity at the 
interface of the inner and outer domains (Figure 31 and Figure 33). It would be 
interesting to see what the effect of replacing Ile4 with more hydrophobic side chains 
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such as phenylalanine would be on peptide/gp120 interactions. The triazole appendage 
makes up the last bit of this “tripartite” pharmacophore, with STD enhancements as high 
as 80% of those observed for the tryptophan protons. We find it rather surprising that 
moving from the triazole ring toward the para-aminophenyl appendage, the STD NMR 
signal seems to decrease. This may indicate burial of this moiety inside a transient or 
flexible pocket. The interface between two flexible domains may be a plausible option for 
such a pocket. We changed the stereochemistry of Pro-Cγ and Trp-Cα simultaneously and 
through ELISA experiments found that, consistent with past reports on a longer 
backbone, an S configuration on both of these chiral centers is necessary for high affinity 
function. Changing the Pro-Cγ to the R configuration reversed the compound potency in 
inhibiting sCD4 binding back to its parent peptide without a triazole, suggesting that such 
a configuration effectively removes the triazole contacts with gp120. Consistent with 
these findings, our STD NMR data failed to show any signal for peptides with R-Trp-
Cα/S-Pro-Cγ or S-Trp-Cα/R-Pro-Cγ (Table 6 and Figure 37). These results are consistent 
with minimum energy poses from simulations (Figure 33) where changing the 
configuration of the Trp sidechain to R will lead to clashes with the protein surface. 
Changing the configuration of the triazole appendage to R will send the long triazole 
derivative into solvent, consistent with both ELISA results (above) and NMR data. 
Surprisingly, we observed weak STD NMR enhancements when both chiral centers were 
changed to R. Because STD NMR has the ability to detect very weak interactions that 
may not be observed with other techniques, this inconsistency with the ELISA results 
may be due to the much higher peptide concentrations used in the NMR experiments 
(113). Overall our STD NMR experiments seem to be in qualitative agreement with our 
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simulation results on the role of the I-X-W motif in gp120 interactions and suggest that a 
specific geometry is required for peptide affinity.  
We have found by mutational analysis (102), that a set of residues lining the inside 
or the rim of the F43 cavity outerdomain wall are important for gp120/peptide triazole 
interactions. Residues which interacted most frequently and most strongly with the 
peptide in the simulated structures reported here, overlapped with the experimentally 
determined gp120 binding partners. In addition, the role of W427 on peptide binding was 
probed by analyzing the interaction of W427A mutant with peptide triazoles (Tuzer, F. et 
al., unpublished). This residue does not contact the peptide or contribute to gp120/peptide 
interaction energy but is important for the formation of the activated state, and W427S or 
W427V were recognized better than WT gp120 by mAb F105 (14). It was found that 
peptide triazoles inhibit the W427A mutant better than WT, arguing that although W427 
does not contact the peptide, its absence promotes a gp120 conformation which exposes 
the F43 pocket residues more frequently, hence sampling a conformation which is more 
amenable to peptide binding. This again lends support to our use of the F105-bound 
structure to build a model of the complex and is consistent with the list of possible 
peptide/gp120 contact sites. 
We recognize that like any other model, this model has potential drawbacks. We do 
not know the conformation of gp120 that is targeted by the peptide. Using the “right” 
target conformation immensely impacts the success of docking models (114). As a test, 
we submitted the CD4-bound (3JWD) and b12-bound (2NY7) conformations of gp120 to 
the SwissDock server (94) for docking of the peptide triazole.  For the CD4-bound 
conformation, the highest scoring poses docked the peptide either to the silent face (15) 
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or the gp41-interacting β-sandwich (20) on gp120, both of which are unlikely to be 
peptide binding sites based on the wealth of experimental evidence on gp120/peptide 
interactions. No binding poses were detected within ~20    of the F43 pocket. For the 
b12- and b13-bound conformations, no results were returned since no suitable pockets 
were detected on the gp120 surface. In using MD to drive conformational sampling of 
both the peptide and the protein, our aim was to start from a potentially “wrong” 
conformation and arrive at a local minimum on some complex free energy surface that 
would provide a better picture of the peptide/gp120 interactions. Our use of similarity-
derived CHARMM parameters for the triazole moiety might have negatively impacted 
the quality of the results. Although surveys of PDB structures have found that ligand 
strain energies of several kT are common (112), supporting some acceptable margin of 
error in dihedral parameters used in this work, we recognize that improving the quality of 
these parameters would be important for improving the current model. Finally, we used a 
simple nonbonded interaction energy score for ranking the MD-generated poses. 
Although other, more advanced scoring schemes can be used, the ambiguity in the target 
conformation of gp120 argues against investing in such expensive methods since, using 
such a simple scoring scheme, we were able to distinguish poses which are consistent 
with independently derived experimental results. Testing the predictions of the current 
model experimentally (i.e. introduction of phenylalanine in place of Ile4 on peptide or 
mutating W112 or I109 on gp120 to probe the effect on peptide binding) can provide 
more direct cues to refining the model using more rigorous simulation methods.  
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Conclusions 
In this work we proposed the first atomistic model of the peptide triazole/gp120 
encounter complex. We used the F105-bound gp120 conformation as the target and 
employed an explicit-solvent MD-based scheme to sample both peptide and peptide-
protein complex conformations. Clusters of conformation with minimum average energy 
and intracluster RMSD were selected for further analysis. Measuring the peptide/gp120 
interaction energy in these clusters showed that the I-X-W hydrophobic cluster is the hot-
spot for peptide/gp120 interactions, contributing 50-60% of the intermolecular 
nonbonded energy. These were consistent with previous reports on the importance of this 
central motif for peptide activity. Moreover, these results show that a specific geometry 
in the peptide hydrophobic core is required to insert into the hydrophobic cavities present 
in the F105-bound gp120. This is in qualitative agreement with our STD NMR 
experiments which confirm the importance of the I-X-W motif in the peptide for gp120 
binding and shows that binding of this tripartite hydrophobic domain is the sole 
contributor to STD NMR signals of the peptide. STD NMR experiments also did not 
show any signal for binding of peptide diastereomers with R-Trp-Cα and R-Pro-Cγ, 
consistent with the minimum energy poses from simulations which show that a change of 
stereochemistry at the above chiral centers will lead to clashes with the protein surface or 
force the triazole moiety away from the protein. We measured the contribution to the 
interaction energies from different gp120 residues and found that those that were 
experimentally determined to be important for peptide triazole binding were also either 
major contributors to the interaction energy or participated in persistent hydrogen bonds 
with the peptide. Furthermore, we identified additional gp120 residues the mutation of 
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which may impact its affinity for peptide triazoles. Together these results provide a self-
consistent model of peptide triazole/gp120 encounter complex which can be used to both 
design a stabilized covalent conjugate for further structural studies or to test ideas for 
rational design of improved entry inhibitors.  
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Table 6. Sequence and functional properties of parent 12p1 and peptide triazole variants. Cit in the peptide sequence denotes citruline.  
Designation Sequence Triazole Derivative 
Chirality  IC
50(ELISA)
 [nM]
[a]  IC
50(SPR)
 [nM]
[b]  
Trp C
α
 Pro C
γ
 sCD4 mAb 
17b sCD4 mAb 17b 
UM101
[c]    Cit1-N2-N3-I4-X5-W6-S7 Phenyl S S 230 670 - - 
UM25   Cit1-N2-N3-I4-X5-W6-S7 para-aminophenyl  S S 1100 18000 - - 
UM25RS   Cit
1
-N
2
-N
3
-I
4
-X
5
-W
6
-S
7
 para-aminophenyl S R >1E+5 >1E+5 - - 
UM25RR    Cit1-N2-N3-I4-X5-W6-S7 para-aminophenyl R R >1E+5 >1E+5 - - 
UM25SR   Cit
1
-N
2
-N
3
-I
4
-X
5
-W
6
-S
7
 para-aminophenyl  R S >1E+5 >1E+5 - - 
12p1 R1-I2-N3-N4-I5-P6-W7-S8-E9-A10-M11-M12 - S - - - 1100 1600 
HNG156 R
1
-I
2
-N
3
-N
4
-I
5
-X
6
-W
7
-S
8
-E
9
-A
10
-M
11
-M
12
 Ferrocenyl S S - - 112 152 
UM24   Cit1-N2-N3-I4-X5-W6-S7 Ferrocenyl  S S - - 118 138 
KR21  R1-I2-N3-N4-I5-X6-W7-βA8[d]-BtLys9[e]-G10 Ferrocenyl  S S 16.4 80 85 110 
 
[a]
 IC50  determined using ELISA as outlined in Materials and Methods. 
[b]
 From references (37) and (41); IC50 was determined using SPR and values are shown 
here for comparison. 
[c]
 X in the sequence denotes derivatized azidoproline. 
[d]
 β  denotes β-alanine. [e] BtLys denotes Ne-biotinyl-L-lysine. 
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Table 7. Percent enhancements for UM25 binding to gp120 observed by STD NMR.  
Residue Proton Enhancement (%) 
Ile
4
 Me ~85a 
 Me ~85a 
X
5
 H 33 
 H-2/6 69
b 
 H-3/5 62
c
 
 H-8Trz 33 
Trp
6
 H-2/5 100
c
 
 H-4 100 
 H-6 100 
 H-7 60 
aAverage of two methyl signals; baverage of H-2/6; caverage of H-3/5. 
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Figure 29. Various conformations of gp120 core crystallographically resolved to date: (a) unliganded (b) 
F105-bound (c) CD4/48d-bound (d) b12- and (e) b13-bound. (d) and (e) were resolved using a highly 
engineered disulfide-stitched gp120 sequence. The sequence used in (c) contained the pocket filling 
S375W/T257S mutations. Inner domain is shown in red, outer domain in blu e and components of the 
bridging sheet in cyan. Gray color depicts the outer domain residues of the F43 pocket (V255, T257, 
E370, F382, Y384, M475, S256bb, S375bb, F376bb and N377bb where the bb suffix indicates backbone 
atoms) which are conformationally invariant  between different structures and yellow depicts the inner 
domain (W112) or β20/β21 (W427, I424, N425bb) members of the pocket.  
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Figure 30. Effect of peptide triazoles on HIV-1YU2 gp120 interaction with (a) sCD4 and (b) 17b. IC50 
values were determined by fitting the UM101 and UM25 data to a logistic function in Origin (OriginLab) 
and are listed in Table 6. 
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Figure 31. (a) F105-bound gp120 with the Fab removed. Red spheres show the residues that make up the 
small pocket at the interface of the inner and outer domains and blue spheres show some of the outer 
domain residues that are part of the (unformed) F43 cavity. The inset shows the placement of the tip of 
F105 CDR H3 loop residues V100a, F100b, Y100c (in cyan stick representation) at the gp120 interface. 
F100b inserts into the small pocket at the interface of the inner and outer domains (red spheres) and 
Y100c buries deep into the (unformed) F43 pocket (blue spheres) (b) Initial conformations of 
UM25/gp120 encounter complex before the start of minimization and equilibration steps. Peptide 
residues are colored based on residue number with red depicting the N -terminal (citruline) and light 
green depicting the C-terminal (serine) residues. Gp120 backbone color-coding is that of Figure 29.  
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Figure 32. Average scoring energy (CHARMM intermolecular interaction energy) of each cluster plotted 
versus average cluster variation (average RMSD over all cluster members) for all the runs after 
clustering of MD-generated conformations. UM101SD and UM25SD were runs initiated from best results 
out of SwissDock. Top three clusters from UM101 and UM25 are labeled in blue and red, respe ctively.  
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Figure 33. Minimum energy representatives from the top scoring clusters for (a) UM101 (cluster 1) and 
(b) UM25 (cluster 22). Panel (c) shows the minimum energy representative of UM25 cluster 8 which 
scores slightly lower than cluster 22 on energy but is almost half as homogenous. Heavy atoms of gp120 
residues which contribute more than 2% of the total interaction energy for each cluster are shown as red 
spheres. Heavy atoms of residues which act as a donor or acceptor of hydrogen bonds with occupancy 
values > 1% are shown as blue spheres. For residues which appear in both groups, those with hydrogen 
bond occupancy < 10% are colored red. Peptide heavy atoms are depicted in licorice rendering. 
Backbones of the gp120 inner and outer domains are color coded as per Figure 29.  
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Figure 34. Contribution of each peptide residue to peptide/protein interaction energy in the three top 
ranking clusters of UM101 and UM25 from the simulations. C1, C25, etc. denote cluster numbers.   
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Figure 35. STD NMR spectrum of UM25.  Reference and difference spectra (see Materials and Methods) 
are shown in black and red, respectively (see Materials and Methods). Proton s exhibiting the largest 
enhancements are labeled (see Table 7 for quantification).  Protons of Trp are located under the curved, 
dotted line. Trz and Ph denote the triazole and p-aminophenyl rings, respectively (see Figure 36).  
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Figure 36. Chemical structure of UM25 showing protons involved in gp120 binding. Percent 
enhancements observed in the STD NMR spectrum are labeled in red ( Table 7). The two stereocenters 
studied for UM25 are indicated as blue carbons.   
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Figure 37. STD NMR spectra of the four diastereomers of UM25 in complex with gp120. 
Stereochemistry of the two chiral centers is indicated on the left of each spectru m. PhTrz denotes the p-
aminophenyl triazole.  
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Appendices 
Table 8. Fraction of peptide/protein interaction energy contributed by various gp120 residues for UM101 
cluster 1 (left) and UM25 cluster 22 (right). Only residues contribut ing more than 1% of the energy are 
shown here. 
UM101  UM25 
gp120 Residue Interaction Energy (%)  gp120 Residue Interaction Energy (%) 
TRP112 9.61  MET426 11.35 
PHE382 8.73  MET475 10.18 
ILE423 7.86  HIS105 8.06 
MET426 6.83  ILE109 7.96 
GLU370 6.35  ARG476 7.89 
MET475 6.11  PHE382 7.62 
ILE109 6.05  TRP112 7.54 
LEU116 4.37  ASP474 3.75 
ASN425 3.51  ILE108 3.75 
VAL255 3.06  TRP479 3.17 
ASP113 2.97  VAL255 3.15 
TYR384 2.80  TYR384 2.79 
THR257 2.36  LYS421 2.53 
HIS105 2.34  SER375 1.74 
LYS421 2.28  ASN425 1.61 
ASP474 2.16  ILE423 1.61 
TRP427 2.15  GLY473 1.44 
SER256 1.87  PHE210 1.44 
LYS117 1.85  ILE424 1.15 
ILE108 1.80  THR257 1.12 
ILE371 1.78    
SER375 1.64    
GLN422 1.43    
ASP368 1.13    
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Table 9. Interfacial hydrogen-bond occupancy for UM101 cluster 1 (left) and UM25 cluster 22 (right). m 
and s denote main and side chains, respectively.  
UM101  UM25 
donor acceptor occupancy (%)  donor acceptor occupancy (%) 
CIT1(m) ASP474(s) 79.22  CIT1(m) ASP474(s) 86.73 
SER7(s) GLN422(m) 24.68  SER7(s) ILE423(m) 68.37 
SER7(s) LYS421(m) 16.88  MET475(m) ASN3(s) 38.78 
SER7(s) TYR384(s) 10.39  LYS421(s) SER7(m) 26.53 
TRP6(s) SER375(s) 10.39  TRP6(s) SER375(s) 6.12 
CIT1(m) GLY473(m) 5.19  SER7(s) TYR384(s) 5.10 
LYS421(s) SER7(m) 3.90  ARG476(s) ASN2(m) 5.10 
CIT1(s) GLY473(m) 1.30  TYR384(s) SER7(m) 3.06 
SER7(s) GLU370(s) 1.30  LYS421(s) SER7(m) 2.04 
    SER7(s) GLU370(s) 1.02 
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Table 10. Chemical Shift Assignments of UM25 a 
Carbon Cit1 N2 N3 I4 X5 W6 S7 
α 4.32 4.68 4.64 4.33 4.53 4.43 4.05 
β 1.78,1.82 2.69,2.69 2.69,2.76 1.79 2.37,2.80 3.02,3.10 3.41,3.52 
γ 1.45,1.47 - - 0.80,1.41,1.08 5.16 - - 
δ 3.03   0.78 4.20,4.35   
1        
2     7.49 7.06  
3     6.80   
4      7.32  
5     6.80 7.06  
6     7.49 6.95  
7      7.36  
8     8.05   
NH      9.98  
a
Assignments were made by analysis of COSY, HOHAHA, HSQC and NOESY spectra. 
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Figure 38. Minimum energy representative conformation of UM101-C1. The coloring scheme is that of 
Figure 32 of the main text.  
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Figure 39. Minimum energy representative conformation of UM25-C22. The coloring scheme is that of 
Figure 32 of the main text.  
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Figure 40. Minimum energy representative conformation of UM25-C8. The coloring scheme is that of 
Figure 32 of the main text.  
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Figure 41. (a) and (b) Highest scoring UM101 and UM25 poses genera ted by SwissDock, 
respectively; (c) and (d) lowest energy poses after clustering and MD-equilibration of the top 
five SwissDock generated complexes of UM101 and UM25, respectively; ( e) lowest energy 
conformation of UM101 cluster 1 (Figure 32 of the main text) and (f) and UM25 cluster 22 
(Figure 32 of the main text). Residues experimentally found to be important for peptide triazole 
binding (102) are shown as orange spheres. Gp120 coloring scheme is that of Figure 29 of the 
main text. 
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CHARMM topology and parameter data for the derivatized azidoproline  
 
Figure 42. X=(2S, 4S)-4-(4-phenyl-1H-1, 2, 3-triazol-1-yl) pyrrolidine 
MASS   341 N250  14.00700 
MASS   342 N251  14.00700 
MASS    61 C261  12.01100 
MASS   277 H261   1.00800 
MASS   275 H252   1.00800 
MASS   299 C251  12.01100 
MASS   338 NS3   14.00700 
MASS   269 HP4    1.00800 
 
RESI H25            0.000 
GROUP 
ATOM N      N      -0.29 
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ATOM CD     CP3     0.000 
ATOM HD1    HA      0.090 
ATOM HD2    HA      0.090 
ATOM CA     CP1     0.020 
ATOM HA     HB      0.090 
GROUP 
ATOM CB     CP2    -0.180 
ATOM HB1    HA      0.090 
ATOM HB2    HA      0.090 
GROUP 
ATOM CG     CP2    -0.090 
ATOM HG1    HA      0.090 
GROUP    
ATOM C      C       0.51  
ATOM O      O      -0.51  
GROUP 
ATOM C1     C251 -0.350   
ATOM C2     C251  0.360   
ATOM N5     N251  0.570   
ATOM H1     H252  0.200   
ATOM N4     N250 -0.370   
ATOM N3     N250 -0.410   
GROUP 
ATOM C4     C261 -0.112   
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ATOM C5     C261 -0.111   
ATOM C6     C261  0.056   
ATOM C7     C261 -0.111   
ATOM C8     C261 -0.112   
ATOM C3     C261  0.105   
ATOM HF4    H261   0.115  
ATOM HF5    H261   0.115  
ATOM HF7    H261   0.115  
ATOM HF8    H261   0.115  
ATOM NR     NS3   -0.834 
ATOM HN9    HP4   0.381 
ATOM HN8    HP4   0.381 
 
BOND N   CD   
BOND N   CA   
BOND CD   HD1  
BOND CD   HD2  
BOND CD   CG   
BOND CA   CB   
BOND CA   HA   
BOND CG   CB   
BOND CG   HG1  
BOND CG   N5   
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BOND CB   HB1  
BOND CB   HB2  
BOND C   CA 
BOND C   +N 
BOND C1   C2   
BOND C1   N5   
BOND C1   H1   
BOND C2   N3   
BOND C2   C3  
BOND N5   N4   
BOND N4   N3   
BOND C4  C5  
BOND C4  C3  
BOND C4  HF4  
BOND C5  C6  
BOND C5  HF5  
BOND C6  C7  
BOND C7  C8  
BOND C7  HF7  
BOND C8  C3  
BOND C8  HF8  
BOND C6  NR 
BOND NR  HN9 
BOND NR  HN8 
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DOUBLE   O  C        
IMPR N -C CA CD    
IMPR C CA +N O    
CMAP -C  N  CA  C   N  CA  C  +N 
 
IC -C   CA   *N   CD    1.3366 122.9400  178.5100 112.7500  
1.4624 
IC -C   N    CA   C     1.3366 122.9400  -76.1200 110.8600  
1.5399 
IC N    CA   C    +N    1.4585 110.8600  180.0000 114.7500  
1.3569 
IC +N   CA   *C   O     1.3569 114.7500  177.1500 120.4600  
1.2316 
IC CA   C    +N   +CA   1.5399 116.1200  180.0000 124.8900  
1.4517 
IC N    C    *CA  CB    1.4585 110.8600  113.7400 111.7400  
1.5399 
IC N    C    *CA  HA    1.4585 110.8600 -122.4000 109.0900  
1.0837 
IC N CA CB CG 1.4963 105.9656 -33.1792 101.7987 1.5471 
IC CA CB CG CD 1.5471 101.7987 39.3381 102.4032 1.5515 
IC N CA CB HB1 1.4963 105.9656 83.6825 110.8627 1.0878 
IC N CA CB HB2 1.4963 105.9656 -153.8428 112.6740 1.0861 
IC CB CG CD HD1 1.5471 102.4032 85.5445 110.1893 1.0908 
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IC CB CG CD HD2 1.5471 102.4032 -153.5422 112.2971 1.0893 
IC N CA CB HB1 1.4963 105.9656 83.6825 110.8627 1.0878 
IC N CA CB HB2 1.4963 105.9656 -153.8428 112.6740 1.0861 
IC CA CB CG HG1 1.5471 101.7987 -77.0979 109.4215 1.0924 
IC CA CB CG N5 1.5471 101.7987 164.0744 114.7453 1.4740 
IC CD CG N5 N4 1.5515 114.5505 -120.6115 120.2349 1.3905 
IC CG N5 N4 N3 1.4740 120.2349 179.9318 107.1677 1.3119 
IC N3 N4 N5 CG 1.3119 107.1677 179.9318 120.2349 1.4740 
IC N3 N4 N5 C1 1.3119 107.1677 0.0244 109.7162 1.3781 
IC C2 C1 N5 N4 1.3585 105.7720 0.0055 109.7162 1.3905 
IC C2 C1 N5 CG 1.3585 105.7720 -179.8900 130.0488 1.4740 
IC C2 N3 N4 N5 1.4088 109.0561 -0.0436 107.1677 1.3905 
IC C1 C2 N3 N4 1.3585 108.2881 0.0484 109.0561 1.3119 
IC N5 C1 C2 N3 1.3781 105.7720 -0.0315 108.2881 1.4088 
IC N5 C1 C2 C3 1.3781 105.7720 -179.9529 130.4237 1.4898 
IC C1 C2 C3 C4 1.3585 130.4237 -0.1272 121.3785 1.3944 
IC C1 C2 C3 C8 1.3585 130.4237 179.8949 119.7210 1.3952 
IC C2 C3 C4 C5 1.4898 121.3785 179.9807 120.4899 1.3842 
IC C2 C3 C4 HF4 1.4898 121.3785 0.0270 119.9626 1.0816 
IC C3 C4 C5 HF5 1.3944 120.4899 179.9864 119.7268 1.0827 
IC C4 C5 C6 NR 1.3842 120.2429 179.9400 120.1838 1.0000 
IC C5 C6 NR HN1 1.3865 120.1838 126.4715 109.4712 1.0000 
IC C5 C6 NR HN2 1.3865 120.1838 -113.5285 109.4712 1.0000 
IC C5 C6 C7 HF7 1.3865 119.6974 -179.9572 120.0206 1.0828 
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IC C5 C6 C7 C8 1.3865 119.6974 0.0660 120.2440 1.3852 
IC C6 C7 C8 HF8 1.3865 120.2440 179.9706 120.5036 1.0820 
IC C6 C7 C8 C3 1.3865 120.2440 -0.0299 120.4253 1.3952 
IC C2 C3 C8 C7 1.4898 119.7210 179.9957 120.4253 1.3852 
IC C3 C4 C5 C6 1.3944 120.4899 0.0782 120.2429 1.3865 
IC C4 C5 C6 C7 1.3842 120.2429 -0.0900 119.6974 1.3865 
 
CHARMM energy parameters: 
BONDS 
C251 C251  410.00     1.3600 
C251 N251  400.00     1.3800 
C251 N250  400.00     1.3800 
C251 H252  375.00     1.0830 
N251 N250  340.00     1.2900 
N250 N250  360.00     1.3550 
CP2  N251  400.00     1.4700 
C251 C261  305.00     1.3750 
C261 C261  305.00     1.3750 
C261 H261  340.00     1.0800 
C261 NS3   400.00     1.3900 
NS3  HP4   488.00     1.0000 
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ANGLES 
C251 C251 N251  130.00    110.00 
C251 C251 N250  130.00    106.00 
C251 N251 N250  110.00    106.80 
N251 N250 N250  160.00    102.20 
C251 N250 N250  160.00    115.00 
CP2  CP2  N251  140.00    108.00 
CP3  CP2  N251  140.00    113.70 
CP2  N251 N250  130.00    127.00 
CP2  N251 C251  130.00    126.00 
HA   CP2  N251   30.00    106.30 
C261 C251 N250  130.00    110.00 
C251 C261 C261   50.00    120.00 
C261 C261 NS3    60.00    121.00 
C261 NS3  HP4    60.00    111.60 
HP4  NS3  HP4    31.00    117.00 
 
DIHEDRALS 
N251 C251 C251 N250    14.0000  2   180.00 
N250 C251 C251 H252     3.0000  2   180.00 
H252 C251 N251 N250     5.5000  2   180.00 
C251 C251 N250 N250    10.0000  2   180.00 
C251 N251 N250 N250    14.0000  2   180.00 
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N251 N250 N250 C251     8.5000  2   180.00 
N251 CP2  CP3  N        0.0     3     0.0 
CP2  N251 C251 C251     0.0     1     0.0 
CP2  CP2  N251 N250     0.3     1     0.0 
CP3  CP2  N251 C251     0.2     4     0.0 
CP3  CP2  N251 N250     0.1     3   180.0 
CP3  CP2  N251 N250     0.3     2     0.0 
CP3  CP2  N251 N250     0.0     1   180.0 
N250 N251 C251 C251    14.0000  2   180.00 
N250 N250 N251 C251    14.0000  2   180.00 
CP2  N251 N250 N250     0.0     2   180.0 
HA   CP2  N251 C251     0.0     3     0.0 
N250 N250 N251 C251    14.0000  2   180.00 
HA   CP2  N251 N250     0.195   3     0.0 
N250 N251 C251 C251    14.0000  2   180.00 
HA   CP2  N251 C251     0.0     3     0.0 
HA   CP2  N251 N250     0.195   3     0.0 
HA   CP3  CP2  N251     0.0     3     0.0 
N251 CP2  CP3  N        0.0     3     0.0 
HA   CP3  CP2  N251     0.0     3     0.0 
CP2  N251 N250 N250     0.0     2   180.0 
H252 C251 N251 CP2      0.0000  2   180.00 
C261 C251 C251 N251     4.0000  2   180.00 
C261 C251 C251 H252     2.8000  2   180.00 
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C251 C251 C261 C261     2.55    2   180.00 
N250 C251 C261 C261     2.55    2   180.00 
C261 C251 N250 N250     8.5000  2   180.00 
C251 C261 C261 C261     3.0000  2   180.00 
C251 C261 C261 H261     3.0000  2   180.00 
C261 C261 C261 C261     3.1000  2   180.00 
C261 C261 C261 H261     4.2000  2   180.00 
H261 C261 C261 H261     2.4000  2   180.00 
C261 C261 C261 NS3      5.0000  2   180.00 
C261 C261 NS3  HP4      1.3500  2   180.00 
NS3  C261 C261 H261     2.4000  2   180.00 
 
NONBONDED 
H252   0.0       -0.0460     0.9000 
C251   0.0       -0.0500     2.1000 
N250   0.0       -0.2000     1.8500 
N251   0.0       -0.2000     1.8500 
C261   0.0       -0.0700     1.9924 
H261   0.0       -0.0300     1.3582 
NS3    0.0       -0.2000     1.8500 
HP4    0.0       -0.0460     0.2245 
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CHAPTER 5: DESIGN, PRODUCTION AND CHARACTERIZATION 
OF A PEPTIDE TRIAZOLE / GP120 COVALENT CONJUGATE
*
 
 
 
 
Abstract 
Prevention of HIV entry into target cells is an attractive goal for development of antiviral 
agents and microbicides. Gp120 glycoprotein is the main component of the viral surface 
envelope spikes responsible for initiation of the entry process and as such, can be targeted 
for development of entry inhibitors. Our lab has developed a class of broadly active 
peptide triazole (PT) dual antagonist compounds which can inhibit gp120 binding to both 
its target receptor and coreceptor, preventing viral entry and infection. Using molecular 
dynamics (MD) and saturation transfer NMR (STD-NMR), we recently proposed a model 
of the mechanism of action of these compounds and put forward a an all-atom 
computational model of the PT/gp120 complex. Here we used this model as a blueprint 
for design of a covalently conjugated PT/gp120 complex. We produced and characterized 
a single-cysteine gp120 mutant (E275C) which maintains excellent binding affinity for 
sCD4 and two other CD4 binding site (CD4bs) ligands, along with functionality toward 
CD4-induced (CD4i) ligands that bind the coreceptor binding site (like mAb 17b). In 
parallel, we synthesized a PEGylated and biotinylated variant of PTs with a maleimide at 
the N-terminus which maintained activity toward gp120. We conjugated this reactive 
peptide to E275C gp120 and probed its ligand binding properties using surface plasmon 
                                                 
* Manuscript in preparation as “ . Emileh, F. Tuzer, A.P. Holmes, C.A. Duffy, I.M. Chaiken, C.F. Abrams  Design and engineering of 
ligand-induced conformational restraints in HIV-1 envelope gp120 ” 
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resonance (SPR) interaction analysis. The results showed that the conjugated complex 
maintains inhibition of sCD4, F105, b12 and 17b binding to gp120, all signatures of PT 
binding to gp120. We further showed that the covalent complex is functional for mAb 
2G12 binding, consistent with previous studies showing that 2G12 does not compete with 
PT binding to gp120. We think this stabilized covalent conjugate can be used to generate 
crystal structures of this presumably flexible complex, which can be used for structure-
based design of peptidomimetic entry inhibitors.  
 
Introduction 
Dual antagonist peptide triazoles (PT) are a novel class of broadly active and non-
toxic (38, 39) entry inhibitors which simultaneously inhibit binding of gp120 to both CD4 
and the coreceptor (CCR5 or CXCR4) (35, 37). A representative member of this family, 
UM24, binds to soluble YU-2 gp120 with low nanomolar affinity (KD= 4.1 nM) and has 
a 50% effective concentration (EC50 ) of 2.6 μM (41). These compounds can be 
synergistically combined with other entry inhibitors and some recent variants show 
virolytic activity (39). All the above properties make PTs attractive candidates for both 
therapeutic and microbicidal applications.  
CD4 binding to gp120 is accompanied by an unusually large decrease in entropy (-
TΔS=44.2 kcalmol-1) (15). This has been suggested to be the signature of a large 
conformational change in gp120 which is thought to structure the latter from an ensemble 
of flexible unstructured states into the activated state (i.e. the CD4-bound state; Figure 
43a). In the activated state, gp120 can be divided into an inner domain, an outer domain 
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and a minidomain at their interface called “the bridging sheet” which is where the 
coreceptor binds (Figure 43a). Folding of the bridging sheet has been suggested to 
account for half of the structuring in gp120 accompanying formation of the activated 
state (21). Peptide triazoles bind with a much smaller structuring effect on gp120 (-
TΔS=6.3 kcalmol-1) compared to CD4 (15, 41) and do not inhibit CD4 binding to a 
gp120 mutant (S375W) engineered to stay in the activated state (33). However the 
peptide triazoles inhibit mAb F105 binding to a gp120 mutant (I423P) which does not 
sample the activated state effectively (33). In absence of a peptide triazole/gp120 
complex crystal structure, these results have been used to suggest that these compounds 
prevent formation of the bridging sheet (41) and effectively “trap” gp120 into an 
ensemble of conformations incommensurate with formation of this functionally important 
domain.  
Currently there are no crystal structures of a peptide triazole/gp120 complex, 
hampering efforts to optimize the peptide potency and develop non-natural 
peptidomimetics through structure-based design. The peptide triazole/gp120 binding is 
characterized by little structuring of gp120 (-TΔS=6.3 kcalmol-1) (41) which combined 
with inherent gp120 structural flexibility (23, 24), may explain our lack of success in 
resolving a crystal structure for this complex. One way to overcome this obstacle would 
be to stabilize the complex into a less flexible state by introducing covalent bonds 
between different parts of the system. A similar approach was adopted before to solve the 
crystal structure of the antigen-binding fragment (Fab) of antibody b12 with gp120 core 
(23). Since b12 binds gp120 with a small structuring effect (-TΔS=6.3 kcalmol-1), Zhou 
et al. stabilized gp120 by introducing multiple pocket filling and disulfide mutations (23). 
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We hypothesized that covalently linking the peptide triazole to gp120 would stabilize the 
peptide/gp120 complex in a similar fashion. Recently, we developed a model of the 
encounter complex between the two molecules (115) and here we used that model to 
guide the design and synthesis of a covalently conjugated peptide triazole/gp120 
complex. This conjugate may help in determining the crystal structure of this interesting 
class of entry inhibitors in complex with gp120. It also lends experimental support to our 
all-atom structural model which in turn can assist in rational design of peptidomimetic 
entry inhibitors based on peptide triazoles. 
 
Materials and Methods 
The following reagents were obtained from the NIH AIDS reference and Reagents 
Program, division of AIDS, NIAID: anti HIV-1 gp120 monoclonal antibodies 2G12 (Dr. 
H. Katinger), IgG1 b12 (Dr. D. Burton & C. Barbas), VRC01 (Dr J. Mascola).  
 
Molecular Dynamics Simulations  
Details of the simulations are explained elsewhere (115). Briefly, starting with an all-
atom, explicit solvent minimum energy structure of PT/gp120-core from our previous 
work (115), we launched a 200 ns equilibration run in the NVT ensemble with the aim of 
probing the stability of the complex. The CHARMM22 force-field (65) was used with 
NAMD v2.7 (50) and all molecular analyses and image renderings were done in VMD 
v1.9 (66). 
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Protein  production 
Soluble CD4 (sCD4) was produced and purified as described before (41). 
Monoclonal antibody 17b was obtained from Strategic BioSolutions. mAb F105 was 
produced in-house. The wild-type (WT) gp120YU-2 construct was created by insertion of 
a V5 (GKPIPNPLLGLDST) coding sequence N-terminal to the C-terminal His6 tag in a 
pcDNA3.1 vector carrying the mammalian codon-optimized sequence for a CM5 
secretion peptide and gp120YU-2 (a gift from Drs. Navid Madani and Joseph Sodroski) 
(102). The E275C mutation was introduced into this backbone using the QuickChange 
site-directed mutagenesis protocol (Stratagene). The primers were ordered for custom-
synthesis at Integrated DNA Technologies (IDT) and the following primer sequence was 
used for E275C: 5’-gatcgtgatccggagctgtaacttcaccaacaacg-3’. Mutagenesis was verified by 
sequencing (Genewiz Inc.) using the in-house primer BGHR (for 3’) or a custom-made 
primer 5’-tccccatccactactgcgccc-3’ (IDT). DN  for transient transfection was purified 
using the Qiagen MaxiPrep kit (Qiagene) and transfected into confluent HEK 293F cells 
according to manufacturer’s protocol (Invitrogen). Five days later, cells were harvested, 
spun down and the supernatant was filtered through 0.2 μm filters. Purification was 
performed over a 17b antibody-coupled column prepared using NHS-activated Sepharose 
according to manufacturer’s instructions (GE Healthcare). Gp120 was eluted from the 
column using 0.1M Glycine buffer pH=2.4 into 1M Tris pH=8.0. Identity of the eluted 
fractions was confirmed through SDS-PAGE and Western blotting using antibody D7324 
(Aalto Bioreagents). After pooling the peak fractions, additional purification and removal 
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of aggregates was performed on a prepacked Superdex 200 HR gel filtration 
chromatography column (GE Healthcare). Monomeric fractions were identified through 
SDS-PAGE/Western blotting with mAb D7324, pooled, concentrated, frozen and stored 
at -80°C. 
 
Peptide synthesis 
Peptide triazoles (Table 11) were synthesized via manual solid-phase synthesis using 
Fmoc chemistry on a Rink amide resin at 0.25 mmol scale, purified using reverse phase 
HPLC (RP-HPLC) and validated by matrix-assisted laser desorption ionization time of 
flight mass spectrometry (MALDI-TOF MS) as detailed in Umashankara et al. (41). All 
preparations were initially run on a semiprep Vydac C18 column and the collected main 
peaks were then run on an analytical Luna C18 column. For L-KR21 synthesis, a 19-atom 
PEG linker N-Fmoc-N″-succinyl-4,7,10-trioxa-1,13-tridecanediamine (Sigma) was 
introduced into the sequence of KR21. For production of the reactive AE21 peptide, 
lyophilized KR21 was dissolved in methanol and reacted with the heterobifunctional 
crosslinker SMPEG2 (succinimidyl-[(N-maleimidopropionamido)-diethyleneglycol] 
ester) (Pierce) with the latter at 40-fold excess. Typically the reactions were performed in 
200-500 μL at KR21 concentration of 500 μL.  fter 24 hours, the reaction mixture was 
lyophilized, dissolved in Triethanolamine(TEA)/Acetate buffer pH=7.0 and immediately 
run over a Luna analytical C18 RP-HPLC column (Phenomenex) with a gradient of 20-
70% CH3CN/(TEA/acetate) over 60 minutes at a flow rate of 1 mL/min. The integrity of 
the product and absence of maleimide hydrolysis was confirmed by MALDI TOF-MS. 
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AE21 was lyophilized and stored at -20°C as a stock solution in dried DMSO. HPLC 
chromatograms and MALDI MS spectra for AE21 and L-KR21 are shown in the 
supporting information (Figures S3-S6).  
 
Competition ELISA 
Peptide inhibition of sCD4 or 17b binding to gp120 was assessed via competition 
ELISA. HIV-1YU-2 gp120 (100 ng) was adsorbed to a 96-well microtiter plate overnight 
at 4°C. After washing the plate 3x with PBST (1x PBS with 0.1% Tween-20 v/v), the 
plate was blocked with 3% BSA in 1x PBS for 2 hours at room temperature, followed by 
3x washing with PBST. All further incubations before detection were done in 0.5% BSA 
in PBS. For sCD4 competition experiments, 100 μL sCD4 (0.1 μg mL-1) was added to 
each well in the presence of increasing concentrations of peptide. After incubation for 1 
h, the plate was washed 3x followed by addition of 100 μL of biotinylated anti-CD4 
antibody OKT4 (eBiosciences) at 1:5000 dilution. After 1 hr incubation, the plate was 
washed 3x and 100 μL streptavidin-conjugated horseradish peroxidase (SA-HRP) was 
added and incubated for 1 h. The extent of HRP conjugate binding was detected by 
adding 200 μL of 40% (m/v) o-phenylenediamine dihydrochloride (Sigma-Aldrich) in 
0.05M phosphate-citrate for 30 mins followed by measuring the optical density (OD) at 
450 nm using a microplate reader (Molecular Devices). For 17b competition, the same 
protocol as above was followed, adding 100 μL of 0.1 μg mL-1 antibody to the 
immobilized gp120 in presence of increasing concentrations of the peptide. Detection 
was done using an HRP-conjugated rabbit anti-human antibody (Millipore) at 1:5000 v/v 
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dilution followed by OPD development. Results were fitted in Origin (OriginLab) to 
extract IC50  values. 
  
Peptide/gp120 covalent conjugate production and purification 
Purified gp120 (E275C or WT) was exchanged into the reaction buffer (filtered and 
degassed 0.1M PBS pH=6.9 with 10 mM EDTA). AE21 as a concentrated solution in 
DMSO was added to this solution and the reaction was continued typically for four hours. 
DMSO content in the reaction mixture was always kept lower than 4% by volume. 
Typically reactions were done in 500 μL and at gp120 concentrations 2-10 μM. Initially a 
high excess ratio of the reactive peptide (40x) was used but since we observed that this 
led to higher non-specific labeling with WT gp120, we significantly reduced this ratio 
down to 1-2x. Maleimide-PEG2-biotin (hereafter MPB, Pierce) was used as a general-
purpose biotinylation reagent and reacted in parallel and similar to AE21 with WT or 
E275C gp120. As a control experiment, AE21 was replaced with the non-reactive KR21 
at the same ratios. Where necessary, E275C was dissolved in 6M guanidium 
hydrochloride and heated at 50C for 30 minutes to denature the protein. This sample was 
exchanged back into the reaction buffer and used as unfolded E275C. 
The reaction mixture was filtered 5x through Ultracel 30K filters (Amicon) and 
exchanged into 0.1M PBS pH=7.4 to remove unreacted small molecules. The results 
from this step were used in SDS-PAGE/Western blot analysis. Then the mixture (~500 
μL) was dialyzed against a large volume (2-4L) of 0.1M PBS pH=7.4 buffer using 10K 
MWCO Slide-A-Lyzer mini dialysis devices (Pierce). CaptAvidin conjugated agarose 
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beads (Invitrogen) were packed into a 2.5 mL column and used for further purification of 
the covalent conjugate using fast protein liquid chromatography (FPLC). The sample 
from the previous step was exchanged into 0.05M citrate buffer pH=4.0, passed over this 
column and eluted in 1 mL fractions using 0.05M carbonate buffer pH=10.0 into 1 mL 
0.1M PBS pH=7.4. Identity of the eluted peaks was confirmed using SDS-
PAGE/Western blotting with a mouse α-biotin antibody (Sigma-Aldrich). 
 
Surface Plasmon Resonance (SPR) assays   
SPR experiments were performed on a Biacore 3000 optical biosensor (GE 
Healthcare). All experiments were carried out at 25°C using standard PBS buffer pH=7.4 
with 0.005% surfactant P-20. A CM5 sensor chip was derivatized by standard 1-ethyl-3-
(3-dimethylaminopropyl) carbodiimide (EDC)/N-hydroxysuccinimide (NHS) chemistry 
and coupling was done through ligand amine groups. For immobilization of the thiol-
containing peptide SR07C, 2-(2-pyridinyldithio)ethaneamine (PDEA) in 0.1M borate 
buffer pH=8.5 was injected over the surface after EDC/NHS activation of the surface 
dextran matrix. SR07C was coupled to this surface through disulfide exchange. 
Antibodies 2E3 (α-human IL5) or 2B6R (α-human IL5R) were immobilized for use as 
control surfaces. In surface capture experiments, NeutrAvidin biotin-binding protein 
(Pierce) was immobilized on the surface through standard EDC/NHS chemistry (above) 
and reaction mixture was flowed over the surface at 5 μL/min to capture the biotinylated 
product. To control for the different amounts of product captured on such a surface and 
E275C-immobilized surfaces, signals were normalized to the maximum signal from 
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injection of 200 nM mAb D7324. For kinetic analyses, typically 200-300 RUs of protein 
reagents were immobilized on SPR chips and analytes were flowed over the surface at 
50-100 μL/min. Surface regeneration was achieved by a quick 5 μL injection of 10 mM 
HCl solution at 100 μL/min.  
Data analysis was performed using BIAEvaluation v4.0 software (GE Healthcare). 
Signals from buffer injections and control surface bindings were subtracted in all 
experiments to account for nonspecific binding. For kinetic parameter determination we 
used a method similar to that used by Morton et al. (116). The signal from the highest 
concentration of the analyte was used to calculate the off rate (kd) using a simple 1:1 
binding model. For each concentration, ka was determined from a fit of the same 1:1 
binding model to the experimental data. Using kd from the previous step, a value for ks 
was reconstructed using the following formula at each concentration: 
          
Then from the slope of a linear fit of the above equation to the ks vs. C plot for all 
concentrations, the final ka was extracted and used to calculate the equilibrium 
dissociation constant (KD). 
 
Results 
Production and characterization of a single cysteine, functional mutant of 
HIV-1 gp120  
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We recently proposed an atomistic model of the peptide triazole/gp120 encounter 
complex (115). Briefly, we proposed that the peptide binds at the junction of the inner 
and outer domains and to a gp120 conformation wherein the bridging sheet is not yet 
formed. Therefore, peptide binding prevents the formation of the bridging sheet and 
hence binding of CD4 and coreceptor (or coreceptor surrogate antibodies like mab 17b). 
Figure 43b shows the lowest energy conformation of the encounter complex from our 
molecular dynamics (MD) simulations.  
Since gp120 does not have any unpaired/free cysteines (18), we chose to introduce a 
cysteine mutation at position 275 (E275C – shown in Figure 43b in green spheres) as a 
connection point on the protein for our conjugation studies. This residue resides on the 
sequentially variable loop D in gp120 and was used by Zhou et al. as part of a disulfide 
linkage between the inner and the outer domains (23). They found that introduction of a 
double cysteine using this position along  with other pocket filling mutations did not 
perturb gp120 conformation or lead to a loss of binding to CD4, 17b (coreceptor 
surrogate antibody) or mAb b12 (23). In addition, this residue is in close proximity to the 
N-terminus of the peptide-triazole in our simulated model of the encounter complex and 
this can facilitate implementation of a conjugation strategy later in the process.  
We first tested the binding affinity of the E275C gp120 mutant to various gp120 
ligands and compared it to the WT protein. sCD4 (soluble receptor) and mAbs 17b 
(coreceptor surrogate / CD4-induced antibody), b12 and VRC01 (CD4 binding site 
antibodies) were used as the analyte in SPR experiments where the purified WT or 
E275C gp120 was immobilized on the SPR chip. A representative sensogram is shown in 
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Figure 44 for b12 binding. Kinetic parameters were extracted (Materials and Methods) 
and the resulting KD values are shown for various ligands in Table 12. The only ligand 
among the four studied here that seems to have been significantly affected by 
introduction of the cysteine mutation is VRC01, as evidenced by its slightly decreased 
affinity for E275C. This is consistent with the published crystal structure of this antibody 
in complex with gp120 which shows loop D and residue 275 on gp120 as main contact 
points (61). These results show that the single cysteine mutant E275C can be expressed, 
purified and is functional toward typical ligands of gp120. 
We next assessed affinity of the E275C mutant for peptide triazoles. A C-terminal 
cysteine was introduced into the peptide sequence after a short spacer from the active 
core (SR07C, Table 11) and was used to immobilize the peptide on the SPR chip. Serial 
dilutions of the purified E275C gp120 were passed over the surface and the resulting 
sensograms were used to extract kinetic parameters of interaction between gp120 (WT 
and E275C) and PTs (Figure 45). Both proteins bind the peptide with similar affinities 
which is evident in the value of the dissociation constant extracted from the sensograms 
(KD = 8.3 nM for WT gp120 and 6.8 nM for E275C, Figure 45). This is consistent with 
previous results which show that the five amino acids in the center of the peptide (N-N-I-
X-W) make up the active pharmacophore for this class of compounds and addition of 
extra amino acids to both ends does not significantly affect the peptide potency (41). 
These results confirm that E275C recognizes PTs with similar affinity as WT gp120 and 
can be a suitable candidate for further modifications. 
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Design and characterization of a thiol -reactive peptide triazole 
Going back to the simulation model of the peptide triazole encounter complex, we 
subjected the minimum energy conformation shown in Figure 43b to 200 ns of 
equilibrium to probe its stability. Figure 46 shows the RMSD (root-mean squared 
deviation) trace of heavy atoms for various peptide residues along with the overall 
peptide RMSD. From this plot, one can see that the N-terminal citruline is substantially 
more flexible than the rest of the peptide. This can be visualized by tracing the 
coordinates of the N-terminal amine nitrogen of peptide backbone during the equilibrium 
as a representative (Figure 47a). We measured the distance of this atom to the γ-carbon of 
E275 during the equilibrium run and from that, constructed a distance frequency 
distribution plot (Figure 47b). It is seen that the most likely distance between these two 
representative points is ~17.41   . This suggests that if the sequence used in the model is 
to be used to synthesize the reactive peptide, there should be a linker of at least ~18    
connecting the N-terminus of the peptide to the thiol group on E275C. Considering that 
this is the linear distance between the two measurement coordinates, we expect it length 
to be a minimum for the linker length.  
We recently reported on the binding characteristics of a biotinylated variant of PTs 
(KR21, compound Z) where a K(ε-Biotinyl) residue is introduced on the peptide C-
terminus after a short spacer from the active core (102). Since the presence of a biotin 
moiety on the peptide sequence can facilitate downstream analysis and purification of the 
final conjugate, we chose to use this PT as the peptide base for further modifications. 
Considering the arguments put forward in the previous paragraphs for the required length 
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of an N-terminal linker to connect the peptide to E275C on gp120, we chose to introduce 
a short (~19   ) PEG (polyethyleneglycol) linker on the peptide N-terminus (L-KR21, 
Table 11). We hypothesized that the additional N-terminal amino acid on the biotinylated 
peptide (KR21) compared to the modeled peptide (UM101), combined with the flexibility 
of a PEG will be sufficient to position the PT close to its (modeled) binding site on 
gp120.  
We tested the activity of the biotinylated, pegylated peptide triazole L-KR21 in a 
competition assay. Fixed concentration of sCD4 or mAb 17b were mixed with serial 
dilutions of L-KR21 and the amount of bound sCD4 or mAb 17b was probed in an 
ELISA format. Figure 48 shows the results. Although these data show a slight decrease in 
the inhibitory potency of L-KR21 compared to KR21 for gp120/sCD4 interaction, the 
inhibitory potencies of both peptides for gp120/mAb 17b interaction are very close. 
Therefore these results show that introduction of the PEG linker on the PT N-terminus 
has a minor effect on the peptide potency toward both WT and E275C gp120 proteins.  
Maleimides react nearly exclusively with thiols in the pH range 6.5-7.5 (117). At the 
same time, a diverse array of heterobifunctional crosslinkers with maleimide and N-
hydroxy succinimide (NHS) ester functionalities are commercially available from various 
suppliers. Since the PT variants we are using in this work lack side-chain primary amines, 
we can utilize this opportunity to introduce our desired PEG linker bearing a maleimide 
moiety by reacting a heterobifunctional crosslinker of suitable length through its NHS 
end with the primary amine on the PT N-terminus. This approach is illustrated in Figure 
49. 
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After reacting AE21 with E275C and filtering the solution to remove as much of the 
small molecules as possible (Materials and Methods), we analyzed the resulting mixture 
using SDS-PAGE followed by Western blotting. Since the biotinylated peptide provides 
us with a versatile marker (biotin) uniquely identifying the final product, we probed the 
blot with an α-biotin antibody. As Figure 50a shows, AE21 successfully biotinylated 
gp120 (lane 3), while KR21 (the non-reactive biotinylated PT variant AE21 is based on) 
did not show any signal (lane 2). We also used a commercially available, thiol-reactive 
biotinylation reagent (MPB, Materials and Methods) to label the free cysteine on gp120. 
Surprisingly, this reagent failed to biotinylate E275C gp120. Further examination showed 
that MPB indeed labels E275C, but at very low yields compared to AE21 labeling of 
E275C (data not shown). The observation that AE21 labels E275C at much higher yields 
than a non-specific biotinylation reagent (MPB), suggests that the affinity of AE21 for 
gp120, which is provided by its PT component, significantly improves the chemical 
reactivity of the maleimide moiety by localizing it close to reactive partners on gp120 
surface. These most probably can be either amine groups on lysines or the thiol on E275C 
side chain. If this hypothesis was true, we would expect AE21 to have reduced reactivity 
toward unfolded gp120 as the peptide is not expected to bind such an unfolded state of 
gp120. This was indeed the case, as can be seen in Figure 50b, where we unfolded E275C 
gp120 in 6M guanidium hydrochloride before the reaction (Materials and Methods). 
Although some signal is seen for AE21 labeling of unfolded E275C gp120 (lane (3) in 
Figure 50b), overall the signal strength is much less (~5% from densitometry, Figure 50c) 
than that for properly folded E275C gp120 reaction with AE21. There might various 
reasons for such observation. As we noted before, AE21 affinity for gp120 might play an 
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important role for its higher reactivity toward the protein. Unfolding gp120 presumably 
removes this affinity and its accompanying boost in reactivity, as AE21 labeling of 
E275C is significantly reduced. The remaining labeling efficiency might be attributed to 
two factors: (1) labeling of a surface exposed single cysteine at position 275 in the molten 
globule state by AE21 and (2) non-specific labeling of surface amines on lysine side 
chains. Considering the relative hydrophobicity of cysteines (118), it is reasonable to 
assume that residue E275C is more likely to end up more buried in the molten globule 
state of gp120 after unfolding. We attempted to examine the latter point further.  
Although maleimides react 1000 times faster with thiols than with amines at optimal 
pH (117), in absence of thiol groups, like E275C which might be buried inside the molten 
globule structure of unfolded gp120, maleimide groups may react with surface exposed 
amines of lysine side chains. To further probe this issue, we reacted AE21 with WT 
gp120 and analyzed the results using SDS-P GE and Western blotting with an α-biotin 
antibody (Figure 51, bottom row). In addition, we performed the reaction in presence of 
increasing concentrations of KR21 (the non-reactive base peptide for AE21) to probe the 
specificity of AE21 labeling for gp120. The results showed that AE21 binding to gp120 
significantly improves labeling of the protein as competition of binding by KR21 leads to 
reduction of labeling efficiency. This is consistent with our results on the labeling of the 
unfolded protein. Some labeling of the WT protein by AE21 is observed in Figure 51. 
Densitometry analysis of the bands suggests that in absence of KR21, the signal from 
labeled WT gp120 is ~40% of the signal from E275C gp120 in the same conditions. The 
presence of KR21 and its competition for binding to gp120 can be taken as decreasing the 
effective concentration of reactive groups proximal to the protein surface. Since the 
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reactions are performed in the presence of large excess of the labeling peptide (R1 = 
n(AE21) / n(gp120) = 10), one can postulate that for every bound peptide which 
potentially labels the protein at the “correct” site (possibly C275 for E275C mutant if we 
accept the validity of our model), there are many other peptide molecules which do not 
bind the protein but still can non-specifically label it at other sites. Again this view is 
consistent with our results on the small amount of labeling which is present for 
AE21/unfolded E275C reaction. This situation will be more pronounced in absence of the 
free thiol on WT gp120. Therefore, we concluded that non-specific labeling issue might 
be partially addressed by using smaller excess amounts of the labeling peptide. We used 
R1=1-2 for our other reactions. Overall these results suggest that we have successfully 
synthesized a reactive PT variant which binds to gp120 and preferentially reacts with 
E275C to form a covalent conjugate. Moreover, labeling of gp120 with AE21 peptide is 
specific and presence of E275C mutation significantly improves the reaction yield and 
improves selectivity toward our desired site of labeling. 
 
Production and characterization of a conformationally altered gp120  
Although the above results provide evidence that the reactive peptide triazole AE21 
covalently binds E275C, our ultimate target will be a conjugated E275C wherein the 
peptide is occupying its “native” binding pocket and imposing the same conformational 
characteristics over the protein that it does if it was not covalently attached. One way of 
probing these conformational characteristics is by testing the binding of various 
antibodies to the AE21/E275C conjugate. Peptide triazole binding to gp120 does not alter 
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the binding properties of most antibodies that bind linear epitopes on gp120 (i.e. D7324 
to the C-terminus of gp120) (Tuzer et al, unpublished). In contrast, peptide triazoles 
inhibit binding of most conformational antibodies to gp120. Examples include mAbs 
F105 and 17b (33). F105 is an antibody to the CD4 binding site (CD4bs) (22) and 17b is 
a coreceptor surrogate, i.e. it binds to the same epitope as the coreceptor. Moreover 17b, 
and other CD4-induced (CD4i) antibodies, have the distinct property that their binding is 
accompanied by formation of the bridging sheet (24). Mutational studies have pointed to 
an overlap of binding epitopes between peptide triazoles and sCD4 (102).  
Additionally, it has been suggested that peptide triazoles allosetrically inhibit binding 
of CD4i antibodies, possibly through inhibition of the bridging sheet formation (33). 
Therefore, we expect the AE21/E275C covalent conjugate to have significantly reduced 
binding affinity to CD4bs and CD4i antibodies. We attempted to probe these 
conformational characteristics of the covalent conjugate using SPR. 
Before attempting to purify the covalent conjugate out of the reaction mixture, we 
attempted to gain some insight on its properties by directly capturing it using the biotin 
handle on the peptide. Briefly, we immobilized NeutrAvidin biotin-binding protein 
(Materials and Methods) on an SPR chip and flowed the extensively filtered and dialyzed 
reaction mixture over this surface.  
Since the only biotinylated components in the reaction mixture are the free AE21 
peptide and the AE21/E275C covalent conjugate and the former was removed via 
extensive filtration and dialysis (Materials and Methods), the only component 
immobilized on the SPR chip surface should be the latter. Figure 52 shows the sCD4 
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binding characteristics of such immobilized covalent conjugate (panel a) along with the 
response from an unaltered E275C gp120 surface (panel b). To correct for the different 
immobilization densities of each surface, we passed 200 nM D7324 over each surface 
beforehand and normalized the response from sCD4 to the maximum in the response 
from D7324. The results clearly show a significant reduction in sCD4 binding affinity for 
the covalent conjugate. Considering the proximity of the E275C mutation to the edge of 
the CD4 binding site on gp120, we were surprised to see any binding of sCD4 to the 
conjugate at all. This might be due to either some residual non-specific labeling of E275C 
by AE21 which may have resulted in a conjugate where the peptide does not bind to its 
binding pocket and inhibit sCD4 binding. Another reason might be due to the steric 
hindrance exerted by binding of the peptide biotin to surface NeutrAvidin which may 
affect the peptide affinity for its binding pocket on gp120.  
If we accept the validity of the peptide/gp120 encounter complex, we would expect 
sCD4 binding to the covalent conjugate to be inhibited by two factors: (1) The presence 
of the peptide in its binding pocket and its action as an inhibitor of the sCD4/gp120 
interaction and (2) steric hindrance exerted on sCD4 binding resulting from partial 
physical blocking of its binding site by presence of the covalently linked peptide. A more 
stringent test of correct binding pose of the peptide on gp120 would be blockade of 17b. 
The 17b binding site is far from position 275 on gp120 (Figure 43b) and considering the 
size of the peptide and the length of the linker used here, it is highly unlikely that 17b 
binding to gp120 will be inhibited merely by physical blockade of its epitope by a 
covalently linked, but unbound peptide triazole. We tested the binding affinity of the 
AE21/E275C covalent conjugate to 17b in a SPR assay similar to that of sCD4 and the 
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results are shown in Figure 53. It can be seen that similar to sCD4, the covalent conjugate 
has lost its affinity to 17b and the effect is even more pronounced than sCD4. Similar 
results were obtained for AE21/E275C interaction with mAbs F105, 15e and b12 (data 
not shown). 
One drawback to the capture method used above is that it is unclear how much the 
presence of NeutrAvidin on the peptide is affecting its affinity for gp120 which in turn 
would affect the affinity of the covalent conjugate for different ligands. In addition we 
are comparing a randomly oriented ligand on the surface (E275C) with a covalent 
conjugate which is oriented on the surface through binding with NeutrAvidin. Therefore 
we pursued further purification of the conjugate using the biotin handle (Materials and 
Methods). Figure 54 shows the sensograms from sCD4 binding to immobilized E275C 
(panel a) and purified AE21/E275C covalent conjugate (panel b). It clearly shows that the 
covalent conjugate does not bind sCD4 even at very high concentrations. Moreover, it 
seems that the residual binding seen in Figure 52 is gone here. Similar results were 
obtained for 17b which show a lack of binding to AE21/E275C covalent conjugate.  
It has been reported that peptide triazoles co-bind with 2G12 (37) which is a glycan 
specific, conformationally sensitive antibody (119). The 2G12 binding epitope is 
suggested to include a non-contiguous patch of glycans on the “backside” of gp120, i.e. 
the face opposite where mutational data and modeling results suggest the peptide might 
be binding to (119). Moreover, due to its non-contiguous binding epitope on gp120, 2G12 
is considered a conformational antibody the binding of which is sensitive to proper 
folding of gp120 (33, 120). These factors all suggest that its binding to the covalent 
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conjugate should not be altered by the presence of the peptide triazole. This was indeed 
our observation from SPR studies, as shown in Figure 56. Here, we see that 2G12 binding 
to covalent conjugate is little affected by the presence of the peptide on gp120 (KD = 39 
nM for E275C and KD = 94 nM for AE21/E275C). These results demonstrate that we 
were successful in producing a peptide triazole/E275C covalent covalent conjugate and 
that the product shows the same conformational epitope properties that are expected of 
the peptide-bound gp120 state.  
 
Discussion 
Peptide triazoles bind the flexible gp120 protein with a thermodynamic signature 
which suggests the resulting complex maintains significant conformational flexibility 
(41). A small structuring effect has been suggested to be a common feature of the few 
gp120-binding, neutralizing antibodies discovered to date (15). This attractive property of 
this class of compounds has had the unwanted consequence of impeding efforts toward 
crystallization of a PT/gp120 complex. One approach to overcome the problem of 
complex flexibility for such gp120 ligands has been engineering mutations into the gp120 
sequence which would reduce its flexibility. Structure-guided pocket-filling mutations or 
disulfide stitches were introduced into the core gp120 sequence to stabilize its complex 
with b12 and b13, two broadly neutralizing antibodies, and resolve their crystal structures 
(22, 23). Inspired by these approaches, we set out to engineer a stabilized complex of 
gp120 and peptide triazoles. Introduction of engineered mutations in such a flexible 
target protein may have the side-effect of affecting its folding properties, as may have 
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happened for the b12-bound complex (44, 45). Therefore, we hypothesized that covalent 
conjugation of the peptides onto gp120 would possibly ameliorate such unwanted effects. 
In addition to its potential use in acquiring a crystal structure of the PT/gp120 complex, 
such a covalent conjugate might be a useful “bait” to identify antibodies that can cobind 
with PTs through screening of sera. These antibodies can perhaps later be used to further 
stabilize the complex to get a crystal complex. 
In the absence of a crystal structure to guide our design, we turned to computational 
modeling of the peptide/gp120 complex. We recently developed an MD-based model of 
the PT/gp120 core complex (115). We used that model as a blueprint for structure-based 
design. In our model (Figure 43b), the peptide binds at the interface of the inner and 
outer domains, preventing the folding of the bridging sheet and formation of the 
coreceptor binding site. Analysis of a long MD equilibration of the complex showed that 
although flexible, the N-terminus of the peptide remains close to the position 275 in 
gp120 sequence which was previously mutated to introduce a disulfide between the 
gp120 inner and outer domains (23). We hypothesized that introduction of a single 
cysteine at this position should lead to an expressible protein which remains functional 
toward typical gp120 ligands and would allow us to use various well-established, thiol-
selective conjugation chemistries in our work. Since we used the YU-2 strain of gp120 
for both our modeling analysis and wet-lab experiments and position 275 is a glutamic 
acid in this strain, we called the mutant E275C. A second conclusion of analyzing our 
modeled structure was that we need a linker of ~18-19     length to connect the N-
terminus of the peptide to gp120 at position 275.  
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We expressed, purified and analyzed the ligand binding properties of E275C gp120. 
Our SPR analysis showed that E275C maintained binding affinity to sCD4 and 17b, the 
two canonical gp120 ligands. Furthermore, the protein was recognized by F105 and b12 
antibodies similar to WT gp120. More importantly, analysis of binding of E752C gp120 
to SR07C, a surface immobilized variant of the peptide triazoles, showed that the peptide 
was able to bind to E275C with similar affinity as that of the WT gp120. These results 
showed that we could use E275C as a minimally altered gp120 variant with a suitable, 
selective conjugation handle for our studies. Since there are no other single cysteines in 
gp120 and E275C overlooks the functionally important and conformationally variable 
domains of gp120 around the F43 pocket, we think this mutant can also be used for future 
efforts in tethering-based strategies (121, 122) to screen for potential entry inhibitors that 
bind to gp120.  
Based on our modeling studies, we employed a modular approach in designing a 
reactive variant of the peptide triazoles. We introduced a PEG-linker on the peptide N-
terminus to allow it to reach E275C. Our ELISA results showed that the presence of the 
linker has no significant effect on the ability of the peptide to inhibit gp120 interactions 
with sCD4 and 17b, the two prototypical gp120 cognate ligands. Further, we placed a 
maleimide moiety at the end of the linker for selective conjugation to the E275C thiol. 
We used a peptide variant with a biotin at the C-terminus which would help us in product 
identification and purification using well-established biotin-based approaches. 
Introduction of the biotin group on peptide triazoles has recently been reported not to 
considerably affect the peptide affinity for gp120 (102).  
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Analysis of the reaction products on SDS-P GE and Western blotting using an α-
biotin antibody showed that the reactive AE21 peptide indeed reacts with E275C and 
successfully biotinylates E275C. Interestingly, a commercially available biotinylation 
reagent, MPB, had significantly lower labeling efficiency compared to AE21. This might 
be due to the advantage that AE21 has as a biotinylation reagent with high affinity for its 
target (gp120). Such affinity translates into localization of the reactive maleimide on the 
peptide in close proximity with chemical groups on the protein surface. We think this 
hypothesis is consistent with the observation of reduced reactivity of AE21 towards 
unfolded E275C. The peptide presumably does not bind the unfolded protein and hence 
its reactivity drops to the same level as a general purpose reagent like MPB. 
We tested the specificity of AE21 labeling by comparing the reaction mixtures of 
AE21/E275C gp120 and AE21/WT gp120 using SDS-PAGE and Western blotting. AE21 
was seen to label WT gp120 at a much lower efficiency which decreased with increasing 
the concentration of a non-reactive peptide (KR21) in the reaction mixture. Such a 
competing peptide would both allow us to probe the specificity of the AE21 reaction 
toward E275C and also provide us with a method of control the reactive peptide/gp120 
ration. The results showed that lower excess ratios of the reactive peptide decreased the 
AE21 reactivity toward WT gp120. We therefore used AE21/E275C gp120 excess ratios 
of 1-2x in our further experiments. It appears that the smaller excess ratios combined 
with specificity of maleimide reaction with thiols at the pH range used here increases the 
specificity of labeling gp120 at position 275.  
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We immobilized the purified reaction product AE21/E275C on a SPR chip and 
probed its binding properties to various gp120 ligands. We hypothesized that if the 
peptide in the covalent complex is indeed occupying the same binding pocket it occupies 
in a non-covalent complex with gp120, the two complexes should have similar ligand 
binding signatures. For example, we expect binding of sCD4 to the covalent complex to 
be inhibited by the presence of a covalently linked peptide. This was indeed what we 
observed on SPR. The same effect was seen for CD4bs antibodies like F105, which is 
consistent with previous work on inhibition of binding of these ligands to gp120 by the 
parent peptide of peptide triazoles, 12p1 (33). A more stringent test of the conformational 
properties of the covalent complex is mAb 17b binding. 17b binds to the bridging sheet in 
gp120 (18) and its epitope is far from position 275 on gp120. Our SPR results showed 
that indeed 17b binding to AE21/E275C is completely suppressed. Previous work has 
showed that antibody 2G12 does not compete with peptide traizole binding to gp120 (37). 
We observed that 2G12 binds to the covalent complex AE21/E275C and its binding 
kinetics is minimally affected by the presence of the peptide. These results demonstrate 
that the covalent conjugate AE21/E275C has similar binding characteristics as that of a 
non-covalently bound peptide triazole/gp120 complex. 
The small structuring effect of peptide triazole on gp120 upon binding are thought to 
contribute to the difficulty we have faced in resolving a crystal complex with the two 
molecules. This problem is similar to the case of b12/gp120 interaction which displays 
similar thermodynamic signatures (23). We hypothesized that a covalently linked peptide 
triazole/gp120 complex will have reduced flexibility due to significantly increased 
affinity of the covalently linked peptide which stems from its dimished translational 
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entropy. This is similar to the tethering approach to fragment-based drug discovery (121, 
122) wherein low affinity fragments are stabilized by a covalent bond to an auxiliary 
surface cysteine adjacent to their binding spot (121, 122). In other words, we 
hypothesized that covalent linkage of the peptide triazoles to gp120 can shift the 
equilibrium of complex formation drastically toward the complex by effectively 
removing the translational entropy of the unbound peptide. Equivalently, a decrease in 
the free energy of the complex formation for the covalently linked case compared to the 
non-covalent case should results in a complex wherein the peptide-bound state is 
significantly more frequently populated than the peptide unbound state. We hypothesize 
such a stabilized complex is more amenable to crystallization. Additionally, since we 
based our conjugation efforts on the computationally generated model of the peptide 
triazole/gp120 interaction, this work lends back some support to the validity of the 
model, too. That in turn can enable us to use the same blueprint to introduce further 
changes in the complex beyond the proof of concept work presented here. For example it 
might be possible to move the cysteine mutation to a different point in gp120, preferably 
away from the outer domain and hence move the linker and the N-terminal hydrophilic 
residue of the peptide away from the binding site of ligands like VRC01 (61).  
 
Conclusion 
Using our recently developed model of peptide triazole/gp120 complexes, we 
introduced changes in gp120 and the peptide triazole that helped us produce a covalent 
conjugate with similar properties to those of a non-covalent PT/gp120 complex. We 
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introduced a cysteine mutation (E275C) on a small variable loop on the outer domain to 
serve as a fusion point on gp120. SPR analysis showed that he mutant maintained binding 
affinity for sCD4 and 17b, the prototypical gp120 ligands, in addition to mAbs F105, b12 
and VRC01. In addition, the mutant was recognized by the peptide triazoles similar to 
WT gp120. We used a biotinylated peptide variant and introduced a PEG linker on the 
peptide N-terminus and observed that this addition did not have any major effects on the 
inhibition potency of the peptide for gp120 interaction with sCD4 and mAb 17b. We 
introduced a maleimide moiety at the end of the PEG linker and reacted the resulting 
peptide AE21 with E275C gp120 and confirmed that the peptide indeed labels this gp120 
mutant. SPR analysis of the purified covalent conjugate showed that it had similar 
binding characteristics as those of other peptide triazoles in that binding of sCD4, 17b, 
F105 and b12 was inhibited but the covalent conjugate recognized 2G12 similar to non-
conjugated E275C gp120. Taken together, these results provide evidence that we were 
able to produce a covalently conjugated PT/gp120 complex which can be used for future 
crystallization studies on the complex. Furthermore, since the covalent conjugate was 
designed based on our model of the PT/gp120 complex, these results lend back support to 
our model and pave the way for further modifications in the covalent complex which can 
lead to design of new stabilized gp120/PT constructs. 
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Table 11. Sequence and functional properties of various peptide triazole variants discussed in this work. IC 50 values are for WT gp120. 
Designation  Sequence  Triazole Derivative  
IC50(ELISA) [nM][a]  IC50(SPR) [nM][b]  
Description  
sCD4  mAb 17b  sCD4  mAb 17b  
UM24                                      Cit1[d]-N2-N3-I4-X5[c]-W6-S7  Ferrocenyl  -  -  118  138  Representative PT  
UM101                                         Cit1-N2-N3-I4-X5-W6-S7  Phenyl  230  670  -  -  PT used in modeling  
KR21                                       R1-I2-N3-N4-I5-X6-W7-β la8-K(ε-Biotinyl)9-G10  Ferrocenyl  25.2  74.6  85  110  Biotinylated PT  
SR07C                                            I1-N2-N3-I4-X5-W6-S7 -S8-S9-G10-Orn11[d]-C12  Ferrocenyl  -  -  ?  ?  PT with C-terminal Cysteine for surface immbilization  
L-KR21                      Linker19[d]-R1-I2-N3-N4-I5-X6-W7-β la8-K(ε-Biotinyl)9-G10  Ferrocenyl  92.7[e]  45.7[e]  -  -  Biotinylated PT with a PEG linker  
AE21 (Maleimide-Linker18) [d]R1-I2-N3-N4-I5-X6-W7-β la8-K(ε-Biotinyl)9  Ferrocenyl  - -  -  -  Biotinylated PT with a PEG linker and a thiol-reactive maleimide  
[a] IC50 determined using ELISA as outlined in Materials and Methods. 
[b] From references (37) and (41); IC50 was determined using SPR and values are shown here for comparison. 
 [c] X in the sequence denotes derivatized azidoproline. 
[d] Orn = Ornithine; Linker19 = 19    PEG linker resulting from coupling from N-Fmoc-N″-succinyl-4,7,10-trioxa-1,13-tridecanediamine; Maleimide-Linker18 = 18    PEG linker with a maleimide 
reactive end resulting from coupling of (succinimidyl-[(N-maleimidopropionamido)-diethyleneglycol] ester) 
[e] From ELISA data of Figure 48 in this work. 
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Table 12. Affinity of various gp120 ligands to WT and E275C YU-2 gp120 assessed using SPR. 
 
Analyte 
KD  (nM) 
WT E275C 
sCD4 8.07 4.12 
17b 5.54 24.47 
b12 1.1 3.43 
VRC01 0.55 24.23 
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Figure 43. (a) Gp120 core in the CD4-bound activated state. Approximate location of the F43 pocket is 
shown with a circle (b) Modeled lowest energy conformation of the peptide triazole/gp120 core 
encounter complex from (115). Residue E275 is shown in green spheres. Heavy atoms of the peptide 
triazole are depicted in stick representation with the N- and C-terminal amine nitrogen and carbonyl 
oxygen marked by blue and red spheres, respectively. Gp120 backbone is shown in carton rendering with 
the inner domain in red, the outer domain in blue and the bridging sheet domain in cyan. Note that the 
latter is unfolded in (b) and folded into a β -sheet in (a).  
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Figure 44. Representative SPR sensograms for direct binding of mAb b12 to immobilized (a) WT YU-2 
gp120 (b) E275C YU-2 gp120. The signals were normalized to the maximum response in each series. 
Numbers on the right show the b12 concentrations in nM.  
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Figure 45. SPR sensograms for direct binding of (a) WT (b) E275C gp120 to a peptide triazole variant 
(SR07C) immobilized on the SPR chip surface. Numbers on the right show the gp120 concentrations in 
nM. 
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Figure 46. Heavy atom RMSD trace for various peptide residues during the equilibrium MD run of the 
minimum energy peptide triazole/gp120 encounter complex. The RMSD for all peptide residues is 
plotted in thick blue. 
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Figure 47. Equilibrium MD run of the minimum energy peptide triazole/gp120 encounter complex. (a) 
The starting conformation of the equilibrium run. The small yellow spheres show the locus of the N -
terminal nitrogen atom of the peptide backbone during the simulation. (b) Frequency plot of the distance 
of peptide backbone N-terminal nitrogen to gp120 E275 (Cγ atom of the side chain) measured throughout 
the 200 ns trajectory. Mean = 19.73   ; Mode = 17.41   . 
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Figure 48. Competition ELISA for inhibition of binding of (a) sCD4 to WT (b) sCD4 to E275C (c) mAb 
17b to WT and (d) mAb 17b to E275C gp120 by KR21 (black squares) or L-KR21 (red circles). Error 
bars represent standard deviations (n=2). The curves are the results of fitting a sigmoidal funct ion to the 
dose response data, with black and red corresponding to KR21 and L-KR21, respectively.  
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Figure 49. Reaction scheme utilized to produce a reactive, biotinylated, pegylated peptide triazole. In 
step 1 the N-terminal amine of the biotinylated peptide KR21 is reacted with the NHS ester of the 
heterobifunctional crosslinker SMPEG2 to produce a pegylated PT bearing a reactive maleimide moiety 
(AE21). Then this peptide is conjugated to E275C gp120 through the reaction of the maleimide with the 
thiol group introduced on gp120 via E275C. 
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Figure 50. SDS-P GE followed by Western blot analysis using an α -biotin antibody to show the 
reactivity of AE21 and its specificity for E275C. (a) Lane (1) is the negative control (E275C protein 
only). Lane (2) is another negative control, where the reactive AE21 pe ptide in the reaction mixture is 
replaced with the non-reactive KR21 peptide (Table 1). Lane (3) shows the positive signal for the 
AE21+E275C gp120 reaction mixture. In lane (4), the AE21 peptide is replaced with a commercially 
available thiol-specific biotinylation reagent (MPB, Materials and Methods). Lane (5) shows the positive 
control (biotinylated WT gp120). (b) Specificity of AE21 reaction for folded E275C. Lane (1) is the 
negative control (WT gp120 only). Lane (2) shows the strong positive signal for  AE21 reaction with 
E275C gp120. In lane (3), AE21 is reacted with an E275C gp120 which was unfolded in 6M Guanidium 
hydrochloride prior to the experiment and then exchanged back into the reaction buffer. All other 
experimental conditions were the same as in panel (a). (c) Densitometry analysis of the results from 
panel (b) showing the relative abundance AE21-labeled E275C for the folded versus the unfolded case. 
Signals were normalized. 
 
  
197 
 
 
CHAPTER 5: DESIGN, PRODUCTION AND CHARACTERIZATION OF A PEPTIDE TRIAZOLE / GP120 
COVALENT CONJUGATE 
 
Figure 51. SDS-PAGE followed by Western blot analysis using an α-biotin antibody of the reaction 
mixture containing (top row) E275C or (bottom row) WT gp120 with a fixed amount of AE21 reactive 
peptide (R1=n(AE21)/n(gp120)=10, where n denotes moles) in presence of increasing concentrations of 
KR21 (the non-reactice base peptide). Results of densitometry analysis on this blot are shown in Figure 
58. 
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Figure 52. SPR sensograms from binding of increasing concentrations of sCD4 (analyte) to (a) E275C 
immobilized in random orientation and (b) AE21/E275C covalent conjugate captured by NeutrAvidin 
biotin-binding protein. The signal for each surface was normalized to the maximum response from 
passage of 200 nM mAb D7324 before each experiment to correct for the different immbilised ligand 
densities for the two cases. Each curve represents the average response from two runs. The cartoon insets 
depict a schematics representation of the assay setup. Numbers on the right show the sCD4 
concentrations in nM. 
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Figure 53. SPR sensograms from binding of increasing concentrations of mAb 17b (analyte) to (a) 
E275C immobilized in random orientation and (b) AE21/E275C covalent conjugate captured by 
NeutrAvidin biotin-binding protein. The signal for each surface was normalized to the maximum 
response from passage of 200 nM mAb D7324 before each experiment to correct for the different 
immbilised ligand densities for the two cases. Each curve represents the average response from two runs. 
Numbers on the right show the 17b concentrations in nM. 
  
200 
 
 
CHAPTER 5: DESIGN, PRODUCTION AND CHARACTERIZATION OF A PEPTIDE TRIAZOLE / GP120 
COVALENT CONJUGATE 
 
Figure 54. SPR sensograms from binding of increasing concentrations of sCD4  (analyte) to (a) E275C 
and (b) purified AE21/E275C covalent conjugate directly immobilized on the SPR chip surface. Each 
curve represents the average response from two runs. Numbers on the right show the sCD4 
concentrations in nM. 
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Figure 55. SPR sensograms from binding of increasing concentrations of mAb  17b (analyte) to (a) 
E275C and (b) purified AE21/E275C covalent conjugate immobilized on the SPR chip surface. Each 
curve represents the average response from two runs. Numbers on the right show the 17b concentrations 
in nM. 
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Figure 56. SPR sensograms from binding of increasing concentrations of mAb 2G12 (analyte) to (a) 
E275C and (b) purified AE21/E275C covalent conjugate immobilized on the SPR chip surface. Each 
curve represents the average response from two runs. Numbers on the right show the 2G12 
concentrations in nM. 
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Figure 57. Our model of PT/gp120 core encounter complex. Residue E275 is shown in yellow spheres. 
Lysine residues within 15    of E275 are shown in green spheres and the rest of lysine residues are shown 
in green halo spheres. Gp120 backbone is shown in carton rendering with the inner domain in red and the 
outer domain in blue. Residue E275 is shown in green spheres. Heavy atoms of the peptide triazole are 
depicted in stick representation with the N- and C-terminal amine nitrogen and carbonyl oxygen marked 
by blue and red spheres, respectively.  
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Figure 58. Densitometry results from the blot shown in  Figure 51. Note that since the signal density 
difference between various bands is out of the linear range of detection, some very low density bands 
may appear in the original blot but not show up in this graph.  
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Figure 59. L-KR21 RP HPLC chromatogram 
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Figure 60. MALDI TOF MS results for L-KR21 
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Figure 61. AE21 RP HPLC chromatogram 
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Figure 62. AE21 RP HPLC chromatogram 
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Blocking of PT-caused HIV-1 virolysis by 2G12 
Some cysteine-containing variants of PTs were shown to have cell-free virolytic 
effects (40). These compounds, exemplified by KR13 (Figure 63), are comprised of the 
active core PTs (NNIXW) and a C-terminal linker followed by a cysteine at the C-
terminus. It has been shown that these peptides have high affinity for gp120 (KD=11.3 
nM), are potent inhibitors of cell infection (IC50=23.6 nM) and lead to inactivation of the 
HIV-1 virion particle and leakage of the p24 structural protein from the virus (40). 
Despite these interesting properties, the exact mechanism by which these peptides exert 
their virolytic effect is not known. It has been found that the virolytic function of the 
peptides is dependent on the presence of C-terminal free sulfhydryl group in the sequence 
(Bastian et al., submitted).  
Target-cell surface protein disulfide isomerase (PDI) or thioredoxin (Trx) can 
catalyze reduction of disulfide bonds in gp120 and enhance the entry process (123, 124). 
It has been suggested that the C296-C331 disulfide at the base of the V3 loop in gp120 
might be the primary target for disulfide exchange by these enzymes (124). Considering 
that the C-terminal cysteine is necessary for the KR13 virolytic effect, it has been 
suggested that a disulfide exchange between this cysteine and a gp120 cysteine might 
play a role in this effect (Bastian et al., submitted).  
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We used the model of UM101-gp120 core encounter complex to explore the 
possible hypotheses that might provide a structural basis for the above disulfide exchange 
mechanism. We first asked the following question: Is it geometrically possible for a C-
terminal cysteine on a KR13 molecule docked to gp120 similar to the UM101 model to 
extend close to C296-C331 disulfide? To answer that, we started with the UM101 model 
generated previously and modified the sequence (CitNNIXWS, X=phenyl triazole) into 
CitNNIXWSEAMMAQAC (compare to the KR13 sequence 
RINNIXWSE MMβ Qβ C, X=ferrocenyl triazole, β =β-alannine). We then used 
steered MD to force the cysteine sulfur atom close to the C296-C331 disulfide. The 
resulting structure was then minimized for 5000 steps keeping all atoms fixed, except for 
the added sequence (E MMβ Qβ C); keeping the sulfur atom in place. The results 
showed that such an extension is possible and even removing the constraints (for 5000 
steps) does not lead to immediate changes in the peptide structure which would have 
indicated large deviations from equilibrium bond lengths and angles. All the above 
experiments where done in vacuum and the aim was only performing a thought 
experiment. The resulting end structure is shown in Figure 64.  
The C296-C331 disulfide is proximal to a pair of aspargine residues (N332 and 
N295) that are critical for binding of mAb 2G12, a broadly neutralizing glycan-specific 
antibody (119). This suggests that one way to test the disulfide exchange hypothesis laid 
out above might be to test and see if 2G12 can protect the virus against the virolytic 
effect of KR13, while still allowing KR13 binding to gp120. Previous studies have shown 
that 2G12 can co-bind with peptide triazoles (37). In addition, in the previous chapter, we 
showed that 2G12 can bind to the AE21/E275C peptide/gp120 covalent conjugate. 
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Therefore, we hypothesized that 2G12 can bind to gp120 in the presence of saturating 
amounts of KR13. While this presumably will not affect KR13 binding to gp120, it might 
prevent a possible disulfide exchange from happening by shielding the sensitive C296-
C331 through steric occlusion. Therefore, if such a disulfide exchange is to play a role in 
virolysis, 2G12 should protect the virus against virolysis.  
Single-round pseudotyped HIV-1BAL virus was produced as described elsewhere 
(40). The viruses were purified over an iodixanol gradient (Bastian et al., submitted). 
KR13 was synthesized through solid phase peptide synthesis and purified over RP HPLC 
on a C-18 column, similar to the method described in chapter 5
*
.  
For standard p24 leakage assays, serial dilutions of KR13 (50 μM to 0.128 nM) in 
PBS were incubated for 30 minutes in working dilutions of the purified virus. For 
2G12/KR13 assays, serial dilution of 2G12 (500 nM to 0.128 nM) in PBS were incubated 
with the virus for 30 minutes in presence of 50 μM KR13. The control samples included 
PBS (“intact virus”) or 2.5% Triton X-100 (“lysed virus”) with virus. For the latter, the 
sample was heated to 90°C for 5 minutes.  ELIS  plates were coated with mouse α-p24 
(Abcam) overnight at 4°C and blocked with 3% BSA in PBS. The blocked plates were 
rinsed 3x with 0.1% PBS-T (PBS with 0.1% Tween-20). Samples were centrifuged at 
16000 rpm (4°C, 2hours) to spin down intact virus post-incubation. The top half of such 
centrifuged aliquots was carefully extracted, mixed with equal volumes of 0.5% BSA in 
PBST and incubated in triplicate on the α-p24 immbilized ELISA plates to capture the 
released p24. Following overnight incubation, the plate was rinsed and rabbit α-p24 
                                                 
*
 KR13 was kindly synthesized by Dr Hiuyuan Lee at Drexel University College of Medicine. Purified 
pseudovirus preparations were a kind gift from Rosemary Bastian, Drexel University College of Medicine. 
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(1:5000 dilution; Abcam) was added to the wells and incubated for 2 hours at room 
temperature, followed by HRP-conjugated α-rabbit antibody (1:5000 dilution; Abcam) 
for detection. The results are shown in Figure 65. As expected, increasing KR13 
concentration leads to increasing amounts of p24 leakage from the virus, consistent with 
past reports (40). Here, at 50 μM KR13, about 30% of the viral p24 leaks out of the virus. 
In presence of the same amount of KR13 and no 2G12 to 1 nM 2G12, the same results 
are observed: about 30% of the viral p24 leaks out. But increasing 2G12 concentration 
above 1 nM quickly reduces p24 leakage where above 4 nM 2G12, leakage is almost 
fully stopped. This is consistent with our hypothesis that blocking access to the C296-
C331 cysteine on gp120 may result in protection of the virus from the virolytic effects of 
KR13.  
These results provide some evidence for the hypothesized mechanism of virlytic 
action by KR13 which posits that the C-terminal cysteine in KR13 may participate in 
disulfide exchange with the C296-C331 disulfide. Such an exchange may initiate a 
similar sequence of conformational changes which leads to viral fusion (124). In absence 
of a target cell, such a sequence may lead to premature activation of the virus or possible 
membrane poration in the virus. Although these results are consistent with our proposed 
hypothesis, further analysis is required to precisely delineate the mechanism of viral 
inactivation by KR13.  
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Figure 63. Structure of the peptide triazole KR13.  
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Figure 64. An approximate representation of how the C-terminal cysteine of a KR13 analogue may reach 
the C296-C331 in gp120 core (a) global view of a possible complex if the C-terminus was “stretched” to 
reach the gp120 disulfide (b) zoomed-in view after a ~120° rotation around the in plane x-axis. N295 and 
N332 represent two glycosylation sites that are critical for 2G12 binding. The other two proximal 
disulfides are shown in stick presentation. The gp120 β-strand from which the V3 loop emanates is 
shown in darker blue.    
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Figure 65. p24 leakage  in presence of (top axis , red curve) serial dilutions of KR13 or (bottom axis , 
blue curve) serial dilutions of 2G12 with constant (50 μM) concentrations of KR13. Raw data are 
normalized to the intact virus (0%) and the lyzed virus (100%).  
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Since the start of this work about five years ago, the fields of HIV immunology and 
structural biology have expanded exponentially. Five years ago only a handful of broadly 
neutralizing antibodies were available (23). Today that list has expanded to extremely 
potent neutralizers like VRC01 and new members with different mechanisms of action 
are quickly identified (80, 84). Furthermore, whereas five years ago the b12-bound state 
of gp120 was the only non-activated state available (23), today two more states have been 
added (22) and recent advances in electron tomography argue that an atomic resolution of 
Env spike structure may be feasible in the near future (9).  
Resolution of the atomic structure of the native spike will represent a pivotal 
advancement in HIV structural biology which can lead to the design of better HIV 
immunogens and entry inhibitors. One such possibility will be probing the dynamics of 
this protein machine using computational techniques like MD. Mechanistic insights are 
greatly needed to facilitate the design of entry inhibitors. In the absence of a spike 
structure, advanced sampling techniques restrained with high resolution electron 
tomograms (like TAMD + molecular dynamics flexible fitting or MDFF) (125) using 
homology models of the full length gp120 can help generate new hypotheses for 
mechanisms of spike function and conformational change. Such hypotheses could 
address questions such as the following: [1] How is the CD4-binding site protected from 
the immune system? [2] How does the spike change following enzymatic cleavage as the 
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cleaved and uncleaved spikes have very different immunogenic characteristics (22, 126)? 
[3] What are the potentially available druggable target sites on a native trimer, even 
transient ones? Towards that goal, we have generated homology models of the full-length 
HIV-1HxBc2 gp120 that can be refined initially using de novo protein folding platforms 
like Rosetta (127) and then, in the context of the various available electron tomograms of 
activated spike (8), through the use of techniques like MDFF. Currently, most MD 
simulations on proteins disregard glycans. However, considering the role of glycans in 
gp120 function, their inclusion can provide some insight as to how glycans affect gp120 
dynamics, and indeed the dynamics of proteins in general. It has been found that in 
contrast to the complex glycans on recombinantly-produced gp120, the glycans on the 
surface of the spike are almost exclusively Man5–9GlcNAc2 (128). Therefore it is possible 
to add further complexity to such models by incorporation of such glycan moieties. This 
could be done using available tools like GLYCAM (129) and the associated force field. 
Since glycosylation plays a major role in correct folding (130), immunogenicity (131) 
and conformational regulation of HIV-1 gp120 (132), inclusion of the glycans can be 
expected to significantly improve the reliability of any conformational dynamics analysis 
performed on such models.  
The PT/gp120 model generated in this work can be tested in the wet-lab through 
structure based design of peptide variants. One prediction of the model was that the 
peptide Trp makes a hydrogen bond to gp120 S375, the latter of which stabilizes the 
bound pose. Preliminary studies have shown that gp120 S375A has 20x less affinity for 
PTs (F. Tuzer, unpublished data). This was the first direct test of our model. Further 
hypotheses can be proposed based on the model. The pocket at the interface of the inner 
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and outer domains, where the peptide Ile binds in the current model, can be filled with 
larger peptide side chains. For example replacement of peptide Ile side chain with bulkier 
side chains like Trp or Phe might increase peptide affinity. As a more straight-forward 
line of investigation, various gp120 mutants can be tested for effect on PT binding: F382, 
Y384, S375 and G473 as possible Trp contacts; W112, I109, H105 and I108 as possible 
Ile contacts and W112, I423, L116, N425, D113, K117 and Q422 as possible triazole 
contacts. In the longer run, simulation of peptide binding to a dynamic gp120 surface 
might become more feasible considering the recent advances in such simulations using 
specialized hardware like Anton (133, 134). Such simulations can immensely help in 
improving peptide properties considering the atomistic details they provide. Extrapolating 
from the fast pace of current improvements in computing power, those goals will not be 
out of reach.  
Parameterization of the triazole moiety within the CHARMM force-field was done 
through similarity with already existing parameters, as is recommended in the framework 
of CHARMM general force field (135, 136). This approach is clearly not optimal. 
Precisely driven parameters are preferable, and efforts towards deriving those will affect 
the modeling results. As expected, this will affect the gp120/peptide interface especially 
at the triazole contacts. Hence, we believe the current model is least reliable around this 
region. Compounding these effects is the fact that the target conformation of gp120 used 
in the model is adapted from another crystal structure. Although we provided various 
reasons why the F105-bound state is the best currently available target conformation, the 
relationship of this structure to the actual PT-bound state of gp120 is not known. 
Considering the role that spike flexibility plays in allowing ligand binding (22, 63), an 
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intriguing possibility might be that binding of the peptide to a less-frequently sampled 
conformation (like the F105-bound state) might stabilize such states which are poorly 
compatible with a native spike. This can in turn lead to gp120 shedding and early 
inactivation of the spike. It would be interesting to probe peptide binding to crosslinked 
spikes which lack such flexibility (22, 63). Glutaraldehyde fixation of gp120 or trimers 
and probing their capacity to bind a biotinylated peptide can be used to further 
characterize the peptide-bound states. It has been shown that the conformational 
landscape for crosslinked core and full-length gp120 are different (26). Hence, one may 
postulate that peptide binding to the crosslinked core should be reduced compared to the 
full length gp120. Comparison of results with other ligands like antibodies or even small 
molecule ligands can provide a better picture of the peptide-bound state.  
We provided a proof-of-principle method for production of the gp120/PT covalent 
conjugate. The process needs to be optimized if enough material for crystallization is to 
be made. Considering the modular, multi-step method of production, there are many 
opportunities for optimizing this protocol. Acquiring a larger amount of the fusion can 
also be useful to perform differential scanning calorimetry (DSC) or cicular dichroism 
(CD) experiments on the fusion to probe its stability. We expect the complex to have 
higher thermal stability toward unfolding. Expansion of the work to include E275C core 
gp120 proteins can potentially lead to a more realistic target for crystallization as the 
variable loops will be an impediment to such efforts.  
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